Compound

all-cis-5,8,11,14,17-icosapentaenoic acid

Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane-2 and prostaglandin-2 families.

Definition from MeSH (D015118), National Library of Medicine, read 2026-09-23. NLM revises MeSH; this copy may not reflect its current record.

CHEBI:28364ChEBI

Open in the graph

Studied for

9 endpoints · 12 findings · 8 papers · 4 null

C-reactive protein concentrationno detected effectEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
HOMA-IRlowersEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
Erythrocyte sedimentation ratelowersEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
LDL cholesterolno detected effectEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
Serum albuminraisesEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.

All 9 endpoints, with the quotes

Structure

An icosapentaenoic acid having five cis-double bonds at positions 5, 8, 11, 14 and 17.

2D depiction · 3D model shown

Loading the model…

A generated conformer of all-cis-5,8,11,14,17-icosapentaenoic acid — one low-energy arrangement PubChem computed, not a measured structure. Hydrogens are not drawn; the formula counts them.

Class: Organic compound
Formula: C20H30O2
Mass: 302.458 g/mol
Charge: 0
InChIKey: JAZBEHYOTPTENJ-JLNKQSITSA-N
SMILES: CC/C=CC/C=CC/C=CC/C=CC/C=CCCCC(=O)O
Look it up: ChEBI PubChem By InChIKey

Identity from ChEBI, geometry from PubChem. Not evidence.

What the evidence says

How to read these marks

12 findings · 9 endpoints · 8 papers · 4 null · by evidence strength

Heavier lines are better evidence, and a line with a gap in the middle is an inference rather than a reported result. Two lines arriving at one endpoint are two findings of it, marked ×2. How evidence strength is computed.

What moved

8 findings

Decreases erythrocyte sedimentation rate
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding
“Serum ESR and CRP levels significantly decreased in the EPA-rich fish oil (p < 0.001).”
Quoted verbatim from Eicosapentaenoic acid decreases inflammation and improves glucose homeostasis in patients with burns: a randomized clinical trial..
Study

RCT
Participants

24
Duration

3 weeks
Dose

1.5 g/day EPA as EPA-rich fish oil capsules (500 mg EPA per capsule, three times daily with meals)
Population

Hospitalised adults aged 18-65 with non-severe burns covering less than 20% of total body surface area, able to take more than 90% of their daily calorie requirement by mouth, without diabetes, organ failure, cancer or immune disorder; both the EPA arm and the control arm also received 600 mg/day DHA.
Eicosapentaenoic acid decreases inflammation and improves glucose homeostasis in patients with burns: a randomized clinical trial.2025PMID:41254027Permalink
Increases serum albumin
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding
“Serum albumin was significantly higher in the EPA-rich fish oil group than the controls (p = 0.03), however this difference was not clinically significant.”
Quoted verbatim from Eicosapentaenoic acid decreases inflammation and improves glucose homeostasis in patients with burns: a randomized clinical trial..
Study

RCT
Participants

24
Duration

3 weeks
Dose

1.5 g/day EPA as EPA-rich fish oil capsules (500 mg EPA per capsule, three times daily with meals)
Population

Hospitalised adults aged 18-65 with non-severe burns covering less than 20% of total body surface area, able to take more than 90% of their daily calorie requirement by mouth, without diabetes, organ failure, cancer or immune disorder; both the EPA arm and the control arm also received 600 mg/day DHA.
Eicosapentaenoic acid decreases inflammation and improves glucose homeostasis in patients with burns: a randomized clinical trial.2025PMID:41254027Permalink
Decreases C-reactive protein concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding
“Serum ESR and CRP levels significantly decreased in the EPA-rich fish oil (p < 0.001).”
Quoted verbatim from Eicosapentaenoic acid decreases inflammation and improves glucose homeostasis in patients with burns: a randomized clinical trial..
Study

RCT
Participants

24
Duration

3 weeks
Dose

1.5 g/day EPA as EPA-rich fish oil capsules (500 mg EPA per capsule, three times daily with meals)
Population

Hospitalised adults aged 18-65 with non-severe burns covering less than 20% of total body surface area, able to take more than 90% of their daily calorie requirement by mouth, without diabetes, organ failure, cancer or immune disorder; both the EPA arm and the control arm also received 600 mg/day DHA.
Eicosapentaenoic acid decreases inflammation and improves glucose homeostasis in patients with burns: a randomized clinical trial.2025PMID:41254027Permalink
Conflicting findings
Another finding disagrees on direction.
Decreases HOMA-IR
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1
“Insulin resistance (HOMA-IR) significantly decreased in the EPA-rich fish oil than the controls (p = 0.001).”
Quoted verbatim from Eicosapentaenoic acid decreases inflammation and improves glucose homeostasis in patients with burns: a randomized clinical trial..
Study

RCT
Participants

24
Duration

3 weeks
Dose

1.5 g/day EPA as EPA-rich fish oil capsules (500 mg EPA per capsule, three times daily with meals)
Population

Hospitalised adults aged 18-65 with non-severe burns covering less than 20% of total body surface area, able to take more than 90% of their daily calorie requirement by mouth, without diabetes, organ failure, cancer or immune disorder; both the EPA arm and the control arm also received 600 mg/day DHA.
Eicosapentaenoic acid decreases inflammation and improves glucose homeostasis in patients with burns: a randomized clinical trial.2025PMID:41254027Permalink
Decreases HOMA-IR
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Findingreplicated ×1
“The HOMA‐IR score was also lowered with EPA in the diet, relative to the mice consuming the HF diet.”
Quoted verbatim from Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner..
Study

animal · not in humans
Duration

3 months
Dose

EPA ethyl esters (Cayman, at least 93% pure) in the high-fat diet, 2% of total energy; the paper states pure EPA ethyl esters were used, not mixtures with DHA
Population

Male C57BL/6J mice fed a high-fat diet (60% kcal from lard) for 15 weeks, with or without EPA ethyl esters
Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner.2020PMID:32579292Permalink
Accumulates in liver
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding
“The amount of hepatic EPA of AHF + EPA group was increased 3.9- and 29-fold in comparison with the chow and AHF groups, respectively.”
Quoted verbatim from Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice..
Study

animal · not in humans
Duration

4 weeks
Dose

EPA ethyl ester (95% grade) at 5% of the atherogenic high-fat diet, 4 weeks
Population

Male C57BL/6J mice fed an atherogenic high-fat diet supplemented with 5% EPA for four weeks, compared with chow and atherogenic high-fat diet alone
Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice.2016PMID:27333187Industry fundedPermalink

Show the remaining 2

Accumulates in adipose tissue
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding
“Free EPA increased EPA in adipose tissue, and both supplements increased EPA and DHA in the liver and heart.”
Quoted verbatim from Dietary lysophosphatidylcholine-EPA enriches both EPA and DHA in the brain: potential treatment for depression..
Study

animal · not in humans
Duration

15 days
Dose

free EPA by gavage, 3.3 umol/day for 15 days
Population

Normal mice gavaged for 15 days with free EPA (3.3 umol/day), compared with a no-EPA control
Dietary lysophosphatidylcholine-EPA enriches both EPA and DHA in the brain: potential treatment for depression.2019PMID:30530735Permalink
Decreases all-cause mortality
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding
“The incidence of postinfarct mortality was significantly lower in the MI+EPA group than in the MI+PBS group (59.3% vs 41.2%, P=0.0361).”
Quoted verbatim from Long-Term Administration of Eicosapentaenoic Acid Improves Post-Myocardial Infarction Cardiac Remodeling in Mice by Regulating Macrophage Polarization..
Study

animal · not in humans
Duration

8 weeks
Dose

EPA ethyl ester (more than 99% purity) 1 g/kg/day by oral gavage, once daily for 4 weeks before and 4 weeks after infarction; control received PBS by gavage
Population

Male 10-week-old C57BL/6J mice with myocardial infarction induced by left coronary artery ligation, followed 28 days after infarction
Long-Term Administration of Eicosapentaenoic Acid Improves Post-Myocardial Infarction Cardiac Remodeling in Mice by Regulating Macrophage Polarization.2017PMID:28223437Permalink
Conflicting findings
Another finding disagrees on direction.

What did not

4 findings

No detected effect on LDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“In Nestel et al.’s study in dyslipidaemic subjects (~3 g/day EPA or DHA for seven weeks), there was no change in total or LDL cholesterol with either EPA or DHA compared to olive oil.”
Quoted verbatim from The Differential Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Cardiometabolic Risk Factors: A Systematic Review..
Study

RCT
Duration

7 weeks
Dose

~3 g/day EPA
Population

dyslipidaemic subjects (Nestel et al. study)
The Differential Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Cardiometabolic Risk Factors: A Systematic Review.2018PMID:29425187An author is affiliated with a producerPermalink
No detected effect on C-reactive protein concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“Changes in hs-CRP and BNDF values are also reported in Table 2; there were no differences between EPA and the placebo (p = 0.747 and p = 0.070, respectively).”
Quoted verbatim from High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels..
Study

RCT
Participants

80
Duration

3 months
Dose

1.2 g/day EPA; the form of the EPA is not stated
Population

Children and adolescents aged 6 to 18 years with a DSM-5 diagnosis of attention deficit hyperactivity disorder, either drug naive or unmedicated for the previous six months, recruited at one hospital in Taiwan
High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels.2019PMID:31745072An author is affiliated with a producerPermalink
Conflicting findings
Another finding disagrees on direction.
No detected effect on incidence of stroke
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result
“However, combined therapy of EPA + statin demonstrated no significant association on incidence of stroke when compared with statin alone or all-cause mortality.”
Quoted verbatim from Meta-analysis Comparing Combined Use of Eicosapentaenoic Acid and Statin to Statin Alone..
Study

meta-analysis
Population

Meta-analysis with trial sequential analysis of 5 RCTs (n=27,415) of EPA + statin vs statin alone; statin given as background therapy in both arms.
Meta-analysis Comparing Combined Use of Eicosapentaenoic Acid and Statin to Statin Alone.2020PMID:31740020Permalink
No detected effect on all-cause mortality
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result
“However, combined therapy of EPA + statin demonstrated no significant association on incidence of stroke when compared with statin alone or all-cause mortality.”
Quoted verbatim from Meta-analysis Comparing Combined Use of Eicosapentaenoic Acid and Statin to Statin Alone..
Study

meta-analysis
Population

Meta-analysis with trial sequential analysis of 5 RCTs (n=27,415) of EPA + statin vs statin alone; statin given as background therapy in both arms.
Meta-analysis Comparing Combined Use of Eicosapentaenoic Acid and Statin to Statin Alone.2020PMID:31740020Permalink
Conflicting findings
Another finding disagrees on direction.

What the reference databases state

Chemical structure

(5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl)-cholesterol has the functional parent all-cis-5,8,11,14,17-icosapentaenoic acidCompoundChEBI CHEBI:84969Inferred only
1-hexadecanoyl-2-(5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl)-sn-glycero-3-phosphocholine has the functional parent all-cis-5,8,11,14,17-icosapentaenoic acidCompoundChEBI CHEBI:86137Inferred only

On the label

Labelled products

386 products

Source: NIH DSLD · Ingredient: all-cis-5,8,11,14,17-icosapentaenoic acid · 386 products · Declared amount per serving: 0.625–4,000 mg (380 products)

382 labels state an amount4 do not

Order

1MDKrillMD174 mgper 2 Softgel(s)DSLD:246767
1st PhormMicro Factor EFAFish Oil Concentrate125 mgper 1 Softgel(s)DSLD:295905
AB American BiologicsImproved Super Omega EPA/DHAEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3440 mgper 2 Softgel(s)DSLD:20294
AB American BiologicsUltra Omega EssentialsEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3150 mgper 2 Softgel(s)DSLD:20491
Absorb HealthOmega DHA & EPAEPA (Alt. Name: Eicosapentaenoic Acid) Note: Gas Chromatography by A%.720 mgper 2 Softgel(s)DSLD:216055
Acella PharmaceuticalsPNV-Omega40 mgper 1 Softgel(s)DSLD:278709
AdvoCareCore Nutrition SystemMarine Lipids · Eicosapentaenoic Acid (Form: from Marine Lipids)600 mgper 1 4-Packet Strip(s)DSLD:177397
AdvoCareMNS 3Marine Lipids · Eicosapentaenoic Acid (Form: from Marine Lipids)600 mgper 2 Packet(s)DSLD:177961
AdvoCareMNS CMarine Lipids · Eicosapentaenoic Acid (Form: from Marine Lipids)300 mgper 2 Packet(s)DSLD:207148
AdvoCareMNS EMarine Lipids · Eicosapentaenoic Acid (Form: from Marine Lipids)300 mgper 1 Packet(s)DSLD:177964
AdvoCareOmegaPlexMarine Lipids600 mgper 2 Softgel(s)DSLD:265350
Alani NuPrenatal40 mgper 2 Softgel(s)DSLD:277637

Show the remaining 374

Allergy Research GroupSteady On160 mgper 20 Gram(s)DSLD:54474
Allergy Research GroupSteady On160 mgper 20 Gram(s)DSLD:54482
Allergy Research GroupTake Heart II Without Hormones145 mgper 20 Gram(s)DSLD:54484
Allergy Research GroupTake Heart II Without Hormones145 mgper 20 Gram(s)DSLD:54477
Amala VeganKids Vegan Omega 3 DHA + EPA Organic Lemon Flavored2.5 mgper 0.5 mLDSLD:276164
AmvilabOmega 3-6-9Fish Oil125 mgper 1 Softgel(s)DSLD:298165
AN Amazing Nutrition Amazing OmegaFish Oil 1000 mg33%180 mgper 1 Softgel(s)DSLD:275821
AN Amazing Nutrition Amazing OmegaKrill Oil 500 mg61 mgper 1 Softgel(s)DSLD:251769
ANTIAGING Institute of CaliforniaFish Oil Concentrate160 mgper 1 Softgel(s)DSLD:210294
AOR Advanced Orthomolecular Research PremiumVegan Omega 3Typical values. Ranges: EPA 150-300 mg246 mgper 1 Softgel(s)DSLD:305920
Apex EnergeticsOmegaCo3 (K-7)500 mgper 1 TbspDSLD:206624
Apex EnergeticsOmegaCo3-SE500 mgper 2 Softgel(s)DSLD:239380
AquaOmegaHigh DHA Omega-3 4500 mg Lemon Flavor670 mgper 7.5 mLDSLD:277089
AquaOmegaHigh EPA Omega-3 Lemon Flavor3,380 mgper 7.5 mLDSLD:275942
AquaOmegaHigh EPA Omega-3 Orange Flavor3,380 mgper 7.5 mLDSLD:275944
aSquared NutritionOmega 3 2400 mg Lemon Flavored860 mgper 2 Softgel(s)DSLD:322074
Avion PharmaceuticalsPrenate Essential40 mgper 1 Softgel(s)DSLD:279279
Avion PharmaceuticalsPrenate Essential40 mgper 1 Softgel(s)DSLD:44774
Avion PharmaceuticalsPrimaCare120 mgper 1 Softgel(s)DSLD:278712
Barlean'sTotal Omega 3-6-9 Lemonade Flavor400 mgper 3 Gram(s)DSLD:218507
Barlean's Organic OilsIdeal Omega 3 Orange Flavored750 mgper 1 Softgel(s)DSLD:220029
Basic VitaminsOderless Coated Fish Oil 1000 mg Omega-3180 mgper 1 Softgel(s)DSLD:250298
BayerArctic Wonder Omega-3 Krill Oil150 mgper 2 Softgel(s)DSLD:12238
Best NaturalsKrill-500 1000 mgTypical fatty Acid162 mgper 1 Softgel(s)DSLD:270590
Best NaturalsKrill-500 500 mgTypical fatty Acid162 mgper 2 Softgel(s)DSLD:270589
Best Nest WellnessOne Fish, Two Fish250 mgper 2 Softgel(s)DSLD:270752
Beyond HealthFish Oil Formula660 mgper 2 Softgel(s)DSLD:306889
Beyond HumanOmega 3 Fish Oil180 mgper 1 Soft Gelatin Capsule(s)DSLD:181952
Bio NutritionK Bio Krill 500 mg81 mgper 1 Softgel(s)DSLD:200593
BioChem SportsOmega Burn300 mgper 6 Softgel(s)DSLD:13312
BiotiviaGreen Omega3Almega PL300 mgper 3 Vegetarian Softgel(s)DSLD:58307
Bronson LaboratoriesKrill Oil 500 mg150 mgper 2 Softgel(s)DSLD:8247
BulkSupplements.comMultivitamins 1000 mg Softgels20 mgper 1 Softgel(s)DSLD:312978
BulkSupplements.comMultivitamins for Men - with Fish Oil Softgels20 mgper 1 Softgel(s)DSLD:312979
BulkSupplements.comMultivitamins for Men - with Fish Oil Softgels20 mgper 1 Softgel(s)DSLD:314919
BulkSupplements.comMultivitamins for Men - with Fish Oil Softgels 1000 mg20 mcgper 1 Softgel(s)DSLD:329942
BulkSupplements.comMultivitamins for Women - with Fish Oil Softgels20 mgper 1 Softgel(s)DSLD:312980
BulkSupplements.comMultivitamins For Women - with Fish Oil Softgels 1000 mg20 mgper 1 Softgel(s)DSLD:313514
BulkSupplements.comMultivitamins Softgels20 mgper 1 Softgel(s)DSLD:294795
BulkSupplements.comMultivitamins Softgels20 mgper 1 Softgel(s)DSLD:294796
BulkSupplements.comMultivitamins with Fish Oil Softgels 1000 mg20 mgper 1 Softgel(s)DSLD:329778
Burbank Glendale ChiropracticUltimate Health Cardio180 mgper 3 Capsule(s)DSLD:22091
Burton NutritionUltimate Men's Daily PackFish Oil125 mgper 1 Packet(s)DSLD:306046
California Academy of HealthPure Premium Antarctic Krill Oil 500 mg130 mgper 2 Softgel(s)DSLD:206422
CarlsonCod Liver Oil Natural Lemon FlavorEPA (Form: reported as Triglycerides) (Alt. Name: Eicosapentaenoic Acid)400 mgper 5 mLDSLD:241832
CarlsonKid's Norwegian Cod Liver Oil Natural Lemon Flavorreported as triglycerides185 mgper 2.5 mLDSLD:337525
CarlsonOlive Your Heart Basil FlavorEPA (Form: reported as Triglycerides) (Alt. Name: Eicosapentaenoic Acid)360 mgper 15 mLDSLD:216674
CarWin Pharmaceutical AssociatesTriStart DHA15 mgper 1 Softgel(s)DSLD:279283
CATALOBaby's Algea Omega-3 Drops216 mgper 0.5 mLDSLD:320578
CATALOBaby's Vegetarian DHA Formula10.2 mgper 500 mgDSLD:303015
CATALOChildren's Vegetarian DHA Formula10.2 mgper 500 mgDSLD:303035
CentrumCentrum Specialist Prenatal15 mgper 1 Tablet(s)DSLD:19028
ChildLife EssentialsOmega-3 DHA + Choline SoftChew Gummies Natural Passion Fruit Flavor50 mgper 1 Tablet(s)DSLD:327007
ChildLife EssentialsPure Arctic Cod Liver Oil Natural Strawberry Flavor800 mgper 2.5 mLDSLD:241499
Country LifeBaby Care Prenatal Omega 3-6-9Fish Oil Concentrate · EPA (Form: from Fish Oil concentrate) (Alt. Name: Eicosapentaenoic Acid) Note: Omega 3100 mgper 2 Softgel(s)DSLD:182476
Country LifeOmega 3 MoodFish Oil Concentrate · Eicosapentaenoic Acid Note: from fish oil concentrate - sardine, anchovy1,000 mgper 2 Softgel(s)DSLD:1609
Custom Health CentersOmega III432 mgper 1 Softgel(s)DSLD:272714
CymbiotikaThe Omega Organic Lemon10 mgper 2 mLDSLD:253167
Daily HealthOmega 8060 Natural Lemon Flavored864 mgper 2 Softgel(s)DSLD:248017
Daily HealthOmega 8060 Natural Lemon Flavored864 mgper 2 Softgel(s)DSLD:248082
Doctor GilmoreHeart Smart Fish Oil Softgels450 mgper 1 Softgel(s)DSLD:182027
Doctor's BestHigh Concentrate EPA plus CoQ10 with KD-Pur EPA and BioPerineEthyl Ester · KD-Pur EPA (Form: as Ethyl Ester) (Alt. Name: Eicosapentaenoic Acid)800 mgper 2 Softgel(s)DSLD:203362
dotFITSuper Omega-3360 mgper 1 Softgel(s)DSLD:12984
Douglas LaboratoriesCardiovascular Health Pack300 mgper 1 Packet(s)DSLD:9599
Douglas LaboratoriesDiabet Support Pack660 mgper 1 Packet(s)DSLD:28174
Douglas LaboratoriesDiabet-Support Pack660 mgper 1 Packet(s)DSLD:9619
Douglas LaboratoriesEssential-4 Nutrition Pack660 mgper 1 Packet(s)DSLD:10038
Douglas LaboratoriesMetabolic Management Pack660 mgper 1 Packet(s)DSLD:9593
Douglas LaboratoriesMetabolic Rejuvenation Week 4 Renew330 mgper 1 PackDSLD:261764
Douglas LaboratoriesSenior Men's Pack660 mgper 1 Packet(s)DSLD:9601
Douglas LaboratoriesUltra Cardio Support Pack660 mgper 1 Packet(s)DSLD:10045
Douglas LaboratoriesUltra Cardio Support Pack660 mgper 1 Packet(s)DSLD:27277
Douglas LaboratoriesUltra Preventive V Plus Chel300 mgper 1 Packet(s)DSLD:9714
Douglas LaboratoriesWeek Four: Renew330 mgper 1 Packet(s)DSLD:231039
Douglas LaboratoriesWeek Four: Renew660 mgper 2 Packet(s)DSLD:63562
Douglas LaboratoriesWeek Four: Repair660 mgper 2 Packet(s)DSLD:6220
Dr. BergCod Liver Oil Capsules44 mgper 3 Capsule(s)DSLD:316054
Dr. Clark StoreOmega-3 1000 mg245 mgper 1 Softgel(s)DSLD:220015
Dr. LaMar's ProductsOmega3580 mgper 2 Capsule(s)DSLD:180401
Dr. SinatraOmega Q Plus 100200 mgper 2 Softgel(s)DSLD:239716
Dr. Stan GubermanUltimate Joint Repair Platinumamount not statedper 4 Capsule(s)DSLD:33067
Dr. Stan GubermanUltimate Omega340 mgper 1 Softgel(s)DSLD:33066
Dr. TobiasOptimum Omega 3 Fish Oil Triple Strength800 mgper 2 Softgel(s)DSLD:73062
Elevation HealthKrill Oil150 mgper 1 Gelcap(s)DSLD:37474
Endo-met LaboratoriesEPA-DHA150 mgper 1 Softgel(s)DSLD:229075
Endo-met LaboratoriesEPA-DHA150 mgper 1 Softgel(s)DSLD:229079
Esmond Natural180/120 Fish Oil 1000 mg180 mgper 1 Softgel(s)DSLD:178602
Evlution NutritionFish Oil 1250 mg450 mgper 1 Softgel(s)DSLD:239648
Evlution NutritionOmega-3 Fish Oil 1250 mg450 mgper 1 Softgel(s)DSLD:326405
Finest NaturalFish Oil Mini-Gels Regular Strength 600 mg162 mgper 1 Softgel(s)DSLD:25940
Finest NaturalFish Oil Triple Strength 1400 mg647 mgper 1 Softgel(s)DSLD:13190
Finest NaturalMen's 50+ AdvancedEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3552 mcgper 1 Capsule(s)DSLD:13254
Finest NutritionCod Liver Oil 415 mg37 mgper 1 Softgel(s)DSLD:207018
Finest NutritionDouble Strength Fish Oil 1200 mgEPA Note: Omega 3 Fatty Acids324 mgper 1 Softgel(s)DSLD:207283
Finest NutritionFish Oil + D3324 mgper 1 Softgel(s)DSLD:65365
FitLineGeneration 50+3.4 mgper 5 Gram(s)DSLD:321592
Fresh NutritionFish OilOmega-3 EPA (Alt. Name: Eicosapentaenoic Acid)180 mgper 2 Softgel Capsule(s)DSLD:241928
Gaspari NutritionOmega-3 2400 mgOmega-3 Eicosapentaenoic Acid (Alt. Name: EPA)960 mgper 1 Softgel(s)DSLD:223186
Genestra BrandsSuper EFA Liquid Natural Orange Flavor950 mgper 2.5 mLDSLD:176640
GesticareDHA Capsule0.625 mgper 1 Gelatin Capsule(s)DSLD:43186
GNCCod Liver Oil160 mgper 1 Softgel Capsule(s)DSLD:328783
GNCDHA 600omega-3250 mgper 1 Softgel Capsule(s)DSLD:305831
GNCTriple Strength EPA 1000 MiniEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-31,000 mgper 2 Softgel(s)DSLD:228789
GNCTriple Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3540 mgper 1 Yellow Softgel Capsule(s)DSLD:44713
GNC Beyond RawTriple Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3540 mgper 1 Yellow Softgel Capsule(s)DSLD:63775
GNC Mega MenConcentrated Mini Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3357 mgper 1 Yellow Softgel Capsule(s)DSLD:27472
GNC Mega MenDouble Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3360 mgper 1 Light Yellow Softgel Capsule(s)DSLD:33551
GNC Mega MenDouble Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3360 mgper 1 Softgel(s)DSLD:3554
GNC Mega MenDouble Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3360 mgper 1 Softgel(s)DSLD:5893
GNC Mega MenDouble Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3360 mgper 1 Light Yellow Softgel Capsule(s)DSLD:66736
GNC Mega MenFish Oil with CoQ-10EPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3360 mgper 1 Softgel(s)DSLD:15716
GNC Mega MenFish Oil with CoQ-10EPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3360 mgper 1 Green Softgel Capsule(s)DSLD:33634
GNC Mega MenHeart & Eye HealthEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3540 mgper 1 Softgel(s)DSLD:220279
GNC Mega MenHigh Potency Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3540 mgper 1 Softgel(s)DSLD:219870
GNC Mega MenMemoralFish Oil · EPA (Form: as Fish Body Oil) (Alt. Name: Eicosapentaenoic Acid, Omega-3)360 mgper 1 Softgel(s)DSLD:15717
GNC Mega MenMemorallFish Oil · EPA (Form: as Fish Body Oil) (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3100 mgper 1 Dark Brown Softgel Capsule(s)DSLD:33652
GNC Mega MenTriple Strength Fish oilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3540 mgper 1 Amber Softgel(s)DSLD:19430
GNC Mega MenTriple Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 1 Softgel(s)DSLD:3560
GNC MilestonesConcentrated Mini Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3357 mgper 1 Yellow Softgel Capsule(s)DSLD:65759
GNC MilestonesConcentrated Mini Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3357 mgper 1 Yellow Softgel Capsule(s)DSLD:65775
GNC Preventive NutritionBlood Pressure FormulaEPA Note: Omega-3 EPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3360 mgper 2 Softgel(s)DSLD:1634
GNC Preventive NutritionEye Health FormulaFish Oil · fish body304 mgper 2 Softgel Capsule(s)DSLD:304446
GNC Preventive NutritionFish Oil With PolysterolsEicosapentaenoic Acid Note: omega-3323.5 mgper 1 Softgel(s)DSLD:3534
GNC Preventive NutritionMemorallFish Oil · EPA (Form: as Fish Body Oil) (Alt. Name: Eicosapentaenoic acid)200 mgper 2 Softgel(s)DSLD:1837
GNC Preventive NutritionMulti-OilEPA - omega-3 (Alt. Name: Eicosapentaenoic Acid)180 mgper 3 Soft Gel Capsule(s)DSLD:1838
GNC Preventive NutritionTriple Strength Fish OilEPA Note: Omega-3 EPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 1 Softgel(s)DSLD:3519
GNC Pro Performance AMPTriple Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 1 Softgel Capsule(s)DSLD:45113
GNC SelectFish Oil160 mgper 1 Softgel(s)DSLD:313698
GNC SelectOmega 3-6-9 LemonOmega-3 Fatty Acids180 mgper 3 Softgel(s)DSLD:313699
GNC Total LeanLiquid CLAFish Oil · Eicosapentaenoic Acid (Form: from Fish Oil) (Alt. Name: EPA)50 mgper 1.5 tspDSLD:69551
GNC Total LeanPremium CLA 3-6-9Fish Oil · EPA (Form: from Fish Oil) (Alt. Name: Eicosapentaenoic Acid) Note: Omega-392 mgper 2 Softgel(s)DSLD:213499
GNC Total LeanPremium CLA ComplexFish Oil · EPA (Form: from Fish Body Oil, Omega-3) (Alt. Name: Eicosapentaenoic Acid)92 mgper 2 Softgel(s)DSLD:27243
GNC Total Lean AdvancedPremium CLA 3-6-9Fish Oil · EPA (Form: from Fish Oil) (Alt. Name: Eicosapentaenoic Acid) Note: Omega-392 mgper 2 Softgel(s)DSLD:74477
GNC Triple StrengthEPA 1000EPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-31,000 mgper 1 Softgel Capsule(s)DSLD:36102
GNC Triple StrengthFish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 1 Softgel(s)DSLD:1024
GNC Triple StrengthFish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 1 Softgel(s)DSLD:219248
GNC Triple StrengthFish Oil + Vitamin D-3EPA Note: Omega-3 EPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 1 Softgel(s)DSLD:830
GNC Triple StrengthFish Oil +Co Q-10EPA Note: Omega-3 EPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 1 Softgel(s)DSLD:831
GNC Triple StrengthFish Oil +KrillEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 2 Softgel(s)DSLD:1073
GNC Triple StrengthFish Oil +ResveratrolEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 1 Softgel(s)DSLD:1071
GNC Triple StrengthFish Oil SportEPA Note: Omega-3 EPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 2 Softgel(s)DSLD:1651
GNC Triple StrengthOmega ComplexEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 3 Softgel(s)DSLD:1050
GNC Ultra Mega GreenOmega ComplexEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3215.7 mgper 1 Softgel(s)DSLD:11609
GNC Women'sFish Body OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3540 mgper 1 Amber Softgel Capsule(s)DSLD:243671
GNC Women's Ultra MegaConcentrated Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3357 mgper 1 Yellow Softgel Capsule(s)DSLD:42241
GNC Women's Ultra MegaConcentrated Mini Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3357 mgper 1 Yellow Softgel Capsule(s)DSLD:33540
GNC Women's Ultra MegaDouble Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3360 mgper 1 Yellow Softgel Capsule(s)DSLD:83088
GNC Women's Ultra MegaFish Oil With CoQ10EPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3360 mgper 1 Green Softgel Capsule(s)DSLD:33505
GNC Women's Ultra MegaHeart & Eye HealthEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3540 mgper 1 Amber Softgel(s)DSLD:69499
GNC Women's Ultra MegaMemorallFish Oil · EPA (Form: as Fish Body Oil) (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3100 mgper 1 Dark Brown Softgel Capsule(s)DSLD:33514
GNC Women's Ultra MegaTriple Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3540 mgper 1 Capsule(s)DSLD:19466
GNC Women's Ultra MegaTriple Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 1 Softgel(s)DSLD:5895
Gottfried InstituteHormone Balancing EssentialsFish Oil · EPA (Form: from Fish Oil) (Alt. Name: Eicosapentaenoic Acid)300 mgper 1 Packet(s)DSLD:45504
hank & brian'sEssential Fats Plus E120 mgper 2 Softgel Capsule(s)DSLD:254898
HBC ProtocolsOmega Complex180 mgper 3 Softgel(s)DSLD:74974
HerbadietOmega 3 (DHA + EPA)Standardized to contain min 9% EPA600 mgper 2 Capsule(s)DSLD:257823
HerbadietOmega 3 (DHA + EPA)Standardized to contain min 9% EPA300 mgper 1 Capsule(s)DSLD:293585
HerbTonicsTriglyceride Form Omega-3 2500 mg Lemon Flavored900 mgper 2 Soft Gel(s)DSLD:287069
High Performance NutritionN(4)1,080 mgper 3 Softgel(s)DSLD:271158
Higher NatureComplete Omegas 3:6:7:9680 mgper 4 Capsule(s)DSLD:228412
Higher NatureComplete Omegas 3:6:7:9170 mgper 1 Capsule(s)DSLD:240570
Higher NatureComplete Omegas 3:6:7:9680 mgper 4 Capsule(s)DSLD:245644
Higher NatureComplete Omegas 3:6:7:9680 mgper 4 Capsule(s)DSLD:245645
Higher NatureComplete Omegas 3:6:7:9680 mgper 4 Capsule(s)DSLD:245653
Higher NatureComplete Omegas 3:6:7:9680 mgper 4 Capsule(s)DSLD:41470
Higher NatureComplete Omegas 3:6:7:9680 mgper 4 Capsule(s)DSLD:41474
Higher NatureComplete Omegas 3:6:7:9680 mgper 4 Capsule(s)DSLD:41475
Higher NatureComplete Omegas 3:6:7:9680 mgper 4 Capsule(s)DSLD:41485
Higher NatureEssential Omegas 3:6:7:9170 mgper 1 Capsule(s)DSLD:42576
Higher NatureKeep Sharp54 mgper 1 Jelly(s)DSLD:178205
Higher NatureLemon Fish Oil690 mgper 2.5 mLDSLD:217005
Higher NatureOmega 3 Fish Oil 1000 mg180 mgper 1 Softgel Capsule(s)DSLD:40716
Higher NatureOmega 3 Fish Oil 1000 mg180 mgper 1 Softgel Capsule(s)DSLD:40930
Higher NatureOmega 3 Fish Oil 1000 mg180 mgper 1 Softgel Capsule(s)DSLD:40933
Higher NatureSuper Potency Fish Oil500 mgper 1 Capsule(s)DSLD:246034
Higher NatureSuper Potency Fish Oil500 mgper 1 Softgel Capsule(s)DSLD:304553
Higher Nature KidsSmart Focus Intensely Fruity Flavoured Jellies155 mgper 1 Jelly(s)DSLD:216996
HoltraCeuticalsUltra Omega420 mgper 1 Softgel(s)DSLD:19884
Igennus Healthcare NutritionMarine Ethyl-EPA 70%280 mgper 1 Capsule(s)DSLD:249520
Indiana Botanic GardensRed Krill Oil 500 mg20:5 - EPA15 mgper 1 Softgel(s)DSLD:46982
Iron-TekEssential Muscle LipidsFish Oil Concentrate · Eicosapentaenoic Acid (Form: from Fish Oil Concentrate (Form: Anchovy, Mackerel, Sardine)) (Alt. Name: EPA)240 mgper 2 Softgel(s)DSLD:2918
Irwin KidsOmega-3 Citrus-Chews Super Citrus Soft ChewsFish Oil · EPA (Form: from Fish Oil) (Alt. Name: Eicosapentaenoic Acid) Note: omega-3 fatty acid63 mgper 1 Soft Chew(s)DSLD:45699
iwiBeautyNannochloropsis · Almega PL (Form: from Nannochloropsis Genus: Nannochloropsis)600 mgper 2 Softgel(s)DSLD:247652
iwiCholesterolNannochloropsis sp. · Almega PL (Form: from Nannochloropsis sp. Genus: Nannochloropsis Species: sp.)1,100 mgper 2 Softgel(s)DSLD:247656
iwiCholesterolNannochloropsis sp. · Almega PL (Form: from Nannochloropsis sp. Genus: Nannochloropsis Species: sp.)1,100 mgper 2 Softgel(s)DSLD:247661
iwiHeartNannochloropsis1,100 mgper 2 Softgel(s)DSLD:295368
iwiImmunityNannochloropsis · Almega PL (Form: from Nannochloropsis Genus: Nannochloropsis)400 mgper 2 Softgel(s)DSLD:247675
John Gilmore, MDHeart Smart Fish Oil Softgels450 mgper 1 Softgel(s)DSLD:267848
JuvenonEssential Omega-3600 mgper 2 Softgel(s)DSLD:261896
KidzPlayBrainy Play155 mgper 1 mLDSLD:22250
KirkmanAll Natural Cod Liver Oil Liquid250 mgper 0.5 Teaspoon(s)DSLD:23981
KirkmanAll Natural Cod Liver Oil Liquid250 mgper 0.5 Teaspoon(s)DSLD:23986
KirkmanCod Liver Oil Liquid150 mgper 2.5 mLDSLD:259995
KirkmanCod Liver Oil Liquid Natural Lemon Lime Flavor150 mgper 2.5 mLDSLD:317718
Krill Doctor ProfessionalKrill Omega-3150 mgper 2 Softgel(s)DSLD:175022
Life ExtensionOmega-3 Lemon Whirl658 mgper 1 TbspDSLD:58974
Life ExtensionOmega-3 Tropical Whirl658 mgper 1 TbspDSLD:58979
Living FuelSuper Essentials Omegas 3EDA+Fish Oil · EPA (Form: from purified Fish Oils) (Alt. Name: Eicosapentanoic Acid) Note: 20:5 omega 3120 mgper 1 Softgel(s)DSLD:282561
Mason NaturalNorwegian Salmon Oil 2000 mg180 mgper 2 Softgel(s)DSLD:244788
Maxi HealthMaxi-Omega-3 Concentrate680 mgper 2 Softgel(s)DSLD:295567
Mental RefreshmentKrill Oil 1000 mg130 mgper 2 Capsule(s)DSLD:247641
MerovenReliven4,000 mgper 2 Sachet(s)DSLD:263380
MetagenicsOmegaGenics EPA 1200 Natural Lemon-Lime FlavorEicosapentaenoic Acid Ethyl Ester1,200 mgper 1 Softgel(s)DSLD:295808
MetagenicsPlusOne670 mgper 1 Packet(s)DSLD:216819
MetagenicsWellness Essentials Brain HealthEPA (Form: Eicosapentaenoic Acid Triglyceride)250 mgper 1 Packet(s)DSLD:211103
Method PharmaceuticalsDothelle DHA Softgels39 mgper 1 Capsule(s)DSLD:263294
Mission Pharmacal CitraNatalCitraNatal 90 DHA 300 mg DHA Soft Gel0.75 mgper 1 Softgel(s)DSLD:240145
Mission Pharmacal CitraNatalCitranatal 90 DHA Gelatin Capsule0.75 mgper 1 Gelatin Capsule(s)DSLD:45458
Mission Pharmacal CitraNatalCitraNatal 90 DHA Gelatin Capsule0.75 mgper 1 Gelatin Capsule(s)DSLD:63755
Mission Pharmacal CitraNatalCitranatal 90 DHA Soft Gel0.75 mgper 1 Softgel(s)DSLD:215339
Mission Pharmacal CitraNatalCitraNatal Assure 300 mg DHA Soft Gel0.75 mgper 1 Softgel(s)DSLD:206922
Mission Pharmacal CitraNatalCitraNatal Assure DHA Capsule0.75 mgper 1 Capsule(s)DSLD:37182
Mission Pharmacal CitraNatalCitraNatal Assure DHA Gelatin Capsule0.75 mgper 1 Capsule(s)DSLD:63989
Mission Pharmacal CitraNatalCitraNatal Assure DHA Soft Gel0.75 mgper 1 Softgel(s)DSLD:215277
Mission Pharmacal CitraNatalCitraNatal DHA Gelatin Capsule0.65 mgper 1 Gelatin Capsule(s)DSLD:45465
Mission Pharmacal CitraNatalCitraNatal DHA Soft Gel0.75 mgper 1 Softgel(s)DSLD:241671
Mountain Meadow HerbsKrill Oil 1000 mg60 mgper 1 Softgel(s)DSLD:327798
Mountain Meadow HerbsKrill Oil 1200 mg170 mgper 1 Softgel(s)DSLD:267493
MRI PerformanceOmega 3omega-3647 mgper 1 Softgel(s)DSLD:313484
MusclePharmFish Oil400 mgper 1 Soft Gel(s)DSLD:17995
MuscleSportLipoSlim for HerDeep Sea Cold Water Fish Oil Complexamount not statedper 2 Softgel(s)DSLD:256919
Natural Cell SupplementsOmegaActiv432 mgper 1 Softgel(s)DSLD:317955
Natural ClinicianClinical EPA/DHA Forte600 mgper 1 Softgel(s)DSLD:18623
Natural Health Improvement CenterEnteric Coated Fish Oil660 mgper 2 Softgel(s)DSLD:71195
Natural NutraKrill Oil65 mgper 1 Softgel(s)DSLD:246973
Nature's BountyHeart Health Support Packamount not statedper 1 Packet(s)DSLD:3788
Nature's LifeOmega 3 EFA Complex540 mgper 3 Softgel(s)DSLD:47347
Natures CraftOmega-3 Fish Oil 1200 mg432 mgper 1 Softgel(s)DSLD:256575
NaturesPlusOmega Krill Oil 600 mg77 mgper 1 Liquid-Filled Capsule(s)DSLD:298566
NCBAlaska Deep Sea Fish Oil360 mgper 2 Softgel(s)DSLD:13732
New AgeFish Oil 2500 mg896 mgper 2 Softgel(s)DSLD:268645
Nordic NaturalsChildren's DHA Strawberry170 mgper 2.5 mLDSLD:214259
Nordic NaturalsChildren's DHA Strawberry170 mgper 2.5 mLDSLD:277314
North American Herb & SpicePurelyPak107 mgper 7.3 Gram(s)DSLD:270080
North American Herb & SpicePurelyPak143 mgper 7.3 Gram(s)DSLD:307960
NOWDouble Strength DHA-500amount not statedper 1 Softgel(s)DSLD:314277
Nutra SportPerformance Omega-3420 mgper 1 Softgel(s)DSLD:319228
NutraChampsOmega 3 Fish Oil 3,600 mg Natural Lemon Flavor1,296 mgper 3 Softgel(s)DSLD:228956
NutraKeyFish Oil 1000 mg180 mgper 1 Softgel(s)DSLD:287400
Nutri-RichUltra EPA + DHA 1,000 mg750 mgper 2 Softgel(s)DSLD:176515
Nutri-RichUltra EPA + DHA 1,000 mg750 mgper 2 Softgel(s)DSLD:214108
Nutri-WestComplete Hi-Potency Omega-3 LiquidFish · EPA (Form: contains Fish) (Alt. Name: Eicosapentaenoic Acid)1,600 mgper 1 Teaspoon(s)DSLD:27617
NutriCologySuper Immuno Complex360 mgper 1 Packet(s)DSLD:183928
NutriSuppzSuper Krill Oil Complex 500 mg165 mgper 1 Softgel(s)DSLD:268894
OL Olympian LabsKrill Oil 1000 mg150 mgper 2 Softgel(s)DSLD:326672
OL Olympian LabsKrill Oil 1000 mg150 mgper 2 Softgel(s)DSLD:326661
OL Olympian LabsKrill Oil 500 mg75 mgper 1 Softgel(s)DSLD:175745
OL Olympian LabsNorwegian Salmon Oil360 mgper 3 Softgel(s)DSLD:9738
OmegaWorksDelicious Omega 3 Liquid Formula800 mgper 1 tspDSLD:7686
OmegaWorksSuper Omega 3300 mgper 1 Softgel(s)DSLD:259729
Orphic NutritionOmega 3 Fish Oil 2160 mg1,296 mgper 1 Softgel(s)DSLD:285532
Ortho Molecular ProductsOrthomega Select DHA130 mgper 1 Softgel Capsule(s)DSLD:174227
Ortho Molecular ProductsOrthomega Select EPA660 mgper 1 Softgel Capsule(s)DSLD:174221
Ortho Molecular ProductsPrenatal Complete with DHA130 mgper 3 Capsule(s)DSLD:175696
PerqueEPA/DHA Guard660 mgper 2 Softgel(s)DSLD:240750
PerqueEPA/DHA Guard660 mgper 2 Softgel(s)DSLD:240753
PerqueEPA/DHA Guard Softgels660 mgper 2 Softgel(s)DSLD:18732
PerqueEPA/DHA Guard Softgels660 mgper 2 Softgel(s)DSLD:18733
PharmaxBerry Frutol500 mgper 10 mLDSLD:238900
PharmaxCardol300 mgper 1 tspDSLD:55422
PharmaxDHA TasteBurst Natural Orange FlavorTuna Oil · Eicosapentaenoic acid (Form: provided as Tuna oil) (Alt. Name: EPA)30 mgper 2 Chewable Soft Gel(s)DSLD:55433
PharmaxFinest Pure Cod Liver Oil377 mgper 0.5 tspDSLD:55776
PharmaxFinest Pure Fish Oil950 mgper 0.5 tspDSLD:176136
PharmaxFinest Pure Fish Oil950 mgper 0.5 tspDSLD:55813
PharmaxFinest Pure Fish Oil850 mgper 1 tspDSLD:70995
PharmaxFinest Pure Fish Oil Capules524 mgper 2 Capsule(s)DSLD:55371
PharmaxFinest Pure Fish Oil Plus CoQ10 Natural Orange Flavor930 mgper 1 tspDSLD:55432
PharmaxFinest Pure Krill Oil130 mgper 2 Capsule(s)DSLD:55436
PharmaxFrutol250 mgper 1 tspDSLD:55369
PharmaxFrutol with Full Spectrum Multivitamins237.5 mgper 1 tspDSLD:55787
PharmaxHigh DHA Berry Frutol296 mgper 2 tspDSLD:55391
PharmaxHigh DHA Omega-3 Fatty AcidsTuna Oil · Eicosapentaenoic acid (Form: provided as Tuna oil) (Alt. Name: EPA)45 mgper 1 Softgel Capsule(s)DSLD:70981
PharmaxHigh EPA Finest Pure Fish Oil Natural Orange Flavor1,225 mgper 1 tspDSLD:55431
PharmaxOmega-3 Fatty Acids395 mgper 1 Capsule(s)DSLD:55838
PharmaxOmega-3 Fatty Acids395 mgper 1 Capsule(s)DSLD:55888
PharmaxOmega-3 Fatty Acids395 mgper 1 Capsule(s)DSLD:56157
PharmaxOmega-3 Fatty Acids395 mgper 1 Softgel(s)DSLD:70941
PharmaxOmega-3 Fatty Acids395 mgper 1 Softgel(s)DSLD:71006
Physician's StrengthPotentPak143 mgper 7.3 Gram(s)DSLD:268772
Phyto ParisPhytophanere3.2 mgper 2 Caplet(s)DSLD:206205
Primal HarvestPrimal Omega-3600 mgper 2 Softgel(s)DSLD:277139
Primal PharmOMEGA432 mgper 1 Softgel(s)DSLD:276404
ProceraOmega-3432 mgper 1 Softgel(s)DSLD:293227
Progressive Professional from Progressive LaboratoriesEPA-DHA 1000 mg150 mgper 1 Softgel Capsule(s)DSLD:261658
Pure EncapsulationsEPA/DHA Vegetarian155 mgper 2 Caplique(R) Capsule(s)DSLD:182879
Pure EncapsulationsEPA/DHA Vegetarian155 mgper 2 Caplique(R) Capsule(s)DSLD:184456
Pure Label NutritionKrill Oil 1000 mg60 mgper 2 Capsule(s)DSLD:269590
Pure OneAlgae Oil3.5 mgper 1 Softgel(s)DSLD:43285
Pure OneAlgae Omega-37 mgper 2 Vegetarian Softgel(s)DSLD:211607
Pure OneDHAlicious Organic Lemon & Green Tea Flavor15 mgper 1 mLDSLD:202540
Pure OneDHAlicious Organic Lemon Flavored3.5 mgper 0.5 mLDSLD:202543
Pure PrescriptionsPremium Omega-3EPA (Form: as Triglycerides) (Alt. Name: Eicosapentaenoic Acid)80 mgper 2 Softgel(s)DSLD:228209
Purely OptimalOmega 3 Fish Oil Natural Lemon Flavor864 mgper 2 Softgel(s)DSLD:244054
Purity LabsAntarctic Krill Oil120 mgper 2 Softgel(s)DSLD:313927
Remedys NutritionUltimate Omega-3 Fish Oil120 mgper 1 Vegetarian Capsule(s)DSLD:272190
Renew LifeSuper Critical Omega1,560 mgper 1 Softgel(s)DSLD:2345
Renew Life Norwegian GoldEPA 1000 Omega Natural Orange FlavorOmega-3 EPA (Alt. Name: Eicosapentaenoic Acid)2,000 mgper 1 Softgel(s)DSLD:62527
Rite Aid PharmacyNatural Fish Oil 1000 mgEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3320 mgper 2 Softgel(s)DSLD:181533
Rite Aid PharmacyNatural Fish Oil 1000 mgEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3320 mgper 2 Softgel(s)DSLD:239751
Rite Aid PharmacyOmega 3-6-9 Lemon Natural FlavorEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3180 mgper 3 Softgel Capsule(s)DSLD:239828
RugbyOmega-3 Krill Oil30 mgper 1 Softgel(s)DSLD:201205
Salaam NutritionalsOmega 3 Fish Oil800 mgper 2 Softgel(s)DSLD:292292
Salaam NutritionalsPrenatal11 mgper 4 Gummy(ies)DSLD:247265
Salaam NutritionalsPrenatal DHA + Folate11 mgper 4 Gummy(ies)DSLD:292290
Science Natural SupplementsOmega-3X EPA 432 mg/DHA 288 mg432 mgper 1 Softgel(s)DSLD:276468
SeniorLife HealthOmega 3-6-9 Complete72 mgper 1 Softgel(s)DSLD:256552
SFHSO3 Super Omega 3 LemonEPA (Alt. Name: Eicosapentaenoic Acid) Note: 1500-1630mg1,630 mgper 1 tspDSLD:16320
SFHSO3 SuperOmega3 LemonEPA (Alt. Name: Eicosapentaenoic Acid) Note: 1500-1630mg1,630 mgper 1 tspDSLD:16322
ShakleeVegan Omega-3Algal100 mgper 2 Softgel(s)DSLD:318625
SimplySupplementsOmega 3 Fish Oil 1000 mg180 mgper 1 Capsule(s)DSLD:22011
SimplySupplementsOmegaMax430 mgper 1 Capsule(s)DSLD:22533
SmarterVitaminsOmega-3 Strawberry Flavored800 mgper 2 Softgel(s)DSLD:243878
SomaLife InternationalOmega-3EPA Note: Min 30%360 mgper 1 Capsule(s)DSLD:33371
Source NaturalsComplete Essential Fatty AcidsEicosapentaenoic Acid (Alt. Name: EPA) Note: Omega-3288 mgper 3 Softgel(s)DSLD:214196
Source NaturalsComplete Essential Fatty AcidsEicosapentaenoic Acid (Alt. Name: EPA) Note: Omega-3288 mgper 3 Softgel(s)DSLD:214207
Source NaturalsOmega 3-6-9Eicosapentaenoic Acid (Alt. Name: EPA) Note: omega-3298 mgper 3 Softgel(s)DSLD:273928
Source NaturalsOmega 3-6-9Omega-3298 mgper 3 Softgel(s)DSLD:275607
Source NaturalsOmegaEPA Fish Oil 175 mgper 1 Softgel(s)DSLD:275432
Source NaturalsVegan Omega-3s 300 mg180 mgper 1 Softgel(s)DSLD:273971
Source NaturalsVegan Omega-3s 300 mg180 mgper 1 Softgel(s)DSLD:273974
Source NaturalsVegan Omega-3s 300 mg180 mgper 1 Softgel(s)DSLD:78805
Source NaturalsVegan True Non-Fish Omega-3s 300 mg180 mgper 1 Softgel(s)DSLD:274005
Source OilAlgae Omega-320 mgper 2 mLDSLD:211605
Source OilAlgae Omega-3 Organic Lemon Flavor20 mgper 0.5 Teaspoon(s)DSLD:211612
SP Standard ProcessCalamari Omega-3 Liquid400 mgper 5 mLDSLD:256403
SP Standard ProcessCod Liver Oil210 mgper 3 Softgel(s)DSLD:256486
SP Standard ProcessCod Liver Oil210 mgper 3 Softgel(s)DSLD:340155
SP Standard ProcessGeneral Health Daily Fundamentals60 mgper 1 Pack(s)DSLD:292105
SP Standard ProcessTuna Omega-3 Chewable50 mgper 2 Softgel(s)DSLD:340291
Spring ValleyAdult Gummy Omega-3 Complex with EPA/DHA10 mgper 2 Gummie(s)DSLD:73430
SuntoryDHA & EPA Sesamin EX100 mgper 4 Softgel(s)DSLD:174978
SuperSmartSuper Omega 3 1500 mgFish Oil · in Triglyceride form465 mgper 1 Softgel(s)DSLD:315661
Supplement SpotEssential Prostate Packfish oil125 mgper 1 Packet(s)DSLD:264557
SynergyNorwegian Cod Liver Oil Lemon400 mgper 5 mLDSLD:277453
Systemic Formulas Bio NutrimentOMGA LQ310 mgper 2 mLDSLD:22120
The Honest Co.Baby DHA140 mgper 1 mLDSLD:206813
The Honest Co.DHA/Omega-322 mgper 1 Softgel(s)DSLD:73709
The Vitamin ShoppeOmega 3 Fish Oil 800 EPA/500 DHA800 mgper 1 Teaspoon(s)DSLD:26980
Theralogix Nutritional ScienceTheraNatal Complete Softgel60 mgper 1 Softgel(s)DSLD:283003
Theralogix Nutritional ScienceTheraNatal One150 mgper 1 Softgel(s)DSLD:282955
Trigen LaboratoriesZatean -Pn Plus40 mgper 1 Softgel Capsule(s)DSLD:264498
TruehopeOmegapower540 mgper 3 Softgel Capsule(s)DSLD:32361
VigorSourceAlaska Deep Sea Fish Oil King360 mgper 1 Softgel(s)DSLD:12936
Village VitalityKrill Oil65 mgper 1 Softgel(s)DSLD:310246
VinsicEPA Fish Oil2,007.2 mgper 2 Softgel(s)DSLD:335761
Virtus PharmaceuticalsVirt-PN PlusEicosapentaenoic Acid (Alt. Name: EPA) Note: from at least 340 mg omega-3s from at least 390 purified fish oils.40 mgper 1 Softgel(s)DSLD:180537
VitabaseComplete Essential Fatty Acids69 mgper 1 Softgel(s)DSLD:6864
VitabaseKrill Oil 500 mg81 mgper 1 Softgel(s)DSLD:6160
VitabaseMaxEPA Omega-3 1000 mg180 mgper 1 Softgel(s)DSLD:6906
VitaCeutical LabsCardio Support Softgels120 mgper 1 Softgel(s)DSLD:6276
VitaCeutical LabsEPA & DHA180 mgper 1 Softgel(s)DSLD:53841
VitaCeutical LabsEPA & DHA180 mgper 1 Softgel(s)DSLD:6307
VitaCeutical LabsKrill Oil65 mgper 1 Softgel(s)DSLD:53560
Vital NutrientsUltra Omega CombinationEPA (Alt. Name: Eicosapentaenoic Acid) Note: 240-264mg264 mgper 2 Softgel(s)DSLD:6322
Vital NutrientsUltra Pure Cod Liver Oil 1025 Lemon Flavored320 mgper 5 mLDSLD:305170
Vital NutrientsUltra Pure Fish Oil 350 Lemon Flavor360 mgper 1 Softgel(s)DSLD:223052
Vital NutrientsUltra Pure Fish Oil 350 Lemon Flavor360 mgper 2 Softgel(s)DSLD:305174
Vitamer LaboratoriesHigh Potency Liquid Omega-3705 mgper 1 tspDSLD:53242
Vitamer LaboratoriesHigh Potency Liquid Omega-3 Orange675 mgper 1 tspDSLD:53168
Vitamer LaboratoriesKrill Oil65 mgper 1 Softgel(s)DSLD:23274
Vitamer LaboratoriesKrill Oil65 mgper 1 Softgel(s)DSLD:67592
Viva NaturalsLiquid Omega-3 Fish Oil Lemon SwirlEPA (Form: as TG) (Alt. Name: Eicosapentaenoic Acid)875 mgper 5 mLDSLD:248115
Viva NaturalsTriple-Strength Omega-3 Fish OilEPA (Form: as TG) (Alt. Name: Eicosapentaenoic Acid)1,400 mgper 2 Softgel(s)DSLD:247978
Viva NaturalsTriple-Strength Omega-3 Fish OilEPA (Form: as TG) (Alt. Name: Eicosapentaenoic Acid)1,400 mgper 2 Softgel(s)DSLD:248141
Viva VitaminsFish Oil Omega-3180 mgper 1 Softgel(s)DSLD:1792
VQ Verified QualityOmega 3 Fish Oil 180 mg EPA/120 mg DHA Lemon FlavorEPA Note: 180-190mg190 mgper 1 Softgel(s)DSLD:33987
Wholly LiquidOmega Plus400 mgper 1 Softgel(s)DSLD:272113
Wholly LiquidOmega Plus400 mgper 1 Softgel(s)DSLD:321788
Women's Choice PharmaceuticalsDHA/EPA CapsuleFish Oil · Eicosapentaenoic Acid (Form: derived from Fish Oil Note: product of Norway) (Alt. Name: EPA)30 mgper 1 Capsule(s)DSLD:241428
Womens Choice PharmaceuticalsOmega 3-DHA180 mgper 1 Softgel(s)DSLD:37269
WP Westminster PharmaceuticalsWestGel DHA15 mgper 1DSLD:264460
XtendlifeOmega 3/QH Premium CoQ10300 mgper 2 Softgel(s)DSLD:331305
ZahlerOmega 3 Liquid1,400 mgper 1 tspDSLD:33312
ZahlerOmega 3 Liquid1,400 mgper 1 tspDSLD:33314

Label record: NIH Office of Dietary Supplements · CC0

Papers screened

1,834 papers

Compound: all-cis-5,8,11,14,17-icosapentaenoic acid
Screened: 1,834
Admitted: 7
Discarded: 1,243
Not read: 584
Showing: 200 of 1,834

The whole record

Produced a finding7 papers

and 7 more.

Read and discarded1,243 papers

PMID:10232294cited by PMID:21939614; not about the subject it would be filed under2026-10-15
PMID:11254754cited by PMID:21939614; not about the subject it would be filed under2026-10-15
PMID:12445491cited by PMID:21939614; not about the subject it would be filed under2026-10-15
PMID:12888186cited by PMID:21939614; not about the subject it would be filed under2026-10-15
PMID:14561523cited by PMID:21939614; not about the subject it would be filed under2026-10-15
PMID:15132735cited by PMID:21939614; not about the subject it would be filed under2026-10-15
PMID:15497675cited by PMID:21939614; not about the subject it would be filed under2026-10-15
PMID:16316783cited by PMID:21939614; not about the subject it would be filed under2026-10-15
PMID:16499974cited by PMID:21939614; not about the subject it would be filed under2026-10-15
PMID:16741213cited by PMID:21939614; not about the subject it would be filed under2026-10-15
PMID:16829066cited by PMID:21939614; not about the subject it would be filed under2026-10-15
PMID:17188654cited by PMID:21939614; not about the subject it would be filed under2026-10-15

and 1,231 more.

Not read yet584 papers

PMID:100241082026-10-15
PMID:104876162026-10-12
PMID:149971962026-10-12
PMID:164377572026-10-12
PMID:88502162026-10-12
PMID:151891332026-10-10
PMID:161882092026-10-10
PMID:164419432026-10-10
PMID:203644382026-10-09
PMID:210592442026-10-09
PMID:21384492026-10-09
PMID:221710452026-10-09

and 572 more.

Measured, not recorded

Compound: all-cis-5,8,11,14,17-icosapentaenoic acid
Endpoints measured: 906 endpoints
Recorded as a finding: No

Show what was measured

atherosclerosis, coronary heart disease, inflammatory disease, and behavioral disorders
decreases
n-3 Fatty acids favorably affect atherosclerosis, coronary heart disease, inflammatory disease, and perhaps even behavioral disorders.
PMID:10617967 · one of two readings recorded this
nutritional status (weight), quality of life and adverse events in cancer-associated cachexia
n = 587
Not recorded as a finding: no estimate is reported anywhere
There were insufficient data to establish whether oral EPA was better than placebo.
PMID:17253515 · one of two readings recorded this
weight/nutritional status
n = 587
There were insufficient data to establish whether oral EPA was better than placebo.
PMID:17253515 · one of two readings recorded this
depression rating scale score (standardized mean difference, change from baseline)
increases, effect size 0.558 for EPA >=60% of EPA+DHA vs placebo; non-significant -0.026 for EPA <60%, n = 916
The overall effect size for 60% or greater EPA in supplements compared with placebo was 0.558 (p<0.001); for EPA at less than 60%, it was non-significant at −0.026, (see Table 2 and.
PMID:21939614 · one of two readings recorded this
depression severity, standardized mean difference from baseline to endpoint on a depression rating scale (mainly Hamilton Depression Rating Scale)
effect size 0.558 for EPA >=60% supplements vs placebo, n = 916
Not recorded as a finding: the intervention held more than the compound
The overall effect size for 60% or greater EPA in supplements compared with placebo was 0.558 (p<0.001); for EPA at less than 60%, it was non-significant at −0.026, (see Table 2 and.
PMID:21939614 · one of two readings recorded this
ADHD severity rating scale score, standardized mean difference, pooled from RCTs of omega-3 fatty acid supplementation (including eicosapentaenoic acid) versus placebo in children with ADHD symptomatology
decreases
Not recorded as a finding: this platform holds no node for the endpoint
Omega-3 fatty acid supplementation demonstrated a small but significant effect in improving ADHD symptoms.
PMID:21961774 · one of two readings recorded this
ADHD severity rating scale score (standardized mean difference)
decreases, n = 699
Omega-3 fatty acid supplementation demonstrated a small but significant effect in improving ADHD symptoms.
PMID:21961774 · one of two readings recorded this
ADHD severity, standardized mean difference on rating scales (primary)
decreases
Omega-3 fatty acid supplementation demonstrated a small but significant effect in improving ADHD symptoms.
PMID:21961774 · one of two readings recorded this
ADHD symptom severity, standardized mean difference on ADHD rating scales, omega-3 fatty acid supplementation vs placebo in children with ADHD
decreases
Not recorded as a finding: this platform holds no node for the endpoint
Omega-3 fatty acid supplementation demonstrated a small but significant effect in improving ADHD symptoms.
PMID:21961774 · one of two readings recorded this
HDL cholesterol
increases
DHA also raised high-density lipoprotein (4.49 mg/dL; 95% CI, 3.50–5.48) compared with placebo, whereas EPA did not
PMID:21975919 · one of two readings recorded this
HDL cholesterol
no effect
DHA also raised high-density lipoprotein (4.49 mg/dL; 95% CI, 3.50–5.48) compared with placebo, whereas EPA did not
PMID:21975919 · one of two readings recorded this
LDL cholesterol
increases
Compared with placebo, DHA raised LDL 7.23 mg/dL (95% CI, 3.98–10.5) whereas EPA non-significantly reduced LDL
PMID:21975919 · one of two readings recorded this
LDL cholesterol
no effect
Compared with placebo, DHA raised LDL 7.23 mg/dL (95% CI, 3.98–10.5) whereas EPA non-significantly reduced LDL
PMID:21975919 · one of two readings recorded this
LDL cholesterol
increases
In direct comparison studies, DHA raised LDL 4.63 mg/dL (95% CI, 2.15–7.10) more than EPA
PMID:21975919 · one of two readings recorded this
triglycerides
decreases
Both EPA and DHA reduced triglycerides, with a greater reduction by DHA in direct comparison studies
PMID:21975919 · one of two readings recorded this
triglycerides
decreases
Both EPA and DHA reduced triglycerides, with a greater reduction by DHA in direct comparison studies
PMID:21975919 · one of two readings recorded this
triglycerides
decreases
Both EPA and DHA reduced triglycerides, with a greater reduction by DHA in direct comparison studies
PMID:21975919 · one of two readings recorded this
membrane enrichment with eicosapentaenoic acid following intake of stearidonic-acid-fortified soybean oil
increases
Not recorded as a finding: the trial gave a chemically different species
Stearidonic acid has been shown in animal and human studies to be more effective than its precursor, α-linolenic acid, in enriching membranes with eicosapentaenoic acid.
PMID:22186661 · one of two readings recorded this
membrane enrichment with eicosapentaenoic acid
increases
Stearidonic acid has been shown in animal and human studies to be more effective than its precursor, α-linolenic acid, in enriching membranes with eicosapentaenoic acid.
PMID:22186661 · one of two readings recorded this
cardiovascular death
decreases
There was a small reduction in cardiovascular death (relative risk, 0.91; 95% CI, 0.84-0.99)
PMID:22493407 · one of two readings recorded this
overall cardiovascular events
no effect
Supplementation with omega-3 fatty acids did not reduce the risk of overall cardiovascular events (relative risk, 0.99; 95% CI, 0.89-1.09)
PMID:22493407 · one of two readings recorded this
aortic pulse pressure and aortic augmentation pressure, in the 6 g fish oil without multivitamin group
decreases
The group receiving 6 g fish oil without the multivitamin displayed a significant decrease in aortic pulse pressure and aortic augmentation pressure, two measures of aortic blood pressure and aortic stiffness.
PMID:25565485 · one of two readings recorded this
aortic pulse pressure and aortic augmentation pressure
decreases
Not recorded as a finding: the intervention held more than the compound
The group receiving 6 g fish oil without the multivitamin displayed a significant decrease in aortic pulse pressure and aortic augmentation pressure, two measures of aortic blood pressure and aortic stiffness.
PMID:25565485 · one of two readings recorded this
aortic pulse pressure and augmentation pressure
decreases
Fish oil decreased aortic pulse pressure and augmentation pressure.
PMID:25565485 · one of two readings recorded this
cognition alongside aortic blood pressure reduction
no effect
Reductions in aortic blood pressure were not accompanied by consistent improvements in cognition.
PMID:25565485 · one of two readings recorded this
cognition, relative to reductions in aortic blood pressure
no effect
Reductions in aortic blood pressure were not accompanied by consistent improvements in cognition.
PMID:25565485 · one of two readings recorded this
cognitive performance, brachial blood pressure, and aortic (central) blood pressure, measured at baseline, 6 weeks, and 16 weeks
decreases
Not recorded as a finding: the intervention held more than the compound
The group receiving 6 g fish oil without the multivitamin displayed a significant decrease in aortic pulse pressure and aortic augmentation pressure, two measures of aortic blood pressure and aortic stiffness.
PMID:25565485 · one of two readings recorded this
primary cognitive outcomes
no effect
Treatment allocation had no effect on the primary cognitive outcomes at endpoint.
PMID:25565485 · both readings recorded this
red blood cell omega-3/6 ratio and spatial working memory
increases
Absolute increases in the red blood cell omega-3/6 ratio were associated with improvements in spatial working memory.
PMID:25565485 · one of two readings recorded this
spatial working memory, in relation to red blood cell omega-3/6 ratio
increases
Absolute increases in the red blood cell omega-3/6 ratio were associated with improvements in spatial working memory.
PMID:25565485 · one of two readings recorded this
B cell antigen (OVA-FITC) uptake
decreases, p = 0.001
B cells from EFO fed mice had significantly decreased antigen uptake by 90 minutes (p < 0.001)
PMID:25616447 · one of two readings recorded this
B cell antigen (OVA-FITC) uptake
increases, p = 0.05
we observed increased antigen uptake in B cells from MO fed mice (p < 0.05) by 90 minutes of incubation with antigen
PMID:25616447 · one of two readings recorded this
B cell membrane lipid microdomain clustering
decreases
Purified B cells from mice fed MO and DFO diets had decreased clustering compared to B cells from CON and EFO mice
PMID:25616447 · one of two readings recorded this
B cell membrane lipid microdomain clustering
increases, p = 0.05
B cells from EFO fed mice had increased clustering compared to CON, MO, and DFO fed mice (all p < 0.05
PMID:25616447 · one of two readings recorded this
B cell phospholipid EPA and arachidonic acid
increases
In B cells, MO, EFO, and DFO feeding resulted in increases of EPA, and decreases of AA compared to CON fed mice
PMID:25616447 · one of two readings recorded this
B cell phospholipid EPA+DHA content
increases
we observed the same fold change between B cells of CON fed mice (2-4% EPA+DHA) compared to the fish oil treatments (7-10%)
PMID:25616447 · one of two readings recorded this
B cell phospholipid EPA ranking across diets
increases
EPA was highest in the phospholipid fatty acids of B cells from mice fed EFO, followed by MO, and lowest in DFO
PMID:25616447 · one of two readings recorded this
bone marrow mature B cells
decreases, p = 0.05
Mature B cells in the bone marrow were decreased in MO, EFO and DFO fed mice compared to CON fed mice (p<0.05
PMID:25616447 · one of two readings recorded this
bone marrow pre-pro-B, pro-B, pre-B and immature B cells
no effect
Bone marrow pre-pro-B cells, pro-B cells, pre-B cells and immature B cell populations were not significantly altered by fish oil diets
PMID:25616447 · one of two readings recorded this
correlation of RBC and B cell phospholipid arachidonic acid
increases, p = 0.0001
significant (all p < 0.0001) linear correlations between RBCs and B cells, as evidenced by Pearson's r coefficients for EPA (r = 0.849, Figure 1B), DHA (r = 0.892, Figure 1C), AA (r = 0.973, Figure 1D), and EPA+DHA (r = 0.927, Figure 1E)
PMID:25616447 · one of two readings recorded this
correlation of RBC and B cell phospholipid DHA
increases, p = 0.0001
significant (all p < 0.0001) linear correlations between RBCs and B cells, as evidenced by Pearson's r coefficients for EPA (r = 0.849, Figure 1B), DHA (r = 0.892, Figure 1C), AA (r = 0.973, Figure 1D), and EPA+DHA (r = 0.927, Figure 1E)
PMID:25616447 · one of two readings recorded this
correlation of RBC and B cell phospholipid EPA+DHA
increases, p = 0.0001
significant (all p < 0.0001) linear correlations between RBCs and B cells, as evidenced by Pearson's r coefficients for EPA (r = 0.849, Figure 1B), DHA (r = 0.892, Figure 1C), AA (r = 0.973, Figure 1D), and EPA+DHA (r = 0.927, Figure 1E)
PMID:25616447 · one of two readings recorded this
correlation of RBC and B cell phospholipid EPA
increases, p = 0.0001
significant (all p < 0.0001) linear correlations between RBCs and B cells, as evidenced by Pearson's r coefficients for EPA (r = 0.849, Figure 1B), DHA (r = 0.892, Figure 1C), AA (r = 0.973, Figure 1D), and EPA+DHA (r = 0.927, Figure 1E)
PMID:25616447 · one of two readings recorded this
IFN-γ production by LPS-stimulated B cells
no effect
IFN-γ production from LPS-stimulated B cells was increased in mice fed MO (p < 0.05) with no change in EFO or DFO
PMID:25616447 · one of two readings recorded this
IFN-γ production by LPS-stimulated B cells
increases, p = 0.05
IFN-γ production from LPS-stimulated B cells was increased in mice fed MO (p < 0.05) with no change in EFO or DFO
PMID:25616447 · one of two readings recorded this
IL-6 production by LPS-stimulated B cells
increases, p = 0.05
There was a statistically significant increase in IL-6 production from DFO mice (p < 0.05)
PMID:25616447 · one of two readings recorded this
IL-6 production by LPS-stimulated B cells
decreases, p = 0.05
IL-6 production from LPS-stimulated B cells of EFO mice was decreased (p < 0.05)
PMID:25616447 · one of two readings recorded this
IL-6 production by LPS-stimulated B cells
no effect, p = 0.11
IL-6 production by LPS-stimulated B cells was increased from MO mice; however, it was not statistically significant (p = 0.11)
PMID:25616447 · one of two readings recorded this
IL-6 production by LPS-stimulated purified splenic B cells ex vivo, plus B-cell membrane microdomain clustering, antigen uptake and B-cell subsets, in SMAD3-/- mice
decreases
Not recorded as a finding: the intervention held more than the compound
There was a statistically significant increase in IL-6 production from DFO mice (p < 0.05), whereas, IL-6 production from LPS-stimulated B cells of EFO mice was decreased (p < 0.05).
PMID:25616447 · one of two readings recorded this
LPS-stimulated B cell CD40 expression
increases
After LPS-stimulation, B cells from mice fed MO and EFO diets had increased CD40 expression compared to CON
PMID:25616447 · one of two readings recorded this
LPS-stimulated B cell MHCII expression
decreases
LPS-stimulated B cells from EFO fed mice had decreased MHCII expression compared to B cells from CON mice
PMID:25616447 · one of two readings recorded this
RBC omega-3 index (EPA+DHA percentage of total lipid)
increases
ranging between 15-22% in fish oil fed mice compared 5-7% in CON fed mice
PMID:25616447 · one of two readings recorded this
RBC phospholipid EPA, DPAn-3 and DHA
increases
In RBCs, MO, EFO, and DFO feeding resulted in increases of palmitic acid (16:0), EPA (20:5n-3), n-3 docosapentaenoic acid (DPAn-3; 22:5n-3), and DHA (22:6n-3)
PMID:25616447 · one of two readings recorded this
splenic marginal zone B cells
no effect
There was a slight nonsignificant reduction in MZ B cells in DFO fed mice
PMID:25616447 · one of two readings recorded this
splenic marginal zone B cells
decreases, p = 0.05
reduced splenic marginal zone (MZ) B cells in the MO and EFO (p < 0.05) fed mice compared to CON fed mice
PMID:25616447 · one of two readings recorded this
splenic marginal zone B cells
decreases, p = 0.05
reduced splenic marginal zone (MZ) B cells in the MO and EFO (p < 0.05) fed mice compared to CON fed mice
PMID:25616447 · one of two readings recorded this
splenic T1, T2 and follicular B cell populations
no effect
Fish oil diets did not significantly alter the splenic T1, T2, and mature follicular B cell populations
PMID:25616447 · one of two readings recorded this
TNF-α production by LPS-stimulated B cells
no effect, p = 0.052
TNF-α production from LPS-stimulated B cells was increased in mice fed MO and DFO; however, these increases were not statistically significant (p = 0.092 and p = 0.052, respectively)
PMID:25616447 · one of two readings recorded this
TNF-α production by LPS-stimulated B cells
no effect
There was no change in TNF-α reduction from LPS-stimulated mice fed EFO
PMID:25616447 · one of two readings recorded this
TNF-α production by LPS-stimulated B cells
no effect, p = 0.092
TNF-α production from LPS-stimulated B cells was increased in mice fed MO and DFO; however, these increases were not statistically significant (p = 0.092 and p = 0.052, respectively)
PMID:25616447 · one of two readings recorded this
inflammation (pro-inflammatory cytokines, TNF-alpha, IL-6)
decreases
With this review we found that EPA can reduce inflammation and has the potential to modulate nutritional status/body composition.
PMID:25770317 · one of two readings recorded this
lean body mass / muscle mass
The paper will cover malignancy, body composition, intervention with EPA, physiological mechanisms of action of EPA, effect of EPA on weight and body composition, future research.
PMID:25770317 · one of two readings recorded this
nutritional status / body composition
increases
With this review we found that EPA can reduce inflammation and has the potential to modulate nutritional status/body composition.
PMID:25770317 · one of two readings recorded this
arthritis score
no effect
Compared with CFA group, administration of MAG-DHA did not significantly reduce arthritis score
PMID:26022389 · one of two readings recorded this
arthritis score
decreases
MAG-EPA and MAG-DPA were observed to have significant activity in preventing the progression of arthritic disease with the arthritis score significantly lowered in treated CFA rats from day 16 to 22
PMID:26022389 · one of two readings recorded this
hind paw swelling and redness
decreases
MAG-EPA displayed a more potent effect on the reduction of hind paw swelling and redness on day 20 to 22 than MAG-DPA treatment
PMID:26022389 · one of two readings recorded this
hind paw thickness by digital caliper (mm) and semiquantitative clinical arthritis score (0-4) in CFA-induced arthritis in female Lewis rats given EPA monoglyceride (MAG-EPA) 318 mg/kg orally; plasma cytokines by ELISA; the dosed form is a monoglyceride, not a form the boundaries list
decreases
Not recorded as a finding: this platform holds no node for the endpoint
In contrast, treatment of CFA rats with MAG-DPA and MAG-EPA resulted in a significant reduction in hind paw thickness when compared to untreated CFA rats.
PMID:26022389 · one of two readings recorded this
hind paw thickness (digital caliper) and clinical arthritis score, MAG-EPA versus untreated CFA rats
decreases
Not recorded as a finding: no outcome node for rat paw thickness or arthritis score
In contrast, treatment of CFA rats with MAG-DPA and MAG-EPA resulted in a significant reduction in hind paw thickness when compared to untreated CFA rats.
PMID:26022389 · one of two readings recorded this
hind paw thickness
increases
hind paw thickness of CFA-untreated rats was significantly increased (7.32 ± 0.22 mm) when compared to control rats (3.96 ± 0.01 mm
PMID:26022389 · one of two readings recorded this
hind paw thickness
no effect
on day 18 to 22, hind paw thickness measurements increased to reach the same level as that of CFA-untreated rats
PMID:26022389 · one of two readings recorded this
hind paw thickness
decreases
treatment of CFA rats with MAG-DPA and MAG-EPA resulted in a significant reduction in hind paw thickness when compared to untreated CFA rats
PMID:26022389 · one of two readings recorded this
hind paw thickness
decreases
treatment of CFA rats with MAG-DPA and MAG-EPA resulted in a significant reduction in hind paw thickness when compared to untreated CFA rats
PMID:26022389 · one of two readings recorded this
hind paw thickness
no effect
combined treatment of MAG-EPA and vitamin E in CFA rats incurred an increase in hind paw thickness similar to that of CFA-untreated animals
PMID:26022389 · one of two readings recorded this
histological arthritic and degenerative changes
decreases
CFA rats treated with MAG-EPA showed a reduced level of severe arthritic and degenerative changes when compared to the morphological changes observed in the untreated CFA group
PMID:26022389 · one of two readings recorded this
MMP-2 and MMP-9 protein expression
increases
Analysis revealed increased MMP-2 and MMP-9 expression levels in cartilage homogenates derived from CFA rats comparatively to controls
PMID:26022389 · one of two readings recorded this
MMP-2 and MMP-9 protein expression
decreases
a reduced staining of MMP-2 and MMP-9 proteins expression was obtained following treatments with MAG-DHA, MAG-EPA and MAG-DPA compounds in CFA rats
PMID:26022389 · one of two readings recorded this
MMP-2 and MMP-9 protein expression
decreases
a reduced staining of MMP-2 and MMP-9 proteins expression was obtained following treatments with MAG-DHA, MAG-EPA and MAG-DPA compounds in CFA rats
PMID:26022389 · one of two readings recorded this
paw COX-2 protein expression
increases
Figure 5b shows that combined treatment of MAG-EPA and vitamin E inhibited the reduction in COX2 protein expression level observed in CFA + MAG-EPA treated animals
PMID:26022389 · one of two readings recorded this
paw p38 MAPK phosphorylation
decreases
MAG-EPA, MAG-DPA and MAG-DHA treatments all decreased CFA-induced phosphorylation of p38 MAPK to a similar extent compared to untreated CFA animals
PMID:26022389 · one of two readings recorded this
paw p38 MAPK phosphorylation
decreases
MAG-EPA, MAG-DPA and MAG-DHA treatments all decreased CFA-induced phosphorylation of p38 MAPK to a similar extent compared to untreated CFA animals
PMID:26022389 · one of two readings recorded this
paw p65 NFκB phosphorylation (P-NFκB/NFκB ratio)
no effect
no significant difference in p65 NFκB phosphorylation levels in CFA + MAG-DHA-treated rats was observed when compared to untreated CFA animals
PMID:26022389 · one of two readings recorded this
paw p65 NFκB phosphorylation (P-NFκB/NFκB ratio)
decreases
Results revealed that MAG-EPA and MAG-DPA treatments decreased p65 NFκB phosphorylation levels in paw tissues compared to that observed in untreated CFA rats, with significant reductions of 81 ± 3.1 % and 76 ± 2.7 %, respectively
PMID:26022389 · one of two readings recorded this
paw p65 NFκB phosphorylation (P-NFκB/NFκB ratio)
decreases
Results revealed that MAG-EPA and MAG-DPA treatments decreased p65 NFκB phosphorylation levels in paw tissues compared to that observed in untreated CFA rats, with significant reductions of 81 ± 3.1 % and 76 ± 2.7 %, respectively
PMID:26022389 · one of two readings recorded this
paw TNFα and COX-2 protein expression
increases
Results revealed a significant increase in TNFα and COX-2 protein expression in CFA rats when compared to expression levels in control animals
PMID:26022389 · one of two readings recorded this
paw TNFα and COX-2 protein expression
decreases
MAG-EPA and MAG-DPA treatment significantly reduced TNFα and COX-2/β-actin staining density ratios when compared to the ratios quantified in untreated CFA rats
PMID:26022389 · one of two readings recorded this
plasma IL-17A, IL-1β, IL-6 and TNFα by ELISA, MAG-EPA-treated versus untreated CFA rats, day 22
decreases
Not recorded as a finding: the sentence reporting the MAG-EPA contrast refers to 'these cytokines' and never names TNFα, so it does not support the tnf-alpha node on its own
In contrast, the levels of these cytokines were significantly lower in the plasma of MAG-EPA- and MAG-DPA-treated animals when compared to untreated CFA rats.
PMID:26022389 · one of two readings recorded this
plasma IL-17A, IL-1β, IL-6 and TNFα
increases
IL-17A, IL-1β, IL-6 and TNFα levels were significantly higher in the plasma of CFA rats when compared to plasma levels in control animals
PMID:26022389 · one of two readings recorded this
plasma IL-17A, IL-1β, IL-6 and TNFα
decreases
the levels of these cytokines were significantly lower in the plasma of MAG-EPA- and MAG-DPA-treated animals when compared to untreated CFA rats
PMID:26022389 · one of two readings recorded this
plasma IL-17A, IL-1β, IL-6 and TNFα
increases
circulating levels of IL-17A, IL-1β, IL-6 and TNFα were less reduced in the presence of MAG-DHA than in MAG-EPA- and MAG-DPA-treated animals
PMID:26022389 · one of two readings recorded this
plasma IL-17A, IL-1β, IL-6 and TNFα
no effect
no significant difference was observed between CFA + MAG-EPA + vitamin E-treated and CFA-untreated rats
PMID:26022389 · one of two readings recorded this
cognitive decline rate
no effect
In case of advanced AD elderly patients, EPA and/or DHA supplementations did not reduce cognitive decline rates
PMID:26268080 · one of two readings recorded this
scores on cognitive tests (MMSE, ADAS-Cog, CDR)
no effect
EPA and/or DHA supplementations did not affect scores obtained on the cognitive tests
PMID:26268080 · one of two readings recorded this
verbal fluency and attention
increases
supplementation with EPA and/or DHA improved verbal fluency and attention in patients who had only very mild dementia or AD or presented APOEε4 negative genotype
PMID:26268080 · one of two readings recorded this
LDL cholesterol
increases
Although EPA/docosahexaenoic acid formulations did lower triglyceride levels, an increase in low-density lipoproteins was observed and outcome data were mixed.
PMID:26825470 · one of two readings recorded this
LDL cholesterol (more recent EPA-only preparations)
decreases
More recent trials have shown that decreased levels of low-density lipoproteins can be achieved with EPA preparations.
PMID:26825470 · one of two readings recorded this
serum triglyceride levels
decreases
Although EPA/docosahexaenoic acid formulations did lower triglyceride levels, an increase in low-density lipoproteins was observed and outcome data were mixed.
PMID:26825470 · one of two readings recorded this
body weight
no effect
Body weight (g) | 27.5 ± 0.52 | 25.3 ± 0.57 | 25.9 ± 0.51 | 26.2 ± 0.40
PMID:27333187 · one of two readings recorded this
epididymal white adipose tissue weight
no effect
eWAT weight (%body weight) | 1.41 ± 0.08 | 1.09 ± 0.09 | 1.15 ± 0.08 ## | 1.38 ± 0.06
PMID:27333187 · one of two readings recorded this
hepatic 8-OHdG
decreases
hepatic 8-hydroxy-2’-deoxyguanosine (8-OHdG) levels were significantly reduced in the AHF + EPA and AHF + DHA groups compared with the AHF group
PMID:27333187 · one of two readings recorded this
hepatic ABCA1, ABCG5 and ABCG8 mRNA
no effect
However, no difference between EPA and DHA administration was observed
PMID:27333187 · one of two readings recorded this
hepatic AOX and Cyp4a10 mRNA
increases
the addition of EPA or DHA to the AHF diet recovered the expression of these genes
PMID:27333187 · one of two readings recorded this
hepatic arachidonic acid and dihomo-gamma-linolenic acid
decreases
The hepatic levels of the n-6 series of PUFA [arachidonic acid (C20:4 n-6) and its precursor, dihomo-gamma-linolenic acid (C20:3 n-6)] were strongly decreased in both AHF + EPA and AHF + DHA groups in comparison with the AHF group
PMID:27333187 · one of two readings recorded this
hepatic Col1a1 and Mmp2 mRNA
decreases
Compared with the AHF group, AHF + EPA group showed significantly decreased Col1a1 and Mmp2 expression but unchanged TGFβ1 expression
PMID:27333187 · one of two readings recorded this
hepatic D6D, D5D, Elovl5 and Elovl2 mRNA
decreases
The mRNA levels of these genes were similarly suppressed in livers of the AHF + EPA and AHF + DHA groups compared to those of the chow and AHF groups
PMID:27333187 · one of two readings recorded this
hepatic DHA content
increases
Dietary DHA also clearly increased hepatic DHA content by 1.8- and 7.4-fold compared with the control and AHF groups, respectively
PMID:27333187 · one of two readings recorded this
hepatic DHA content
increases
Dietary DHA also clearly increased hepatic DHA content by 1.8- and 7.4-fold compared with the control and AHF groups, respectively
PMID:27333187 · one of two readings recorded this
hepatic DPA and DHA content
increases
Mice fed AHF + DHA showed increased hepatic EPA, and mice fed AHF + EPA showed increased hepatic docosapentaenoic acid (DPA) and DHA content compared with the AHF group to the similar extent
PMID:27333187 · one of two readings recorded this
hepatic EPA content
increases
Mice fed AHF + DHA showed increased hepatic EPA, and mice fed AHF + EPA showed increased hepatic docosapentaenoic acid (DPA) and DHA content compared with the AHF group to the similar extent
PMID:27333187 · one of two readings recorded this
hepatic EPA content
increases
The amount of hepatic EPA of AHF + EPA group was increased 3.9- and 29-fold in comparison with the chow and AHF groups, respectively
PMID:27333187 · one of two readings recorded this
hepatic EPA content
increases
The amount of hepatic EPA of AHF + EPA group was increased 3.9- and 29-fold in comparison with the chow and AHF groups, respectively
PMID:27333187 · one of two readings recorded this
hepatic F4/80-positive Kupffer cell accumulation
decreases
these cells were decreased in livers of the AHF + EPA and AHF + DHA groups compared to those of the AHF groups
PMID:27333187 · one of two readings recorded this
hepatic FAS, Elovl6 and GPAT-1 mRNA
decreases
Compared to the AHF + DHA group, the AHF + EPA group showed significantly decreased FAS, Elovl6, and GPAT-1 expression
PMID:27333187 · one of two readings recorded this
hepatic HEL (hexanoyl-lysine) staining intensity
decreases
The AHF + EPA and AHF + DHA groups showed decreased the intensity of the staining, with the effect on DHA group stronger
PMID:27333187 · one of two readings recorded this
hepatic JNK phosphorylation
decreases
The AHF + EPA and AHF + DHA groups showed significantly decreased the AHF diet-induced JNK activation
PMID:27333187 · one of two readings recorded this
hepatic lobular inflammatory clusters
decreases
significantly fewer hepatic lobular inflammatory clusters than in the AHF diet group
PMID:27333187 · one of two readings recorded this
hepatic Mmp2 mRNA
decreases
The AHF + DHA group showed significantly decreased Mmp2 expression with a tendency to decreased expression of both Col1a1 and TGFβ1 compared with the AHF group
PMID:27333187 · one of two readings recorded this
hepatic n-6/n-3 fatty acid ratio
decreases
The hepatic n-6/n-3 FA ratio was strongly decreased in the AHF + EPA and AHF + DHA groups in comparison with the AHF group
PMID:27333187 · one of two readings recorded this
hepatic n-6/n-3 fatty acid ratio
decreases
This ratio for the AHF + EPA group was slightly but significantly lower than that of AHF + DHA group
PMID:27333187 · one of two readings recorded this
hepatic p47phox and p22phox mRNA
decreases
The induction of p47phox and p22phox was attenuated in the AHF + DHA group but not in the AHF + EPA group
PMID:27333187 · one of two readings recorded this
hepatic p47phox and p22phox mRNA
no effect
The induction of p47phox and p22phox was attenuated in the AHF + DHA group but not in the AHF + EPA group
PMID:27333187 · one of two readings recorded this
hepatic PPARγ2 and Cidec mRNA
no effect
Compared to the AHF group, the AHF + EPA group showed significantly decreased PPARγ2 and Cidec expression, whereas the AHF + DHA group did not suppress the expression of these genes
PMID:27333187 · one of two readings recorded this
hepatic PPARγ2 and Cidec mRNA
decreases
Compared to the AHF group, the AHF + EPA group showed significantly decreased PPARγ2 and Cidec expression, whereas the AHF + DHA group did not suppress the expression of these genes
PMID:27333187 · one of two readings recorded this
hepatic PPARα and CPT-1a mRNA
no effect
the addition of EPA or DHA to the AHF diet did not change the expression of PPARα and CPT-1a
PMID:27333187 · one of two readings recorded this
hepatic α-SMA protein
decreases
The AHF + EPA and AHF + DHA groups showed significantly decreased α-SMA protein levels compared with the AHF group to a similar extent after loading correction
PMID:27333187 · one of two readings recorded this
hepatic SOD1 mRNA
no effect
addition of EPA or DHA to the AHF diet did not change the expression of SOD1
PMID:27333187 · one of two readings recorded this
hepatic SREBP-1c mRNA and mature SREBP-1 protein
decreases
Addition of EPA or DHA to the AHF diet markedly reduced the levels of SREBP-1c mRNA expression, mature SREBP-1 protein, and FA synthesis gene expression in comparison with both chow and AHF diet groups
PMID:27333187 · one of two readings recorded this
hepatic SREBP-1c mRNA and mature SREBP-1 protein
decreases
Addition of EPA or DHA to the AHF diet markedly reduced the levels of SREBP-1c mRNA expression, mature SREBP-1 protein, and FA synthesis gene expression in comparison with both chow and AHF diet groups
PMID:27333187 · one of two readings recorded this
hepatic SREBP-2, LDLR and HMG-CoA reductase mRNA
decreases
the mRNA abundances of SREBP-2 and its target, low-density lipoprotein receptor (LDLR) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA Red) were significantly decreased in both AHF + EPA and AHF + DHA groups compared with the chow and AHF diet groups
PMID:27333187 · one of two readings recorded this
hepatic TGFβ1 mRNA
no effect
Compared with the AHF group, AHF + EPA group showed significantly decreased Col1a1 and Mmp2 expression but unchanged TGFβ1 expression
PMID:27333187 · one of two readings recorded this
hepatic TNFα and MCP-1 mRNA
decreases
The AHF + DHA but not the AHF + EPA diet significantly attenuated the induction of TNFα and MCP-1 expression relative to the AHF group
PMID:27333187 · one of two readings recorded this
hepatic TNFα and MCP-1 mRNA
no effect
The AHF + DHA but not the AHF + EPA diet significantly attenuated the induction of TNFα and MCP-1 expression relative to the AHF group
PMID:27333187 · one of two readings recorded this
hepatic total cholesterol
decreases
hepatic cholesterol accumulation was equally decreased in both AHF + EPA and AHF + DHA groups
PMID:27333187 · one of two readings recorded this
hepatic total cholesterol
decreases
hepatic cholesterol accumulation was equally decreased in both AHF + EPA and AHF + DHA groups
PMID:27333187 · one of two readings recorded this
hepatic triacylglycerol content, AHF diet with 5% EPA versus AHF diet
decreases
Not recorded as a finding: no outcome node for liver tissue triglyceride (the triglycerides node is serum or plasma after a stated fast)
EPA prevented AHF diet-induced increase in liver TG, but DHA did not significantly prevent the AHF diet-induced increase.
PMID:27333187 · one of two readings recorded this
hepatic triacylglycerol content in AHF diet-fed mice, EPA versus AHF diet alone
decreases, EPA prevented the AHF diet-induced increase in liver TG
Not recorded as a finding: no outcome node for hepatic (tissue) triglyceride content; serum-triglycerides node is a fasting serum assay
EPA prevented AHF diet-induced increase in liver TG, but DHA did not significantly prevent the AHF diet-induced increase.
PMID:27333187 · one of two readings recorded this
hepatic triacylglycerol
no effect
EPA prevented AHF diet-induced increase in liver TG, but DHA did not significantly prevent the AHF diet-induced increase
PMID:27333187 · one of two readings recorded this
hepatic triacylglycerol
decreases
EPA prevented AHF diet-induced increase in liver TG, but DHA did not significantly prevent the AHF diet-induced increase
PMID:27333187 · one of two readings recorded this
liver weight
increases
Liver weight (%body weight) | 4.77 ± 0.11 | 5.14 ± 0.12 | 5.39 ± 0.21 * | 4.97 ± 0.07
PMID:27333187 · one of two readings recorded this
plasma ALT and AST, AHF diet with 5% EPA versus AHF diet
decreases
Not recorded as a finding: the sentence says 'biochemical liver injury markers' and does not name ALT or AST, and it pools the EPA and DHA arms in one clause
These biochemical liver injury markers induced by AHF diet were similarly reduced by dietary EPA and DHA.
PMID:27333187 · one of two readings recorded this
plasma ALT and AST (serum transaminase activities) in AHF diet-fed mice given EPA or DHA
decreases
Not recorded as a finding: the only sentence naming EPA gives 'serum transaminase activities' without saying which enzyme; ALT and AST are separate nodes
In addition, EPA or DHA administration was found to improve liver injury as assessed by serum transaminase activities.
PMID:27333187 · one of two readings recorded this
plasma ALT
decreases
These biochemical liver injury markers induced by AHF diet were similarly reduced by dietary EPA and DHA
PMID:27333187 · one of two readings recorded this
plasma ALT
decreases
These biochemical liver injury markers induced by AHF diet were similarly reduced by dietary EPA and DHA
PMID:27333187 · one of two readings recorded this
plasma ALT
increases
Feeding mice with the AHF diet resulted in approximately 4- and 3-fold increases in levels of plasma ALT and AST, respectively
PMID:27333187 · one of two readings recorded this
plasma AST
decreases
These biochemical liver injury markers induced by AHF diet were similarly reduced by dietary EPA and DHA
PMID:27333187 · one of two readings recorded this
plasma AST
decreases
These biochemical liver injury markers induced by AHF diet were similarly reduced by dietary EPA and DHA
PMID:27333187 · one of two readings recorded this
plasma AST
increases
Feeding mice with the AHF diet resulted in approximately 4- and 3-fold increases in levels of plasma ALT and AST, respectively
PMID:27333187 · one of two readings recorded this
plasma free fatty acids
decreases
Plasma FFA (mM) | 0.55 ± 0.06 | 0.48 ± 0.03 | 0.38 ± 0.03 * | 0.45 ± 0.02
PMID:27333187 · one of two readings recorded this
plasma glucose
no effect
Glucose (mg/dl) | 164 ± 9.4 | 169 ±9.0 | 152 ± 6.7 | 149 ± 5.8
PMID:27333187 · one of two readings recorded this
plasma insulin
no effect
Insulin (ng/ml) | 0.72 ± 0.21 | 0.31 ± 0.07 | 0.52 ± 0.18 | 0.61 ± 0.23
PMID:27333187 · one of two readings recorded this
plasma total cholesterol, AHF + EPA versus AHF
decreases
Not recorded as a finding: sentence says hypercholesterolemia attenuated, not the plasma total cholesterol assay, and uses the arm label AHF + EPA
Hypercholesterolemia was attenuated in both AHF + EPA and AHF + DHA groups.
PMID:27333187 · one of two readings recorded this
plasma total cholesterol
decreases
Plasma T-Cho (mg/dl) | 79.3 ± 2.9 | 143.5 ± 7.0 ** | 114.1 ± 5.5 **, ## | 124.7 ± 5.4 **, ##
PMID:27333187 · one of two readings recorded this
plasma triglycerides
no effect
Plasma TG (mg/dl) | 85.7 ± 5.8 | 54.6 ± 5.3 ** | 56.0 ± 4.5 ** | 64.0 ± 5.1 **
PMID:27333187 · one of two readings recorded this
EPA effect on Trail-induced Tak-1 and JNK phosphorylation and Mmp-9 expression with Gpr-120/Ffar-4 knockdown
no effect
Knockdown of Gpr-120/Ffar-4 abrogated the inhibitory effects of EPA on Trail-induced phosphorylation of Tak-1 and JNK and Mmp-9 expression
PMID:27764222 · one of two readings recorded this
external aortic diameter after AAA induction
decreases
this enlargement was significantly reduced in mice fed the EPA (+) diet
PMID:27764222 · one of two readings recorded this
external aortic diameter after AAA induction
no effect
No significant difference was found in external aortic diameters with or without EPA
PMID:27764222 · one of two readings recorded this
external aortic diameter after CaCl2 aneurysm induction, Opg-KO mice fed EPA (+) versus EPA (-) diet, six weeks
decreases
Not recorded as a finding: no outcome node for aortic diameter
At six weeks, however, obvious enlargement of the external aortic diameter was observed in mice fed the EPA (-) diet, while this enlargement was significantly reduced in mice fed the EPA (+) diet.
PMID:27764222 · one of two readings recorded this
maximum external aortic diameter and medial width in a CaCl2-induced abdominal aortic aneurysm model in Opg-KO mice, 5% EPA diet versus EPA-free diet, measured on aortic photographs and histology (Photoshop, Image-J); cell-culture mechanism work used EPA sodium salt
decreases
Not recorded as a finding: this platform holds no node for the endpoint
At six weeks, however, obvious enlargement of the external aortic diameter was observed in mice fed the EPA (-) diet, while this enlargement was significantly reduced in mice fed the EPA (+) diet.
PMID:27764222 · one of two readings recorded this
medial elastic fiber disruption
decreases
in Opg-KO mice fed the EPA (+) diet, elastic fibers were retained with flattened structures
PMID:27764222 · one of two readings recorded this
mouse body weight, EPA diet versus control diet in CaCl2 aneurysm model
no effect
Not recorded as a finding: agentless one-line statement referring to a supplementary figure, mixed wild-type and Opg-KO mice, no estimate; body-mass node needs scale conditions
No significant change in mouse body weight by EPA was observed (S1A Fig).
PMID:27764222 · one of two readings recorded this
mouse body weight
no effect
No significant change in mouse body weight by EPA was observed
PMID:27764222 · one of two readings recorded this
pJNK and Mmp-9 double-positive area in aortic media
decreases
Mmp-9 and pJNK double-positive areas were significantly increased in Opg-KO mice fed the EPA (-) diet compared to mice fed the EPA (+) diet
PMID:27764222 · one of two readings recorded this
rh-TRAIL-induced Trail mRNA in SMCs with JNK inhibitors
decreases
Trail expression was reduced in a dose-dependent manner, suggesting that Trail induces its own expression via JNK activation in SMCs
PMID:27764222 · one of two readings recorded this
Trail and Mmp-9 up-regulation in aortic media
decreases
EPA suppressed the up-regulation of Trail and Mmp-9 in the media of Opg-KO mice
PMID:27764222 · one of two readings recorded this
Trail-induced JNK phosphorylation and Mmp-9 expression in SMCs
decreases
In addition to Tak-1 inactivation, JNK phosphorylation and Mmp-9 expression were inhibited by GW9508 in a dose-dependent manner
PMID:27764222 · one of two readings recorded this
Trail-induced JNK phosphorylation in SMCs
decreases
EPA reduced Trail-induced JNK phosphorylation and Mmp-9 expression
PMID:27764222 · one of two readings recorded this
Trail-induced Mmp-9 expression in SMCs
decreases
EPA reduced Trail-induced JNK phosphorylation and Mmp-9 expression
PMID:27764222 · one of two readings recorded this
Trail-induced Tak-1 phosphorylation in SMCs
decreases
Tak-1 phosphorylation was completely inhibited with EPA or GW9508 treatment
PMID:27764222 · one of two readings recorded this
width of the medial layer after AAA induction
decreases
This enlargement was significantly reduced with the EPA (+) diet
PMID:27764222 · one of two readings recorded this
ANP mRNA in left ventricle
decreases
but were significantly lower in the MI+EPA group than in the MI+PBS group 28 days after MI
PMID:28223437 · one of two readings recorded this
BNP mRNA in left ventricle
decreases
but were significantly lower in the MI+EPA group than in the MI+PBS group 28 days after MI
PMID:28223437 · one of two readings recorded this
cardiac myocyte cross-sectional area (hypertrophy) in noninfarcted area
decreases
cardiac myocyte hypertrophy was significantly inhibited by EPA treatment 28 days after MI
PMID:28223437 · one of two readings recorded this
cardiac rupture after MI
no effect, p = 0.4248
the occurrence of cardiac rupture was similar between the MI+PBS and MI+EPA groups (38.2% vs 33.9%, P=0.4248
PMID:28223437 · one of two readings recorded this
cardiac rupture mortality after MI in mice
no effect, 38.2% vs 33.9%, p = 0.4248
Not recorded as a finding: no outcome node for cause-specific death by cardiac rupture
However, the occurrence of cardiac rupture was similar between the MI+PBS and MI+EPA groups (38.2% vs 33.9%, P=0.4248; Figure 1C).
PMID:28223437 · one of two readings recorded this
CCL2 mRNA
decreases
gene expression levels of CCL2, mucin‐like hormone receptor‐like 1, and IL‐6, which are proinflammatory genes and are also known as M1 macrophage genes, were lower in the MI+EPA group than in the MI+PBS group
PMID:28223437 · one of two readings recorded this
collagen I mRNA
decreases
The expression levels of the TGF‐β1 gene and downstream genes, such as collagen I and collagen III, during the remodeling phase were significantly lower in the MI+EPA group than in the MI+PBS group
PMID:28223437 · one of two readings recorded this
collagen III mRNA
decreases
The expression levels of the TGF‐β1 gene and downstream genes, such as collagen I and collagen III, during the remodeling phase were significantly lower in the MI+EPA group than in the MI+PBS group
PMID:28223437 · one of two readings recorded this
collagen volume fraction in noninfarcted area
decreases
the collagen volume fraction detected by picro‐sirius red staining in the noninfarcted area was significantly higher in the MI+PBS group than in the MI+EPA group
PMID:28223437 · one of two readings recorded this
death due to heart failure after MI in mice
decreases, 20.6% vs 6.8%, p = 0.0102
Not recorded as a finding: no outcome node for cause-specific death from heart failure
We also found that the incidence of death due to heart failure after MI was significantly higher in the MI+PBS group than in the MI+EPA group (20.6% vs 6.8%, P=0.0102; Figure 1B).
PMID:28223437 · one of two readings recorded this
death due to heart failure after MI, mice
decreases, 20.6% vs 6.8% (MI+PBS vs MI+EPA), p = 0.0102
Not recorded as a finding: cause-specific death classified by autopsy; cardiovascular-mortality node requires an adjudicated or registry underlying cause in a stated follow-up, not mouse autopsy classification
We also found that the incidence of death due to heart failure after MI was significantly higher in the MI+PBS group than in the MI+EPA group (20.6% vs 6.8%, P=0.0102; Figure 1B).
PMID:28223437 · one of two readings recorded this
death due to heart failure after MI
decreases, p = 0.0102
the incidence of death due to heart failure after MI was significantly higher in the MI+PBS group than in the MI+EPA group (20.6% vs 6.8%, P=0.0102
PMID:28223437 · one of two readings recorded this
EMR1 (mucin-like hormone receptor-like 1) mRNA
decreases
gene expression levels of CCL2, mucin‐like hormone receptor‐like 1, and IL‐6, which are proinflammatory genes and are also known as M1 macrophage genes, were lower in the MI+EPA group than in the MI+PBS group
PMID:28223437 · one of two readings recorded this
F4/80-positive macrophages in noninfarcted area
decreases
significantly more macrophages in the noninfarcted areas of the hearts of the MI+PBS group than in those of the MI+EPA group 28 days after MI
PMID:28223437 · one of two readings recorded this
fibrosis area in noninfarcted area
decreases
fibrosis detected by AZAN staining in the noninfarcted area 28 days after MI was significantly attenuated by EPA treatment
PMID:28223437 · one of two readings recorded this
heart and lung weight to tibial length ratios in sham mice
no effect
were similar between the sham+PBS and sham+EPA groups 28 days after the sham operation
PMID:28223437 · one of two readings recorded this
heart weight to tibial length ratio
decreases
EPA administration significantly decreased both ratios
PMID:28223437 · one of two readings recorded this
IL-6 mRNA
decreases
gene expression levels of CCL2, mucin‐like hormone receptor‐like 1, and IL‐6, which are proinflammatory genes and are also known as M1 macrophage genes, were lower in the MI+EPA group than in the MI+PBS group
PMID:28223437 · one of two readings recorded this
IRF5 mRNA and protein upregulation after MI
decreases
EPA treatment significantly attenuated this upregulation in the infarcted heart 28 days after MI
PMID:28223437 · one of two readings recorded this
lung weight to tibial length ratio
decreases
EPA administration significantly decreased both ratios
PMID:28223437 · one of two readings recorded this
LV systolic function (LVEF and %FS)
increases
A greater deterioration in LV systolic function was observed in the MI+PBS group than in the MI+EPA group 28 days after MI
PMID:28223437 · one of two readings recorded this
LVEDD and LVESD
decreases
LVEDD and LVESD were significantly larger in the MI+PBS group than in the MI+EPA group 28 days after MI
PMID:28223437 · one of two readings recorded this
LVEF, %FS, LVEDD and LVESD
no effect
However, LVEF, %FS, LVEDD, and LVESD were comparable between the MI+PBS and MI+EPA groups within 7 days after MI
PMID:28223437 · one of two readings recorded this
MRC1 mRNA
increases
gene expression levels of MRC1 and VEGF, which are anti‐inflammatory (M2 macrophage) genes, were higher in the MI+EPA group than in the MI+PBS group
PMID:28223437 · one of two readings recorded this
percentage of CD11b+F4/80+ macrophages
no effect, p = 0.9999
the percentage of CD11b+F4/80+ macrophages in the MI+PBS group was similar to that in the MI+EPA group (72.73±1.2% vs 72.0±2.4%, respectively; P>0.9999)
PMID:28223437 · one of two readings recorded this
percentage of M1 macrophages
decreases, p = 0.0317
the percentage of M1 macrophages was significantly higher in the MI+PBS group than in the MI+EPA group (7.6±0.4% vs 5.4±0.6%, P=0.0317)
PMID:28223437 · one of two readings recorded this
percentage of M2 macrophages
no effect, p = 0.9999
The same observation was made regarding the percentage of M2 macrophages (56.1±2.0% vs 57.7±0.5%, respectively; P>0.9999)
PMID:28223437 · one of two readings recorded this
post-infarct mortality
decreases, p = 0.0361
The incidence of postinfarct mortality was significantly lower in the MI+EPA group than in the MI+PBS group (59.3% vs 41.2%, P=0.0361)
PMID:28223437 · one of two readings recorded this
ratio of M1 to M2 macrophages
decreases, p = 0.0317
the ratio of M1 to M2 macrophages was significantly higher in the MI+PBS group than in the MI+EPA group (0.1355±0.004% vs 0.0944±0.010%, P=0.0317)
PMID:28223437 · one of two readings recorded this
Smad2 and Smad3 phosphorylation
decreases
EPA treatment significantly attenuated the phosphorylation of Smad2 and Smad3 28 days after MI
PMID:28223437 · one of two readings recorded this
TGF-β1 mRNA
decreases
The expression levels of the TGF‐β1 gene and downstream genes, such as collagen I and collagen III, during the remodeling phase were significantly lower in the MI+EPA group than in the MI+PBS group
PMID:28223437 · one of two readings recorded this
total CD45+ cells and macrophages infiltrating left ventricle
no effect
there were no significant differences in the total number of CD45+ cells and macrophages infiltrated into the left ventricle between the MI+PBS and MI+EPA groups 28 days after MI
PMID:28223437 · one of two readings recorded this

The whole record — 906 rows

Sources cited

8 papers

Subject: all-cis-5,8,11,14,17-icosapentaenoic acid
Findings: 12
Papers: 8

Other names

23 names

Resolves to: all-cis-5,8,11,14,17-icosapentaenoic acid

Also called: (5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid(all-Z)-5,8,11,14,17-eicosapentaenoic acid5,8,11,14,17-EICOSAPENTAENOIC ACID5,8,11,14,17-Icosapentaenoic acid5Z,8Z,11Z,14Z,17Z-eicosapentaenoic acidall-cis-5,8,11,14,17-eicosapentaenoic acidall-cis-icosa-5,8,11,14,17-pentaenoic acidC20:5n-3,6,9,12,15cis-5,8,11,14,17-eicosapentaenoic acidcis-5,8,11,14,17-EPAcis-Delta(5,8,11,14,17)-eicosapentaenoic acidcis-Δ5,8,11,14,17-eicosapentaenoic acidcis, cis, cis, cis, cis-eicosa-5,8,11,14,17-pentaenoic acidEicosapentaenoic acidEPAFA 20:5icosapentIcosapentaenoic acidTimnodonic acid
Systematic name: (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid

all-cis-5,8,11,14,17-icosapentaenoic acid

Definition from MeSH (D015118), National Library of Medicine, read 2026-09-23. NLM revises MeSH; this copy may not reflect its current record.

CHEBI:28364ChEBI

Structure

An icosapentaenoic acid having five cis-double bonds at positions 5, 8, 11, 14 and 17.

2D depiction · 3D model shown

Loading the model…

A generated conformer of all-cis-5,8,11,14,17-icosapentaenoic acid — one low-energy arrangement PubChem computed, not a measured structure. Hydrogens are not drawn; the formula counts them.

Class: Organic compound
Formula: C20H30O2
Mass: 302.458 g/mol
Charge: 0
InChIKey: JAZBEHYOTPTENJ-JLNKQSITSA-N
SMILES: CC/C=CC/C=CC/C=CC/C=CC/C=CCCCC(=O)O
Look it up: ChEBI PubChem By InChIKey

Identity from ChEBI, geometry from PubChem. Not evidence.

On the label

Labelled products

386 products

Source: NIH DSLD · Ingredient: all-cis-5,8,11,14,17-icosapentaenoic acid · 386 products · Declared amount per serving: 0.625–4,000 mg (380 products)

382 labels state an amount4 do not

Order

1MDKrillMD174 mgper 2 Softgel(s)DSLD:246767
1st PhormMicro Factor EFAFish Oil Concentrate125 mgper 1 Softgel(s)DSLD:295905
AB American BiologicsImproved Super Omega EPA/DHAEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3440 mgper 2 Softgel(s)DSLD:20294
AB American BiologicsUltra Omega EssentialsEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3150 mgper 2 Softgel(s)DSLD:20491
Absorb HealthOmega DHA & EPAEPA (Alt. Name: Eicosapentaenoic Acid) Note: Gas Chromatography by A%.720 mgper 2 Softgel(s)DSLD:216055
Acella PharmaceuticalsPNV-Omega40 mgper 1 Softgel(s)DSLD:278709
AdvoCareCore Nutrition SystemMarine Lipids · Eicosapentaenoic Acid (Form: from Marine Lipids)600 mgper 1 4-Packet Strip(s)DSLD:177397
AdvoCareMNS 3Marine Lipids · Eicosapentaenoic Acid (Form: from Marine Lipids)600 mgper 2 Packet(s)DSLD:177961
AdvoCareMNS CMarine Lipids · Eicosapentaenoic Acid (Form: from Marine Lipids)300 mgper 2 Packet(s)DSLD:207148
AdvoCareMNS EMarine Lipids · Eicosapentaenoic Acid (Form: from Marine Lipids)300 mgper 1 Packet(s)DSLD:177964
AdvoCareOmegaPlexMarine Lipids600 mgper 2 Softgel(s)DSLD:265350
Alani NuPrenatal40 mgper 2 Softgel(s)DSLD:277637

Show the remaining 374

Allergy Research GroupSteady On160 mgper 20 Gram(s)DSLD:54474
Allergy Research GroupSteady On160 mgper 20 Gram(s)DSLD:54482
Allergy Research GroupTake Heart II Without Hormones145 mgper 20 Gram(s)DSLD:54484
Allergy Research GroupTake Heart II Without Hormones145 mgper 20 Gram(s)DSLD:54477
Amala VeganKids Vegan Omega 3 DHA + EPA Organic Lemon Flavored2.5 mgper 0.5 mLDSLD:276164
AmvilabOmega 3-6-9Fish Oil125 mgper 1 Softgel(s)DSLD:298165
AN Amazing Nutrition Amazing OmegaFish Oil 1000 mg33%180 mgper 1 Softgel(s)DSLD:275821
AN Amazing Nutrition Amazing OmegaKrill Oil 500 mg61 mgper 1 Softgel(s)DSLD:251769
ANTIAGING Institute of CaliforniaFish Oil Concentrate160 mgper 1 Softgel(s)DSLD:210294
AOR Advanced Orthomolecular Research PremiumVegan Omega 3Typical values. Ranges: EPA 150-300 mg246 mgper 1 Softgel(s)DSLD:305920
Apex EnergeticsOmegaCo3 (K-7)500 mgper 1 TbspDSLD:206624
Apex EnergeticsOmegaCo3-SE500 mgper 2 Softgel(s)DSLD:239380
AquaOmegaHigh DHA Omega-3 4500 mg Lemon Flavor670 mgper 7.5 mLDSLD:277089
AquaOmegaHigh EPA Omega-3 Lemon Flavor3,380 mgper 7.5 mLDSLD:275942
AquaOmegaHigh EPA Omega-3 Orange Flavor3,380 mgper 7.5 mLDSLD:275944
aSquared NutritionOmega 3 2400 mg Lemon Flavored860 mgper 2 Softgel(s)DSLD:322074
Avion PharmaceuticalsPrenate Essential40 mgper 1 Softgel(s)DSLD:279279
Avion PharmaceuticalsPrenate Essential40 mgper 1 Softgel(s)DSLD:44774
Avion PharmaceuticalsPrimaCare120 mgper 1 Softgel(s)DSLD:278712
Barlean'sTotal Omega 3-6-9 Lemonade Flavor400 mgper 3 Gram(s)DSLD:218507
Barlean's Organic OilsIdeal Omega 3 Orange Flavored750 mgper 1 Softgel(s)DSLD:220029
Basic VitaminsOderless Coated Fish Oil 1000 mg Omega-3180 mgper 1 Softgel(s)DSLD:250298
BayerArctic Wonder Omega-3 Krill Oil150 mgper 2 Softgel(s)DSLD:12238
Best NaturalsKrill-500 1000 mgTypical fatty Acid162 mgper 1 Softgel(s)DSLD:270590
Best NaturalsKrill-500 500 mgTypical fatty Acid162 mgper 2 Softgel(s)DSLD:270589
Best Nest WellnessOne Fish, Two Fish250 mgper 2 Softgel(s)DSLD:270752
Beyond HealthFish Oil Formula660 mgper 2 Softgel(s)DSLD:306889
Beyond HumanOmega 3 Fish Oil180 mgper 1 Soft Gelatin Capsule(s)DSLD:181952
Bio NutritionK Bio Krill 500 mg81 mgper 1 Softgel(s)DSLD:200593
BioChem SportsOmega Burn300 mgper 6 Softgel(s)DSLD:13312
BiotiviaGreen Omega3Almega PL300 mgper 3 Vegetarian Softgel(s)DSLD:58307
Bronson LaboratoriesKrill Oil 500 mg150 mgper 2 Softgel(s)DSLD:8247
BulkSupplements.comMultivitamins 1000 mg Softgels20 mgper 1 Softgel(s)DSLD:312978
BulkSupplements.comMultivitamins for Men - with Fish Oil Softgels20 mgper 1 Softgel(s)DSLD:312979
BulkSupplements.comMultivitamins for Men - with Fish Oil Softgels20 mgper 1 Softgel(s)DSLD:314919
BulkSupplements.comMultivitamins for Men - with Fish Oil Softgels 1000 mg20 mcgper 1 Softgel(s)DSLD:329942
BulkSupplements.comMultivitamins for Women - with Fish Oil Softgels20 mgper 1 Softgel(s)DSLD:312980
BulkSupplements.comMultivitamins For Women - with Fish Oil Softgels 1000 mg20 mgper 1 Softgel(s)DSLD:313514
BulkSupplements.comMultivitamins Softgels20 mgper 1 Softgel(s)DSLD:294795
BulkSupplements.comMultivitamins Softgels20 mgper 1 Softgel(s)DSLD:294796
BulkSupplements.comMultivitamins with Fish Oil Softgels 1000 mg20 mgper 1 Softgel(s)DSLD:329778
Burbank Glendale ChiropracticUltimate Health Cardio180 mgper 3 Capsule(s)DSLD:22091
Burton NutritionUltimate Men's Daily PackFish Oil125 mgper 1 Packet(s)DSLD:306046
California Academy of HealthPure Premium Antarctic Krill Oil 500 mg130 mgper 2 Softgel(s)DSLD:206422
CarlsonCod Liver Oil Natural Lemon FlavorEPA (Form: reported as Triglycerides) (Alt. Name: Eicosapentaenoic Acid)400 mgper 5 mLDSLD:241832
CarlsonKid's Norwegian Cod Liver Oil Natural Lemon Flavorreported as triglycerides185 mgper 2.5 mLDSLD:337525
CarlsonOlive Your Heart Basil FlavorEPA (Form: reported as Triglycerides) (Alt. Name: Eicosapentaenoic Acid)360 mgper 15 mLDSLD:216674
CarWin Pharmaceutical AssociatesTriStart DHA15 mgper 1 Softgel(s)DSLD:279283
CATALOBaby's Algea Omega-3 Drops216 mgper 0.5 mLDSLD:320578
CATALOBaby's Vegetarian DHA Formula10.2 mgper 500 mgDSLD:303015
CATALOChildren's Vegetarian DHA Formula10.2 mgper 500 mgDSLD:303035
CentrumCentrum Specialist Prenatal15 mgper 1 Tablet(s)DSLD:19028
ChildLife EssentialsOmega-3 DHA + Choline SoftChew Gummies Natural Passion Fruit Flavor50 mgper 1 Tablet(s)DSLD:327007
ChildLife EssentialsPure Arctic Cod Liver Oil Natural Strawberry Flavor800 mgper 2.5 mLDSLD:241499
Country LifeBaby Care Prenatal Omega 3-6-9Fish Oil Concentrate · EPA (Form: from Fish Oil concentrate) (Alt. Name: Eicosapentaenoic Acid) Note: Omega 3100 mgper 2 Softgel(s)DSLD:182476
Country LifeOmega 3 MoodFish Oil Concentrate · Eicosapentaenoic Acid Note: from fish oil concentrate - sardine, anchovy1,000 mgper 2 Softgel(s)DSLD:1609
Custom Health CentersOmega III432 mgper 1 Softgel(s)DSLD:272714
CymbiotikaThe Omega Organic Lemon10 mgper 2 mLDSLD:253167
Daily HealthOmega 8060 Natural Lemon Flavored864 mgper 2 Softgel(s)DSLD:248017
Daily HealthOmega 8060 Natural Lemon Flavored864 mgper 2 Softgel(s)DSLD:248082
Doctor GilmoreHeart Smart Fish Oil Softgels450 mgper 1 Softgel(s)DSLD:182027
Doctor's BestHigh Concentrate EPA plus CoQ10 with KD-Pur EPA and BioPerineEthyl Ester · KD-Pur EPA (Form: as Ethyl Ester) (Alt. Name: Eicosapentaenoic Acid)800 mgper 2 Softgel(s)DSLD:203362
dotFITSuper Omega-3360 mgper 1 Softgel(s)DSLD:12984
Douglas LaboratoriesCardiovascular Health Pack300 mgper 1 Packet(s)DSLD:9599
Douglas LaboratoriesDiabet Support Pack660 mgper 1 Packet(s)DSLD:28174
Douglas LaboratoriesDiabet-Support Pack660 mgper 1 Packet(s)DSLD:9619
Douglas LaboratoriesEssential-4 Nutrition Pack660 mgper 1 Packet(s)DSLD:10038
Douglas LaboratoriesMetabolic Management Pack660 mgper 1 Packet(s)DSLD:9593
Douglas LaboratoriesMetabolic Rejuvenation Week 4 Renew330 mgper 1 PackDSLD:261764
Douglas LaboratoriesSenior Men's Pack660 mgper 1 Packet(s)DSLD:9601
Douglas LaboratoriesUltra Cardio Support Pack660 mgper 1 Packet(s)DSLD:10045
Douglas LaboratoriesUltra Cardio Support Pack660 mgper 1 Packet(s)DSLD:27277
Douglas LaboratoriesUltra Preventive V Plus Chel300 mgper 1 Packet(s)DSLD:9714
Douglas LaboratoriesWeek Four: Renew330 mgper 1 Packet(s)DSLD:231039
Douglas LaboratoriesWeek Four: Renew660 mgper 2 Packet(s)DSLD:63562
Douglas LaboratoriesWeek Four: Repair660 mgper 2 Packet(s)DSLD:6220
Dr. BergCod Liver Oil Capsules44 mgper 3 Capsule(s)DSLD:316054
Dr. Clark StoreOmega-3 1000 mg245 mgper 1 Softgel(s)DSLD:220015
Dr. LaMar's ProductsOmega3580 mgper 2 Capsule(s)DSLD:180401
Dr. SinatraOmega Q Plus 100200 mgper 2 Softgel(s)DSLD:239716
Dr. Stan GubermanUltimate Joint Repair Platinumamount not statedper 4 Capsule(s)DSLD:33067
Dr. Stan GubermanUltimate Omega340 mgper 1 Softgel(s)DSLD:33066
Dr. TobiasOptimum Omega 3 Fish Oil Triple Strength800 mgper 2 Softgel(s)DSLD:73062
Elevation HealthKrill Oil150 mgper 1 Gelcap(s)DSLD:37474
Endo-met LaboratoriesEPA-DHA150 mgper 1 Softgel(s)DSLD:229075
Endo-met LaboratoriesEPA-DHA150 mgper 1 Softgel(s)DSLD:229079
Esmond Natural180/120 Fish Oil 1000 mg180 mgper 1 Softgel(s)DSLD:178602
Evlution NutritionFish Oil 1250 mg450 mgper 1 Softgel(s)DSLD:239648
Evlution NutritionOmega-3 Fish Oil 1250 mg450 mgper 1 Softgel(s)DSLD:326405
Finest NaturalFish Oil Mini-Gels Regular Strength 600 mg162 mgper 1 Softgel(s)DSLD:25940
Finest NaturalFish Oil Triple Strength 1400 mg647 mgper 1 Softgel(s)DSLD:13190
Finest NaturalMen's 50+ AdvancedEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3552 mcgper 1 Capsule(s)DSLD:13254
Finest NutritionCod Liver Oil 415 mg37 mgper 1 Softgel(s)DSLD:207018
Finest NutritionDouble Strength Fish Oil 1200 mgEPA Note: Omega 3 Fatty Acids324 mgper 1 Softgel(s)DSLD:207283
Finest NutritionFish Oil + D3324 mgper 1 Softgel(s)DSLD:65365
FitLineGeneration 50+3.4 mgper 5 Gram(s)DSLD:321592
Fresh NutritionFish OilOmega-3 EPA (Alt. Name: Eicosapentaenoic Acid)180 mgper 2 Softgel Capsule(s)DSLD:241928
Gaspari NutritionOmega-3 2400 mgOmega-3 Eicosapentaenoic Acid (Alt. Name: EPA)960 mgper 1 Softgel(s)DSLD:223186
Genestra BrandsSuper EFA Liquid Natural Orange Flavor950 mgper 2.5 mLDSLD:176640
GesticareDHA Capsule0.625 mgper 1 Gelatin Capsule(s)DSLD:43186
GNCCod Liver Oil160 mgper 1 Softgel Capsule(s)DSLD:328783
GNCDHA 600omega-3250 mgper 1 Softgel Capsule(s)DSLD:305831
GNCTriple Strength EPA 1000 MiniEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-31,000 mgper 2 Softgel(s)DSLD:228789
GNCTriple Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3540 mgper 1 Yellow Softgel Capsule(s)DSLD:44713
GNC Beyond RawTriple Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3540 mgper 1 Yellow Softgel Capsule(s)DSLD:63775
GNC Mega MenConcentrated Mini Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3357 mgper 1 Yellow Softgel Capsule(s)DSLD:27472
GNC Mega MenDouble Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3360 mgper 1 Light Yellow Softgel Capsule(s)DSLD:33551
GNC Mega MenDouble Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3360 mgper 1 Softgel(s)DSLD:3554
GNC Mega MenDouble Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3360 mgper 1 Softgel(s)DSLD:5893
GNC Mega MenDouble Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3360 mgper 1 Light Yellow Softgel Capsule(s)DSLD:66736
GNC Mega MenFish Oil with CoQ-10EPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3360 mgper 1 Softgel(s)DSLD:15716
GNC Mega MenFish Oil with CoQ-10EPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3360 mgper 1 Green Softgel Capsule(s)DSLD:33634
GNC Mega MenHeart & Eye HealthEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3540 mgper 1 Softgel(s)DSLD:220279
GNC Mega MenHigh Potency Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3540 mgper 1 Softgel(s)DSLD:219870
GNC Mega MenMemoralFish Oil · EPA (Form: as Fish Body Oil) (Alt. Name: Eicosapentaenoic Acid, Omega-3)360 mgper 1 Softgel(s)DSLD:15717
GNC Mega MenMemorallFish Oil · EPA (Form: as Fish Body Oil) (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3100 mgper 1 Dark Brown Softgel Capsule(s)DSLD:33652
GNC Mega MenTriple Strength Fish oilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3540 mgper 1 Amber Softgel(s)DSLD:19430
GNC Mega MenTriple Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 1 Softgel(s)DSLD:3560
GNC MilestonesConcentrated Mini Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3357 mgper 1 Yellow Softgel Capsule(s)DSLD:65759
GNC MilestonesConcentrated Mini Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3357 mgper 1 Yellow Softgel Capsule(s)DSLD:65775
GNC Preventive NutritionBlood Pressure FormulaEPA Note: Omega-3 EPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3360 mgper 2 Softgel(s)DSLD:1634
GNC Preventive NutritionEye Health FormulaFish Oil · fish body304 mgper 2 Softgel Capsule(s)DSLD:304446
GNC Preventive NutritionFish Oil With PolysterolsEicosapentaenoic Acid Note: omega-3323.5 mgper 1 Softgel(s)DSLD:3534
GNC Preventive NutritionMemorallFish Oil · EPA (Form: as Fish Body Oil) (Alt. Name: Eicosapentaenoic acid)200 mgper 2 Softgel(s)DSLD:1837
GNC Preventive NutritionMulti-OilEPA - omega-3 (Alt. Name: Eicosapentaenoic Acid)180 mgper 3 Soft Gel Capsule(s)DSLD:1838
GNC Preventive NutritionTriple Strength Fish OilEPA Note: Omega-3 EPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 1 Softgel(s)DSLD:3519
GNC Pro Performance AMPTriple Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 1 Softgel Capsule(s)DSLD:45113
GNC SelectFish Oil160 mgper 1 Softgel(s)DSLD:313698
GNC SelectOmega 3-6-9 LemonOmega-3 Fatty Acids180 mgper 3 Softgel(s)DSLD:313699
GNC Total LeanLiquid CLAFish Oil · Eicosapentaenoic Acid (Form: from Fish Oil) (Alt. Name: EPA)50 mgper 1.5 tspDSLD:69551
GNC Total LeanPremium CLA 3-6-9Fish Oil · EPA (Form: from Fish Oil) (Alt. Name: Eicosapentaenoic Acid) Note: Omega-392 mgper 2 Softgel(s)DSLD:213499
GNC Total LeanPremium CLA ComplexFish Oil · EPA (Form: from Fish Body Oil, Omega-3) (Alt. Name: Eicosapentaenoic Acid)92 mgper 2 Softgel(s)DSLD:27243
GNC Total Lean AdvancedPremium CLA 3-6-9Fish Oil · EPA (Form: from Fish Oil) (Alt. Name: Eicosapentaenoic Acid) Note: Omega-392 mgper 2 Softgel(s)DSLD:74477
GNC Triple StrengthEPA 1000EPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-31,000 mgper 1 Softgel Capsule(s)DSLD:36102
GNC Triple StrengthFish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 1 Softgel(s)DSLD:1024
GNC Triple StrengthFish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 1 Softgel(s)DSLD:219248
GNC Triple StrengthFish Oil + Vitamin D-3EPA Note: Omega-3 EPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 1 Softgel(s)DSLD:830
GNC Triple StrengthFish Oil +Co Q-10EPA Note: Omega-3 EPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 1 Softgel(s)DSLD:831
GNC Triple StrengthFish Oil +KrillEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 2 Softgel(s)DSLD:1073
GNC Triple StrengthFish Oil +ResveratrolEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 1 Softgel(s)DSLD:1071
GNC Triple StrengthFish Oil SportEPA Note: Omega-3 EPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 2 Softgel(s)DSLD:1651
GNC Triple StrengthOmega ComplexEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 3 Softgel(s)DSLD:1050
GNC Ultra Mega GreenOmega ComplexEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3215.7 mgper 1 Softgel(s)DSLD:11609
GNC Women'sFish Body OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3540 mgper 1 Amber Softgel Capsule(s)DSLD:243671
GNC Women's Ultra MegaConcentrated Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3357 mgper 1 Yellow Softgel Capsule(s)DSLD:42241
GNC Women's Ultra MegaConcentrated Mini Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3357 mgper 1 Yellow Softgel Capsule(s)DSLD:33540
GNC Women's Ultra MegaDouble Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3360 mgper 1 Yellow Softgel Capsule(s)DSLD:83088
GNC Women's Ultra MegaFish Oil With CoQ10EPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3360 mgper 1 Green Softgel Capsule(s)DSLD:33505
GNC Women's Ultra MegaHeart & Eye HealthEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3540 mgper 1 Amber Softgel(s)DSLD:69499
GNC Women's Ultra MegaMemorallFish Oil · EPA (Form: as Fish Body Oil) (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3100 mgper 1 Dark Brown Softgel Capsule(s)DSLD:33514
GNC Women's Ultra MegaTriple Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3540 mgper 1 Capsule(s)DSLD:19466
GNC Women's Ultra MegaTriple Strength Fish OilEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3647 mgper 1 Softgel(s)DSLD:5895
Gottfried InstituteHormone Balancing EssentialsFish Oil · EPA (Form: from Fish Oil) (Alt. Name: Eicosapentaenoic Acid)300 mgper 1 Packet(s)DSLD:45504
hank & brian'sEssential Fats Plus E120 mgper 2 Softgel Capsule(s)DSLD:254898
HBC ProtocolsOmega Complex180 mgper 3 Softgel(s)DSLD:74974
HerbadietOmega 3 (DHA + EPA)Standardized to contain min 9% EPA600 mgper 2 Capsule(s)DSLD:257823
HerbadietOmega 3 (DHA + EPA)Standardized to contain min 9% EPA300 mgper 1 Capsule(s)DSLD:293585
HerbTonicsTriglyceride Form Omega-3 2500 mg Lemon Flavored900 mgper 2 Soft Gel(s)DSLD:287069
High Performance NutritionN(4)1,080 mgper 3 Softgel(s)DSLD:271158
Higher NatureComplete Omegas 3:6:7:9680 mgper 4 Capsule(s)DSLD:228412
Higher NatureComplete Omegas 3:6:7:9170 mgper 1 Capsule(s)DSLD:240570
Higher NatureComplete Omegas 3:6:7:9680 mgper 4 Capsule(s)DSLD:245644
Higher NatureComplete Omegas 3:6:7:9680 mgper 4 Capsule(s)DSLD:245645
Higher NatureComplete Omegas 3:6:7:9680 mgper 4 Capsule(s)DSLD:245653
Higher NatureComplete Omegas 3:6:7:9680 mgper 4 Capsule(s)DSLD:41470
Higher NatureComplete Omegas 3:6:7:9680 mgper 4 Capsule(s)DSLD:41474
Higher NatureComplete Omegas 3:6:7:9680 mgper 4 Capsule(s)DSLD:41475
Higher NatureComplete Omegas 3:6:7:9680 mgper 4 Capsule(s)DSLD:41485
Higher NatureEssential Omegas 3:6:7:9170 mgper 1 Capsule(s)DSLD:42576
Higher NatureKeep Sharp54 mgper 1 Jelly(s)DSLD:178205
Higher NatureLemon Fish Oil690 mgper 2.5 mLDSLD:217005
Higher NatureOmega 3 Fish Oil 1000 mg180 mgper 1 Softgel Capsule(s)DSLD:40716
Higher NatureOmega 3 Fish Oil 1000 mg180 mgper 1 Softgel Capsule(s)DSLD:40930
Higher NatureOmega 3 Fish Oil 1000 mg180 mgper 1 Softgel Capsule(s)DSLD:40933
Higher NatureSuper Potency Fish Oil500 mgper 1 Capsule(s)DSLD:246034
Higher NatureSuper Potency Fish Oil500 mgper 1 Softgel Capsule(s)DSLD:304553
Higher Nature KidsSmart Focus Intensely Fruity Flavoured Jellies155 mgper 1 Jelly(s)DSLD:216996
HoltraCeuticalsUltra Omega420 mgper 1 Softgel(s)DSLD:19884
Igennus Healthcare NutritionMarine Ethyl-EPA 70%280 mgper 1 Capsule(s)DSLD:249520
Indiana Botanic GardensRed Krill Oil 500 mg20:5 - EPA15 mgper 1 Softgel(s)DSLD:46982
Iron-TekEssential Muscle LipidsFish Oil Concentrate · Eicosapentaenoic Acid (Form: from Fish Oil Concentrate (Form: Anchovy, Mackerel, Sardine)) (Alt. Name: EPA)240 mgper 2 Softgel(s)DSLD:2918
Irwin KidsOmega-3 Citrus-Chews Super Citrus Soft ChewsFish Oil · EPA (Form: from Fish Oil) (Alt. Name: Eicosapentaenoic Acid) Note: omega-3 fatty acid63 mgper 1 Soft Chew(s)DSLD:45699
iwiBeautyNannochloropsis · Almega PL (Form: from Nannochloropsis Genus: Nannochloropsis)600 mgper 2 Softgel(s)DSLD:247652
iwiCholesterolNannochloropsis sp. · Almega PL (Form: from Nannochloropsis sp. Genus: Nannochloropsis Species: sp.)1,100 mgper 2 Softgel(s)DSLD:247656
iwiCholesterolNannochloropsis sp. · Almega PL (Form: from Nannochloropsis sp. Genus: Nannochloropsis Species: sp.)1,100 mgper 2 Softgel(s)DSLD:247661
iwiHeartNannochloropsis1,100 mgper 2 Softgel(s)DSLD:295368
iwiImmunityNannochloropsis · Almega PL (Form: from Nannochloropsis Genus: Nannochloropsis)400 mgper 2 Softgel(s)DSLD:247675
John Gilmore, MDHeart Smart Fish Oil Softgels450 mgper 1 Softgel(s)DSLD:267848
JuvenonEssential Omega-3600 mgper 2 Softgel(s)DSLD:261896
KidzPlayBrainy Play155 mgper 1 mLDSLD:22250
KirkmanAll Natural Cod Liver Oil Liquid250 mgper 0.5 Teaspoon(s)DSLD:23981
KirkmanAll Natural Cod Liver Oil Liquid250 mgper 0.5 Teaspoon(s)DSLD:23986
KirkmanCod Liver Oil Liquid150 mgper 2.5 mLDSLD:259995
KirkmanCod Liver Oil Liquid Natural Lemon Lime Flavor150 mgper 2.5 mLDSLD:317718
Krill Doctor ProfessionalKrill Omega-3150 mgper 2 Softgel(s)DSLD:175022
Life ExtensionOmega-3 Lemon Whirl658 mgper 1 TbspDSLD:58974
Life ExtensionOmega-3 Tropical Whirl658 mgper 1 TbspDSLD:58979
Living FuelSuper Essentials Omegas 3EDA+Fish Oil · EPA (Form: from purified Fish Oils) (Alt. Name: Eicosapentanoic Acid) Note: 20:5 omega 3120 mgper 1 Softgel(s)DSLD:282561
Mason NaturalNorwegian Salmon Oil 2000 mg180 mgper 2 Softgel(s)DSLD:244788
Maxi HealthMaxi-Omega-3 Concentrate680 mgper 2 Softgel(s)DSLD:295567
Mental RefreshmentKrill Oil 1000 mg130 mgper 2 Capsule(s)DSLD:247641
MerovenReliven4,000 mgper 2 Sachet(s)DSLD:263380
MetagenicsOmegaGenics EPA 1200 Natural Lemon-Lime FlavorEicosapentaenoic Acid Ethyl Ester1,200 mgper 1 Softgel(s)DSLD:295808
MetagenicsPlusOne670 mgper 1 Packet(s)DSLD:216819
MetagenicsWellness Essentials Brain HealthEPA (Form: Eicosapentaenoic Acid Triglyceride)250 mgper 1 Packet(s)DSLD:211103
Method PharmaceuticalsDothelle DHA Softgels39 mgper 1 Capsule(s)DSLD:263294
Mission Pharmacal CitraNatalCitraNatal 90 DHA 300 mg DHA Soft Gel0.75 mgper 1 Softgel(s)DSLD:240145
Mission Pharmacal CitraNatalCitranatal 90 DHA Gelatin Capsule0.75 mgper 1 Gelatin Capsule(s)DSLD:45458
Mission Pharmacal CitraNatalCitraNatal 90 DHA Gelatin Capsule0.75 mgper 1 Gelatin Capsule(s)DSLD:63755
Mission Pharmacal CitraNatalCitranatal 90 DHA Soft Gel0.75 mgper 1 Softgel(s)DSLD:215339
Mission Pharmacal CitraNatalCitraNatal Assure 300 mg DHA Soft Gel0.75 mgper 1 Softgel(s)DSLD:206922
Mission Pharmacal CitraNatalCitraNatal Assure DHA Capsule0.75 mgper 1 Capsule(s)DSLD:37182
Mission Pharmacal CitraNatalCitraNatal Assure DHA Gelatin Capsule0.75 mgper 1 Capsule(s)DSLD:63989
Mission Pharmacal CitraNatalCitraNatal Assure DHA Soft Gel0.75 mgper 1 Softgel(s)DSLD:215277
Mission Pharmacal CitraNatalCitraNatal DHA Gelatin Capsule0.65 mgper 1 Gelatin Capsule(s)DSLD:45465
Mission Pharmacal CitraNatalCitraNatal DHA Soft Gel0.75 mgper 1 Softgel(s)DSLD:241671
Mountain Meadow HerbsKrill Oil 1000 mg60 mgper 1 Softgel(s)DSLD:327798
Mountain Meadow HerbsKrill Oil 1200 mg170 mgper 1 Softgel(s)DSLD:267493
MRI PerformanceOmega 3omega-3647 mgper 1 Softgel(s)DSLD:313484
MusclePharmFish Oil400 mgper 1 Soft Gel(s)DSLD:17995
MuscleSportLipoSlim for HerDeep Sea Cold Water Fish Oil Complexamount not statedper 2 Softgel(s)DSLD:256919
Natural Cell SupplementsOmegaActiv432 mgper 1 Softgel(s)DSLD:317955
Natural ClinicianClinical EPA/DHA Forte600 mgper 1 Softgel(s)DSLD:18623
Natural Health Improvement CenterEnteric Coated Fish Oil660 mgper 2 Softgel(s)DSLD:71195
Natural NutraKrill Oil65 mgper 1 Softgel(s)DSLD:246973
Nature's BountyHeart Health Support Packamount not statedper 1 Packet(s)DSLD:3788
Nature's LifeOmega 3 EFA Complex540 mgper 3 Softgel(s)DSLD:47347
Natures CraftOmega-3 Fish Oil 1200 mg432 mgper 1 Softgel(s)DSLD:256575
NaturesPlusOmega Krill Oil 600 mg77 mgper 1 Liquid-Filled Capsule(s)DSLD:298566
NCBAlaska Deep Sea Fish Oil360 mgper 2 Softgel(s)DSLD:13732
New AgeFish Oil 2500 mg896 mgper 2 Softgel(s)DSLD:268645
Nordic NaturalsChildren's DHA Strawberry170 mgper 2.5 mLDSLD:214259
Nordic NaturalsChildren's DHA Strawberry170 mgper 2.5 mLDSLD:277314
North American Herb & SpicePurelyPak107 mgper 7.3 Gram(s)DSLD:270080
North American Herb & SpicePurelyPak143 mgper 7.3 Gram(s)DSLD:307960
NOWDouble Strength DHA-500amount not statedper 1 Softgel(s)DSLD:314277
Nutra SportPerformance Omega-3420 mgper 1 Softgel(s)DSLD:319228
NutraChampsOmega 3 Fish Oil 3,600 mg Natural Lemon Flavor1,296 mgper 3 Softgel(s)DSLD:228956
NutraKeyFish Oil 1000 mg180 mgper 1 Softgel(s)DSLD:287400
Nutri-RichUltra EPA + DHA 1,000 mg750 mgper 2 Softgel(s)DSLD:176515
Nutri-RichUltra EPA + DHA 1,000 mg750 mgper 2 Softgel(s)DSLD:214108
Nutri-WestComplete Hi-Potency Omega-3 LiquidFish · EPA (Form: contains Fish) (Alt. Name: Eicosapentaenoic Acid)1,600 mgper 1 Teaspoon(s)DSLD:27617
NutriCologySuper Immuno Complex360 mgper 1 Packet(s)DSLD:183928
NutriSuppzSuper Krill Oil Complex 500 mg165 mgper 1 Softgel(s)DSLD:268894
OL Olympian LabsKrill Oil 1000 mg150 mgper 2 Softgel(s)DSLD:326672
OL Olympian LabsKrill Oil 1000 mg150 mgper 2 Softgel(s)DSLD:326661
OL Olympian LabsKrill Oil 500 mg75 mgper 1 Softgel(s)DSLD:175745
OL Olympian LabsNorwegian Salmon Oil360 mgper 3 Softgel(s)DSLD:9738
OmegaWorksDelicious Omega 3 Liquid Formula800 mgper 1 tspDSLD:7686
OmegaWorksSuper Omega 3300 mgper 1 Softgel(s)DSLD:259729
Orphic NutritionOmega 3 Fish Oil 2160 mg1,296 mgper 1 Softgel(s)DSLD:285532
Ortho Molecular ProductsOrthomega Select DHA130 mgper 1 Softgel Capsule(s)DSLD:174227
Ortho Molecular ProductsOrthomega Select EPA660 mgper 1 Softgel Capsule(s)DSLD:174221
Ortho Molecular ProductsPrenatal Complete with DHA130 mgper 3 Capsule(s)DSLD:175696
PerqueEPA/DHA Guard660 mgper 2 Softgel(s)DSLD:240750
PerqueEPA/DHA Guard660 mgper 2 Softgel(s)DSLD:240753
PerqueEPA/DHA Guard Softgels660 mgper 2 Softgel(s)DSLD:18732
PerqueEPA/DHA Guard Softgels660 mgper 2 Softgel(s)DSLD:18733
PharmaxBerry Frutol500 mgper 10 mLDSLD:238900
PharmaxCardol300 mgper 1 tspDSLD:55422
PharmaxDHA TasteBurst Natural Orange FlavorTuna Oil · Eicosapentaenoic acid (Form: provided as Tuna oil) (Alt. Name: EPA)30 mgper 2 Chewable Soft Gel(s)DSLD:55433
PharmaxFinest Pure Cod Liver Oil377 mgper 0.5 tspDSLD:55776
PharmaxFinest Pure Fish Oil950 mgper 0.5 tspDSLD:176136
PharmaxFinest Pure Fish Oil950 mgper 0.5 tspDSLD:55813
PharmaxFinest Pure Fish Oil850 mgper 1 tspDSLD:70995
PharmaxFinest Pure Fish Oil Capules524 mgper 2 Capsule(s)DSLD:55371
PharmaxFinest Pure Fish Oil Plus CoQ10 Natural Orange Flavor930 mgper 1 tspDSLD:55432
PharmaxFinest Pure Krill Oil130 mgper 2 Capsule(s)DSLD:55436
PharmaxFrutol250 mgper 1 tspDSLD:55369
PharmaxFrutol with Full Spectrum Multivitamins237.5 mgper 1 tspDSLD:55787
PharmaxHigh DHA Berry Frutol296 mgper 2 tspDSLD:55391
PharmaxHigh DHA Omega-3 Fatty AcidsTuna Oil · Eicosapentaenoic acid (Form: provided as Tuna oil) (Alt. Name: EPA)45 mgper 1 Softgel Capsule(s)DSLD:70981
PharmaxHigh EPA Finest Pure Fish Oil Natural Orange Flavor1,225 mgper 1 tspDSLD:55431
PharmaxOmega-3 Fatty Acids395 mgper 1 Capsule(s)DSLD:55838
PharmaxOmega-3 Fatty Acids395 mgper 1 Capsule(s)DSLD:55888
PharmaxOmega-3 Fatty Acids395 mgper 1 Capsule(s)DSLD:56157
PharmaxOmega-3 Fatty Acids395 mgper 1 Softgel(s)DSLD:70941
PharmaxOmega-3 Fatty Acids395 mgper 1 Softgel(s)DSLD:71006
Physician's StrengthPotentPak143 mgper 7.3 Gram(s)DSLD:268772
Phyto ParisPhytophanere3.2 mgper 2 Caplet(s)DSLD:206205
Primal HarvestPrimal Omega-3600 mgper 2 Softgel(s)DSLD:277139
Primal PharmOMEGA432 mgper 1 Softgel(s)DSLD:276404
ProceraOmega-3432 mgper 1 Softgel(s)DSLD:293227
Progressive Professional from Progressive LaboratoriesEPA-DHA 1000 mg150 mgper 1 Softgel Capsule(s)DSLD:261658
Pure EncapsulationsEPA/DHA Vegetarian155 mgper 2 Caplique(R) Capsule(s)DSLD:182879
Pure EncapsulationsEPA/DHA Vegetarian155 mgper 2 Caplique(R) Capsule(s)DSLD:184456
Pure Label NutritionKrill Oil 1000 mg60 mgper 2 Capsule(s)DSLD:269590
Pure OneAlgae Oil3.5 mgper 1 Softgel(s)DSLD:43285
Pure OneAlgae Omega-37 mgper 2 Vegetarian Softgel(s)DSLD:211607
Pure OneDHAlicious Organic Lemon & Green Tea Flavor15 mgper 1 mLDSLD:202540
Pure OneDHAlicious Organic Lemon Flavored3.5 mgper 0.5 mLDSLD:202543
Pure PrescriptionsPremium Omega-3EPA (Form: as Triglycerides) (Alt. Name: Eicosapentaenoic Acid)80 mgper 2 Softgel(s)DSLD:228209
Purely OptimalOmega 3 Fish Oil Natural Lemon Flavor864 mgper 2 Softgel(s)DSLD:244054
Purity LabsAntarctic Krill Oil120 mgper 2 Softgel(s)DSLD:313927
Remedys NutritionUltimate Omega-3 Fish Oil120 mgper 1 Vegetarian Capsule(s)DSLD:272190
Renew LifeSuper Critical Omega1,560 mgper 1 Softgel(s)DSLD:2345
Renew Life Norwegian GoldEPA 1000 Omega Natural Orange FlavorOmega-3 EPA (Alt. Name: Eicosapentaenoic Acid)2,000 mgper 1 Softgel(s)DSLD:62527
Rite Aid PharmacyNatural Fish Oil 1000 mgEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3320 mgper 2 Softgel(s)DSLD:181533
Rite Aid PharmacyNatural Fish Oil 1000 mgEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3320 mgper 2 Softgel(s)DSLD:239751
Rite Aid PharmacyOmega 3-6-9 Lemon Natural FlavorEPA (Alt. Name: Eicosapentaenoic Acid) Note: Omega-3180 mgper 3 Softgel Capsule(s)DSLD:239828
RugbyOmega-3 Krill Oil30 mgper 1 Softgel(s)DSLD:201205
Salaam NutritionalsOmega 3 Fish Oil800 mgper 2 Softgel(s)DSLD:292292
Salaam NutritionalsPrenatal11 mgper 4 Gummy(ies)DSLD:247265
Salaam NutritionalsPrenatal DHA + Folate11 mgper 4 Gummy(ies)DSLD:292290
Science Natural SupplementsOmega-3X EPA 432 mg/DHA 288 mg432 mgper 1 Softgel(s)DSLD:276468
SeniorLife HealthOmega 3-6-9 Complete72 mgper 1 Softgel(s)DSLD:256552
SFHSO3 Super Omega 3 LemonEPA (Alt. Name: Eicosapentaenoic Acid) Note: 1500-1630mg1,630 mgper 1 tspDSLD:16320
SFHSO3 SuperOmega3 LemonEPA (Alt. Name: Eicosapentaenoic Acid) Note: 1500-1630mg1,630 mgper 1 tspDSLD:16322
ShakleeVegan Omega-3Algal100 mgper 2 Softgel(s)DSLD:318625
SimplySupplementsOmega 3 Fish Oil 1000 mg180 mgper 1 Capsule(s)DSLD:22011
SimplySupplementsOmegaMax430 mgper 1 Capsule(s)DSLD:22533
SmarterVitaminsOmega-3 Strawberry Flavored800 mgper 2 Softgel(s)DSLD:243878
SomaLife InternationalOmega-3EPA Note: Min 30%360 mgper 1 Capsule(s)DSLD:33371
Source NaturalsComplete Essential Fatty AcidsEicosapentaenoic Acid (Alt. Name: EPA) Note: Omega-3288 mgper 3 Softgel(s)DSLD:214196
Source NaturalsComplete Essential Fatty AcidsEicosapentaenoic Acid (Alt. Name: EPA) Note: Omega-3288 mgper 3 Softgel(s)DSLD:214207
Source NaturalsOmega 3-6-9Eicosapentaenoic Acid (Alt. Name: EPA) Note: omega-3298 mgper 3 Softgel(s)DSLD:273928
Source NaturalsOmega 3-6-9Omega-3298 mgper 3 Softgel(s)DSLD:275607
Source NaturalsOmegaEPA Fish Oil 175 mgper 1 Softgel(s)DSLD:275432
Source NaturalsVegan Omega-3s 300 mg180 mgper 1 Softgel(s)DSLD:273971
Source NaturalsVegan Omega-3s 300 mg180 mgper 1 Softgel(s)DSLD:273974
Source NaturalsVegan Omega-3s 300 mg180 mgper 1 Softgel(s)DSLD:78805
Source NaturalsVegan True Non-Fish Omega-3s 300 mg180 mgper 1 Softgel(s)DSLD:274005
Source OilAlgae Omega-320 mgper 2 mLDSLD:211605
Source OilAlgae Omega-3 Organic Lemon Flavor20 mgper 0.5 Teaspoon(s)DSLD:211612
SP Standard ProcessCalamari Omega-3 Liquid400 mgper 5 mLDSLD:256403
SP Standard ProcessCod Liver Oil210 mgper 3 Softgel(s)DSLD:256486
SP Standard ProcessCod Liver Oil210 mgper 3 Softgel(s)DSLD:340155
SP Standard ProcessGeneral Health Daily Fundamentals60 mgper 1 Pack(s)DSLD:292105
SP Standard ProcessTuna Omega-3 Chewable50 mgper 2 Softgel(s)DSLD:340291
Spring ValleyAdult Gummy Omega-3 Complex with EPA/DHA10 mgper 2 Gummie(s)DSLD:73430
SuntoryDHA & EPA Sesamin EX100 mgper 4 Softgel(s)DSLD:174978
SuperSmartSuper Omega 3 1500 mgFish Oil · in Triglyceride form465 mgper 1 Softgel(s)DSLD:315661
Supplement SpotEssential Prostate Packfish oil125 mgper 1 Packet(s)DSLD:264557
SynergyNorwegian Cod Liver Oil Lemon400 mgper 5 mLDSLD:277453
Systemic Formulas Bio NutrimentOMGA LQ310 mgper 2 mLDSLD:22120
The Honest Co.Baby DHA140 mgper 1 mLDSLD:206813
The Honest Co.DHA/Omega-322 mgper 1 Softgel(s)DSLD:73709
The Vitamin ShoppeOmega 3 Fish Oil 800 EPA/500 DHA800 mgper 1 Teaspoon(s)DSLD:26980
Theralogix Nutritional ScienceTheraNatal Complete Softgel60 mgper 1 Softgel(s)DSLD:283003
Theralogix Nutritional ScienceTheraNatal One150 mgper 1 Softgel(s)DSLD:282955
Trigen LaboratoriesZatean -Pn Plus40 mgper 1 Softgel Capsule(s)DSLD:264498
TruehopeOmegapower540 mgper 3 Softgel Capsule(s)DSLD:32361
VigorSourceAlaska Deep Sea Fish Oil King360 mgper 1 Softgel(s)DSLD:12936
Village VitalityKrill Oil65 mgper 1 Softgel(s)DSLD:310246
VinsicEPA Fish Oil2,007.2 mgper 2 Softgel(s)DSLD:335761
Virtus PharmaceuticalsVirt-PN PlusEicosapentaenoic Acid (Alt. Name: EPA) Note: from at least 340 mg omega-3s from at least 390 purified fish oils.40 mgper 1 Softgel(s)DSLD:180537
VitabaseComplete Essential Fatty Acids69 mgper 1 Softgel(s)DSLD:6864
VitabaseKrill Oil 500 mg81 mgper 1 Softgel(s)DSLD:6160
VitabaseMaxEPA Omega-3 1000 mg180 mgper 1 Softgel(s)DSLD:6906
VitaCeutical LabsCardio Support Softgels120 mgper 1 Softgel(s)DSLD:6276
VitaCeutical LabsEPA & DHA180 mgper 1 Softgel(s)DSLD:53841
VitaCeutical LabsEPA & DHA180 mgper 1 Softgel(s)DSLD:6307
VitaCeutical LabsKrill Oil65 mgper 1 Softgel(s)DSLD:53560
Vital NutrientsUltra Omega CombinationEPA (Alt. Name: Eicosapentaenoic Acid) Note: 240-264mg264 mgper 2 Softgel(s)DSLD:6322
Vital NutrientsUltra Pure Cod Liver Oil 1025 Lemon Flavored320 mgper 5 mLDSLD:305170
Vital NutrientsUltra Pure Fish Oil 350 Lemon Flavor360 mgper 1 Softgel(s)DSLD:223052
Vital NutrientsUltra Pure Fish Oil 350 Lemon Flavor360 mgper 2 Softgel(s)DSLD:305174
Vitamer LaboratoriesHigh Potency Liquid Omega-3705 mgper 1 tspDSLD:53242
Vitamer LaboratoriesHigh Potency Liquid Omega-3 Orange675 mgper 1 tspDSLD:53168
Vitamer LaboratoriesKrill Oil65 mgper 1 Softgel(s)DSLD:23274
Vitamer LaboratoriesKrill Oil65 mgper 1 Softgel(s)DSLD:67592
Viva NaturalsLiquid Omega-3 Fish Oil Lemon SwirlEPA (Form: as TG) (Alt. Name: Eicosapentaenoic Acid)875 mgper 5 mLDSLD:248115
Viva NaturalsTriple-Strength Omega-3 Fish OilEPA (Form: as TG) (Alt. Name: Eicosapentaenoic Acid)1,400 mgper 2 Softgel(s)DSLD:247978
Viva NaturalsTriple-Strength Omega-3 Fish OilEPA (Form: as TG) (Alt. Name: Eicosapentaenoic Acid)1,400 mgper 2 Softgel(s)DSLD:248141
Viva VitaminsFish Oil Omega-3180 mgper 1 Softgel(s)DSLD:1792
VQ Verified QualityOmega 3 Fish Oil 180 mg EPA/120 mg DHA Lemon FlavorEPA Note: 180-190mg190 mgper 1 Softgel(s)DSLD:33987
Wholly LiquidOmega Plus400 mgper 1 Softgel(s)DSLD:272113
Wholly LiquidOmega Plus400 mgper 1 Softgel(s)DSLD:321788
Women's Choice PharmaceuticalsDHA/EPA CapsuleFish Oil · Eicosapentaenoic Acid (Form: derived from Fish Oil Note: product of Norway) (Alt. Name: EPA)30 mgper 1 Capsule(s)DSLD:241428
Womens Choice PharmaceuticalsOmega 3-DHA180 mgper 1 Softgel(s)DSLD:37269
WP Westminster PharmaceuticalsWestGel DHA15 mgper 1DSLD:264460
XtendlifeOmega 3/QH Premium CoQ10300 mgper 2 Softgel(s)DSLD:331305
ZahlerOmega 3 Liquid1,400 mgper 1 tspDSLD:33312
ZahlerOmega 3 Liquid1,400 mgper 1 tspDSLD:33314

Label record: NIH Office of Dietary Supplements · CC0

Measured, not recorded

Compound

all-cis-5,8,11,14,17-icosapentaenoic acid

Endpoints measured

906 endpoints

Recorded as a finding

Show what was measured

atherosclerosis, coronary heart disease, inflammatory disease, and behavioral disorders
decreases
n-3 Fatty acids favorably affect atherosclerosis, coronary heart disease, inflammatory disease, and perhaps even behavioral disorders.
PMID:10617967 · one of two readings recorded this
nutritional status (weight), quality of life and adverse events in cancer-associated cachexia
n = 587
Not recorded as a finding: no estimate is reported anywhere
There were insufficient data to establish whether oral EPA was better than placebo.
PMID:17253515 · one of two readings recorded this
weight/nutritional status
n = 587
There were insufficient data to establish whether oral EPA was better than placebo.
PMID:17253515 · one of two readings recorded this
depression rating scale score (standardized mean difference, change from baseline)
increases, effect size 0.558 for EPA >=60% of EPA+DHA vs placebo; non-significant -0.026 for EPA <60%, n = 916
The overall effect size for 60% or greater EPA in supplements compared with placebo was 0.558 (p<0.001); for EPA at less than 60%, it was non-significant at −0.026, (see Table 2 and.
PMID:21939614 · one of two readings recorded this
depression severity, standardized mean difference from baseline to endpoint on a depression rating scale (mainly Hamilton Depression Rating Scale)
effect size 0.558 for EPA >=60% supplements vs placebo, n = 916
Not recorded as a finding: the intervention held more than the compound
The overall effect size for 60% or greater EPA in supplements compared with placebo was 0.558 (p<0.001); for EPA at less than 60%, it was non-significant at −0.026, (see Table 2 and.
PMID:21939614 · one of two readings recorded this
ADHD severity rating scale score, standardized mean difference, pooled from RCTs of omega-3 fatty acid supplementation (including eicosapentaenoic acid) versus placebo in children with ADHD symptomatology
decreases
Not recorded as a finding: this platform holds no node for the endpoint
Omega-3 fatty acid supplementation demonstrated a small but significant effect in improving ADHD symptoms.
PMID:21961774 · one of two readings recorded this
ADHD severity rating scale score (standardized mean difference)
decreases, n = 699
Omega-3 fatty acid supplementation demonstrated a small but significant effect in improving ADHD symptoms.
PMID:21961774 · one of two readings recorded this
ADHD severity, standardized mean difference on rating scales (primary)
decreases
Omega-3 fatty acid supplementation demonstrated a small but significant effect in improving ADHD symptoms.
PMID:21961774 · one of two readings recorded this
ADHD symptom severity, standardized mean difference on ADHD rating scales, omega-3 fatty acid supplementation vs placebo in children with ADHD
decreases
Not recorded as a finding: this platform holds no node for the endpoint
Omega-3 fatty acid supplementation demonstrated a small but significant effect in improving ADHD symptoms.
PMID:21961774 · one of two readings recorded this
HDL cholesterol
increases
DHA also raised high-density lipoprotein (4.49 mg/dL; 95% CI, 3.50–5.48) compared with placebo, whereas EPA did not
PMID:21975919 · one of two readings recorded this
HDL cholesterol
no effect
DHA also raised high-density lipoprotein (4.49 mg/dL; 95% CI, 3.50–5.48) compared with placebo, whereas EPA did not
PMID:21975919 · one of two readings recorded this
LDL cholesterol
increases
Compared with placebo, DHA raised LDL 7.23 mg/dL (95% CI, 3.98–10.5) whereas EPA non-significantly reduced LDL
PMID:21975919 · one of two readings recorded this
LDL cholesterol
no effect
Compared with placebo, DHA raised LDL 7.23 mg/dL (95% CI, 3.98–10.5) whereas EPA non-significantly reduced LDL
PMID:21975919 · one of two readings recorded this
LDL cholesterol
increases
In direct comparison studies, DHA raised LDL 4.63 mg/dL (95% CI, 2.15–7.10) more than EPA
PMID:21975919 · one of two readings recorded this
triglycerides
decreases
Both EPA and DHA reduced triglycerides, with a greater reduction by DHA in direct comparison studies
PMID:21975919 · one of two readings recorded this
triglycerides
decreases
Both EPA and DHA reduced triglycerides, with a greater reduction by DHA in direct comparison studies
PMID:21975919 · one of two readings recorded this
triglycerides
decreases
Both EPA and DHA reduced triglycerides, with a greater reduction by DHA in direct comparison studies
PMID:21975919 · one of two readings recorded this
membrane enrichment with eicosapentaenoic acid following intake of stearidonic-acid-fortified soybean oil
increases
Not recorded as a finding: the trial gave a chemically different species
Stearidonic acid has been shown in animal and human studies to be more effective than its precursor, α-linolenic acid, in enriching membranes with eicosapentaenoic acid.
PMID:22186661 · one of two readings recorded this
membrane enrichment with eicosapentaenoic acid
increases
Stearidonic acid has been shown in animal and human studies to be more effective than its precursor, α-linolenic acid, in enriching membranes with eicosapentaenoic acid.
PMID:22186661 · one of two readings recorded this
cardiovascular death
decreases
There was a small reduction in cardiovascular death (relative risk, 0.91; 95% CI, 0.84-0.99)
PMID:22493407 · one of two readings recorded this
overall cardiovascular events
no effect
Supplementation with omega-3 fatty acids did not reduce the risk of overall cardiovascular events (relative risk, 0.99; 95% CI, 0.89-1.09)
PMID:22493407 · one of two readings recorded this
aortic pulse pressure and aortic augmentation pressure, in the 6 g fish oil without multivitamin group
decreases
The group receiving 6 g fish oil without the multivitamin displayed a significant decrease in aortic pulse pressure and aortic augmentation pressure, two measures of aortic blood pressure and aortic stiffness.
PMID:25565485 · one of two readings recorded this
aortic pulse pressure and aortic augmentation pressure
decreases
Not recorded as a finding: the intervention held more than the compound
The group receiving 6 g fish oil without the multivitamin displayed a significant decrease in aortic pulse pressure and aortic augmentation pressure, two measures of aortic blood pressure and aortic stiffness.
PMID:25565485 · one of two readings recorded this
aortic pulse pressure and augmentation pressure
decreases
Fish oil decreased aortic pulse pressure and augmentation pressure.
PMID:25565485 · one of two readings recorded this
cognition alongside aortic blood pressure reduction
no effect
Reductions in aortic blood pressure were not accompanied by consistent improvements in cognition.
PMID:25565485 · one of two readings recorded this
cognition, relative to reductions in aortic blood pressure
no effect
Reductions in aortic blood pressure were not accompanied by consistent improvements in cognition.
PMID:25565485 · one of two readings recorded this
cognitive performance, brachial blood pressure, and aortic (central) blood pressure, measured at baseline, 6 weeks, and 16 weeks
decreases
Not recorded as a finding: the intervention held more than the compound
The group receiving 6 g fish oil without the multivitamin displayed a significant decrease in aortic pulse pressure and aortic augmentation pressure, two measures of aortic blood pressure and aortic stiffness.
PMID:25565485 · one of two readings recorded this
primary cognitive outcomes
no effect
Treatment allocation had no effect on the primary cognitive outcomes at endpoint.
PMID:25565485 · both readings recorded this
red blood cell omega-3/6 ratio and spatial working memory
increases
Absolute increases in the red blood cell omega-3/6 ratio were associated with improvements in spatial working memory.
PMID:25565485 · one of two readings recorded this
spatial working memory, in relation to red blood cell omega-3/6 ratio
increases
Absolute increases in the red blood cell omega-3/6 ratio were associated with improvements in spatial working memory.
PMID:25565485 · one of two readings recorded this
B cell antigen (OVA-FITC) uptake
decreases, p = 0.001
B cells from EFO fed mice had significantly decreased antigen uptake by 90 minutes (p < 0.001)
PMID:25616447 · one of two readings recorded this
B cell antigen (OVA-FITC) uptake
increases, p = 0.05
we observed increased antigen uptake in B cells from MO fed mice (p < 0.05) by 90 minutes of incubation with antigen
PMID:25616447 · one of two readings recorded this
B cell membrane lipid microdomain clustering
decreases
Purified B cells from mice fed MO and DFO diets had decreased clustering compared to B cells from CON and EFO mice
PMID:25616447 · one of two readings recorded this
B cell membrane lipid microdomain clustering
increases, p = 0.05
B cells from EFO fed mice had increased clustering compared to CON, MO, and DFO fed mice (all p < 0.05
PMID:25616447 · one of two readings recorded this
B cell phospholipid EPA and arachidonic acid
increases
In B cells, MO, EFO, and DFO feeding resulted in increases of EPA, and decreases of AA compared to CON fed mice
PMID:25616447 · one of two readings recorded this
B cell phospholipid EPA+DHA content
increases
we observed the same fold change between B cells of CON fed mice (2-4% EPA+DHA) compared to the fish oil treatments (7-10%)
PMID:25616447 · one of two readings recorded this
B cell phospholipid EPA ranking across diets
increases
EPA was highest in the phospholipid fatty acids of B cells from mice fed EFO, followed by MO, and lowest in DFO
PMID:25616447 · one of two readings recorded this
bone marrow mature B cells
decreases, p = 0.05
Mature B cells in the bone marrow were decreased in MO, EFO and DFO fed mice compared to CON fed mice (p<0.05
PMID:25616447 · one of two readings recorded this
bone marrow pre-pro-B, pro-B, pre-B and immature B cells
no effect
Bone marrow pre-pro-B cells, pro-B cells, pre-B cells and immature B cell populations were not significantly altered by fish oil diets
PMID:25616447 · one of two readings recorded this
correlation of RBC and B cell phospholipid arachidonic acid
increases, p = 0.0001
significant (all p < 0.0001) linear correlations between RBCs and B cells, as evidenced by Pearson's r coefficients for EPA (r = 0.849, Figure 1B), DHA (r = 0.892, Figure 1C), AA (r = 0.973, Figure 1D), and EPA+DHA (r = 0.927, Figure 1E)
PMID:25616447 · one of two readings recorded this
correlation of RBC and B cell phospholipid DHA
increases, p = 0.0001
significant (all p < 0.0001) linear correlations between RBCs and B cells, as evidenced by Pearson's r coefficients for EPA (r = 0.849, Figure 1B), DHA (r = 0.892, Figure 1C), AA (r = 0.973, Figure 1D), and EPA+DHA (r = 0.927, Figure 1E)
PMID:25616447 · one of two readings recorded this
correlation of RBC and B cell phospholipid EPA+DHA
increases, p = 0.0001
significant (all p < 0.0001) linear correlations between RBCs and B cells, as evidenced by Pearson's r coefficients for EPA (r = 0.849, Figure 1B), DHA (r = 0.892, Figure 1C), AA (r = 0.973, Figure 1D), and EPA+DHA (r = 0.927, Figure 1E)
PMID:25616447 · one of two readings recorded this
correlation of RBC and B cell phospholipid EPA
increases, p = 0.0001
significant (all p < 0.0001) linear correlations between RBCs and B cells, as evidenced by Pearson's r coefficients for EPA (r = 0.849, Figure 1B), DHA (r = 0.892, Figure 1C), AA (r = 0.973, Figure 1D), and EPA+DHA (r = 0.927, Figure 1E)
PMID:25616447 · one of two readings recorded this
IFN-γ production by LPS-stimulated B cells
no effect
IFN-γ production from LPS-stimulated B cells was increased in mice fed MO (p < 0.05) with no change in EFO or DFO
PMID:25616447 · one of two readings recorded this
IFN-γ production by LPS-stimulated B cells
increases, p = 0.05
IFN-γ production from LPS-stimulated B cells was increased in mice fed MO (p < 0.05) with no change in EFO or DFO
PMID:25616447 · one of two readings recorded this
IL-6 production by LPS-stimulated B cells
increases, p = 0.05
There was a statistically significant increase in IL-6 production from DFO mice (p < 0.05)
PMID:25616447 · one of two readings recorded this
IL-6 production by LPS-stimulated B cells
decreases, p = 0.05
IL-6 production from LPS-stimulated B cells of EFO mice was decreased (p < 0.05)
PMID:25616447 · one of two readings recorded this
IL-6 production by LPS-stimulated B cells
no effect, p = 0.11
IL-6 production by LPS-stimulated B cells was increased from MO mice; however, it was not statistically significant (p = 0.11)
PMID:25616447 · one of two readings recorded this
IL-6 production by LPS-stimulated purified splenic B cells ex vivo, plus B-cell membrane microdomain clustering, antigen uptake and B-cell subsets, in SMAD3-/- mice
decreases
Not recorded as a finding: the intervention held more than the compound
There was a statistically significant increase in IL-6 production from DFO mice (p < 0.05), whereas, IL-6 production from LPS-stimulated B cells of EFO mice was decreased (p < 0.05).
PMID:25616447 · one of two readings recorded this
LPS-stimulated B cell CD40 expression
increases
After LPS-stimulation, B cells from mice fed MO and EFO diets had increased CD40 expression compared to CON
PMID:25616447 · one of two readings recorded this
LPS-stimulated B cell MHCII expression
decreases
LPS-stimulated B cells from EFO fed mice had decreased MHCII expression compared to B cells from CON mice
PMID:25616447 · one of two readings recorded this
RBC omega-3 index (EPA+DHA percentage of total lipid)
increases
ranging between 15-22% in fish oil fed mice compared 5-7% in CON fed mice
PMID:25616447 · one of two readings recorded this
RBC phospholipid EPA, DPAn-3 and DHA
increases
In RBCs, MO, EFO, and DFO feeding resulted in increases of palmitic acid (16:0), EPA (20:5n-3), n-3 docosapentaenoic acid (DPAn-3; 22:5n-3), and DHA (22:6n-3)
PMID:25616447 · one of two readings recorded this
splenic marginal zone B cells
no effect
There was a slight nonsignificant reduction in MZ B cells in DFO fed mice
PMID:25616447 · one of two readings recorded this
splenic marginal zone B cells
decreases, p = 0.05
reduced splenic marginal zone (MZ) B cells in the MO and EFO (p < 0.05) fed mice compared to CON fed mice
PMID:25616447 · one of two readings recorded this
splenic marginal zone B cells
decreases, p = 0.05
reduced splenic marginal zone (MZ) B cells in the MO and EFO (p < 0.05) fed mice compared to CON fed mice
PMID:25616447 · one of two readings recorded this
splenic T1, T2 and follicular B cell populations
no effect
Fish oil diets did not significantly alter the splenic T1, T2, and mature follicular B cell populations
PMID:25616447 · one of two readings recorded this
TNF-α production by LPS-stimulated B cells
no effect, p = 0.052
TNF-α production from LPS-stimulated B cells was increased in mice fed MO and DFO; however, these increases were not statistically significant (p = 0.092 and p = 0.052, respectively)
PMID:25616447 · one of two readings recorded this
TNF-α production by LPS-stimulated B cells
no effect
There was no change in TNF-α reduction from LPS-stimulated mice fed EFO
PMID:25616447 · one of two readings recorded this
TNF-α production by LPS-stimulated B cells
no effect, p = 0.092
TNF-α production from LPS-stimulated B cells was increased in mice fed MO and DFO; however, these increases were not statistically significant (p = 0.092 and p = 0.052, respectively)
PMID:25616447 · one of two readings recorded this
inflammation (pro-inflammatory cytokines, TNF-alpha, IL-6)
decreases
With this review we found that EPA can reduce inflammation and has the potential to modulate nutritional status/body composition.
PMID:25770317 · one of two readings recorded this
lean body mass / muscle mass
The paper will cover malignancy, body composition, intervention with EPA, physiological mechanisms of action of EPA, effect of EPA on weight and body composition, future research.
PMID:25770317 · one of two readings recorded this
nutritional status / body composition
increases
With this review we found that EPA can reduce inflammation and has the potential to modulate nutritional status/body composition.
PMID:25770317 · one of two readings recorded this
arthritis score
no effect
Compared with CFA group, administration of MAG-DHA did not significantly reduce arthritis score
PMID:26022389 · one of two readings recorded this
arthritis score
decreases
MAG-EPA and MAG-DPA were observed to have significant activity in preventing the progression of arthritic disease with the arthritis score significantly lowered in treated CFA rats from day 16 to 22
PMID:26022389 · one of two readings recorded this
hind paw swelling and redness
decreases
MAG-EPA displayed a more potent effect on the reduction of hind paw swelling and redness on day 20 to 22 than MAG-DPA treatment
PMID:26022389 · one of two readings recorded this
hind paw thickness by digital caliper (mm) and semiquantitative clinical arthritis score (0-4) in CFA-induced arthritis in female Lewis rats given EPA monoglyceride (MAG-EPA) 318 mg/kg orally; plasma cytokines by ELISA; the dosed form is a monoglyceride, not a form the boundaries list
decreases
Not recorded as a finding: this platform holds no node for the endpoint
In contrast, treatment of CFA rats with MAG-DPA and MAG-EPA resulted in a significant reduction in hind paw thickness when compared to untreated CFA rats.
PMID:26022389 · one of two readings recorded this
hind paw thickness (digital caliper) and clinical arthritis score, MAG-EPA versus untreated CFA rats
decreases
Not recorded as a finding: no outcome node for rat paw thickness or arthritis score
In contrast, treatment of CFA rats with MAG-DPA and MAG-EPA resulted in a significant reduction in hind paw thickness when compared to untreated CFA rats.
PMID:26022389 · one of two readings recorded this
hind paw thickness
increases
hind paw thickness of CFA-untreated rats was significantly increased (7.32 ± 0.22 mm) when compared to control rats (3.96 ± 0.01 mm
PMID:26022389 · one of two readings recorded this
hind paw thickness
no effect
on day 18 to 22, hind paw thickness measurements increased to reach the same level as that of CFA-untreated rats
PMID:26022389 · one of two readings recorded this
hind paw thickness
decreases
treatment of CFA rats with MAG-DPA and MAG-EPA resulted in a significant reduction in hind paw thickness when compared to untreated CFA rats
PMID:26022389 · one of two readings recorded this
hind paw thickness
decreases
treatment of CFA rats with MAG-DPA and MAG-EPA resulted in a significant reduction in hind paw thickness when compared to untreated CFA rats
PMID:26022389 · one of two readings recorded this
hind paw thickness
no effect
combined treatment of MAG-EPA and vitamin E in CFA rats incurred an increase in hind paw thickness similar to that of CFA-untreated animals
PMID:26022389 · one of two readings recorded this
histological arthritic and degenerative changes
decreases
CFA rats treated with MAG-EPA showed a reduced level of severe arthritic and degenerative changes when compared to the morphological changes observed in the untreated CFA group
PMID:26022389 · one of two readings recorded this
MMP-2 and MMP-9 protein expression
increases
Analysis revealed increased MMP-2 and MMP-9 expression levels in cartilage homogenates derived from CFA rats comparatively to controls
PMID:26022389 · one of two readings recorded this
MMP-2 and MMP-9 protein expression
decreases
a reduced staining of MMP-2 and MMP-9 proteins expression was obtained following treatments with MAG-DHA, MAG-EPA and MAG-DPA compounds in CFA rats
PMID:26022389 · one of two readings recorded this
MMP-2 and MMP-9 protein expression
decreases
a reduced staining of MMP-2 and MMP-9 proteins expression was obtained following treatments with MAG-DHA, MAG-EPA and MAG-DPA compounds in CFA rats
PMID:26022389 · one of two readings recorded this
paw COX-2 protein expression
increases
Figure 5b shows that combined treatment of MAG-EPA and vitamin E inhibited the reduction in COX2 protein expression level observed in CFA + MAG-EPA treated animals
PMID:26022389 · one of two readings recorded this
paw p38 MAPK phosphorylation
decreases
MAG-EPA, MAG-DPA and MAG-DHA treatments all decreased CFA-induced phosphorylation of p38 MAPK to a similar extent compared to untreated CFA animals
PMID:26022389 · one of two readings recorded this
paw p38 MAPK phosphorylation
decreases
MAG-EPA, MAG-DPA and MAG-DHA treatments all decreased CFA-induced phosphorylation of p38 MAPK to a similar extent compared to untreated CFA animals
PMID:26022389 · one of two readings recorded this
paw p65 NFκB phosphorylation (P-NFκB/NFκB ratio)
no effect
no significant difference in p65 NFκB phosphorylation levels in CFA + MAG-DHA-treated rats was observed when compared to untreated CFA animals
PMID:26022389 · one of two readings recorded this
paw p65 NFκB phosphorylation (P-NFκB/NFκB ratio)
decreases
Results revealed that MAG-EPA and MAG-DPA treatments decreased p65 NFκB phosphorylation levels in paw tissues compared to that observed in untreated CFA rats, with significant reductions of 81 ± 3.1 % and 76 ± 2.7 %, respectively
PMID:26022389 · one of two readings recorded this
paw p65 NFκB phosphorylation (P-NFκB/NFκB ratio)
decreases
Results revealed that MAG-EPA and MAG-DPA treatments decreased p65 NFκB phosphorylation levels in paw tissues compared to that observed in untreated CFA rats, with significant reductions of 81 ± 3.1 % and 76 ± 2.7 %, respectively
PMID:26022389 · one of two readings recorded this
paw TNFα and COX-2 protein expression
increases
Results revealed a significant increase in TNFα and COX-2 protein expression in CFA rats when compared to expression levels in control animals
PMID:26022389 · one of two readings recorded this
paw TNFα and COX-2 protein expression
decreases
MAG-EPA and MAG-DPA treatment significantly reduced TNFα and COX-2/β-actin staining density ratios when compared to the ratios quantified in untreated CFA rats
PMID:26022389 · one of two readings recorded this
plasma IL-17A, IL-1β, IL-6 and TNFα by ELISA, MAG-EPA-treated versus untreated CFA rats, day 22
decreases
Not recorded as a finding: the sentence reporting the MAG-EPA contrast refers to 'these cytokines' and never names TNFα, so it does not support the tnf-alpha node on its own
In contrast, the levels of these cytokines were significantly lower in the plasma of MAG-EPA- and MAG-DPA-treated animals when compared to untreated CFA rats.
PMID:26022389 · one of two readings recorded this
plasma IL-17A, IL-1β, IL-6 and TNFα
increases
IL-17A, IL-1β, IL-6 and TNFα levels were significantly higher in the plasma of CFA rats when compared to plasma levels in control animals
PMID:26022389 · one of two readings recorded this
plasma IL-17A, IL-1β, IL-6 and TNFα
decreases
the levels of these cytokines were significantly lower in the plasma of MAG-EPA- and MAG-DPA-treated animals when compared to untreated CFA rats
PMID:26022389 · one of two readings recorded this
plasma IL-17A, IL-1β, IL-6 and TNFα
increases
circulating levels of IL-17A, IL-1β, IL-6 and TNFα were less reduced in the presence of MAG-DHA than in MAG-EPA- and MAG-DPA-treated animals
PMID:26022389 · one of two readings recorded this
plasma IL-17A, IL-1β, IL-6 and TNFα
no effect
no significant difference was observed between CFA + MAG-EPA + vitamin E-treated and CFA-untreated rats
PMID:26022389 · one of two readings recorded this
cognitive decline rate
no effect
In case of advanced AD elderly patients, EPA and/or DHA supplementations did not reduce cognitive decline rates
PMID:26268080 · one of two readings recorded this
scores on cognitive tests (MMSE, ADAS-Cog, CDR)
no effect
EPA and/or DHA supplementations did not affect scores obtained on the cognitive tests
PMID:26268080 · one of two readings recorded this
verbal fluency and attention
increases
supplementation with EPA and/or DHA improved verbal fluency and attention in patients who had only very mild dementia or AD or presented APOEε4 negative genotype
PMID:26268080 · one of two readings recorded this
LDL cholesterol
increases
Although EPA/docosahexaenoic acid formulations did lower triglyceride levels, an increase in low-density lipoproteins was observed and outcome data were mixed.
PMID:26825470 · one of two readings recorded this
LDL cholesterol (more recent EPA-only preparations)
decreases
More recent trials have shown that decreased levels of low-density lipoproteins can be achieved with EPA preparations.
PMID:26825470 · one of two readings recorded this
serum triglyceride levels
decreases
Although EPA/docosahexaenoic acid formulations did lower triglyceride levels, an increase in low-density lipoproteins was observed and outcome data were mixed.
PMID:26825470 · one of two readings recorded this
body weight
no effect
Body weight (g) | 27.5 ± 0.52 | 25.3 ± 0.57 | 25.9 ± 0.51 | 26.2 ± 0.40
PMID:27333187 · one of two readings recorded this
epididymal white adipose tissue weight
no effect
eWAT weight (%body weight) | 1.41 ± 0.08 | 1.09 ± 0.09 | 1.15 ± 0.08 ## | 1.38 ± 0.06
PMID:27333187 · one of two readings recorded this
hepatic 8-OHdG
decreases
hepatic 8-hydroxy-2’-deoxyguanosine (8-OHdG) levels were significantly reduced in the AHF + EPA and AHF + DHA groups compared with the AHF group
PMID:27333187 · one of two readings recorded this
hepatic ABCA1, ABCG5 and ABCG8 mRNA
no effect
However, no difference between EPA and DHA administration was observed
PMID:27333187 · one of two readings recorded this
hepatic AOX and Cyp4a10 mRNA
increases
the addition of EPA or DHA to the AHF diet recovered the expression of these genes
PMID:27333187 · one of two readings recorded this
hepatic arachidonic acid and dihomo-gamma-linolenic acid
decreases
The hepatic levels of the n-6 series of PUFA [arachidonic acid (C20:4 n-6) and its precursor, dihomo-gamma-linolenic acid (C20:3 n-6)] were strongly decreased in both AHF + EPA and AHF + DHA groups in comparison with the AHF group
PMID:27333187 · one of two readings recorded this
hepatic Col1a1 and Mmp2 mRNA
decreases
Compared with the AHF group, AHF + EPA group showed significantly decreased Col1a1 and Mmp2 expression but unchanged TGFβ1 expression
PMID:27333187 · one of two readings recorded this
hepatic D6D, D5D, Elovl5 and Elovl2 mRNA
decreases
The mRNA levels of these genes were similarly suppressed in livers of the AHF + EPA and AHF + DHA groups compared to those of the chow and AHF groups
PMID:27333187 · one of two readings recorded this
hepatic DHA content
increases
Dietary DHA also clearly increased hepatic DHA content by 1.8- and 7.4-fold compared with the control and AHF groups, respectively
PMID:27333187 · one of two readings recorded this
hepatic DHA content
increases
Dietary DHA also clearly increased hepatic DHA content by 1.8- and 7.4-fold compared with the control and AHF groups, respectively
PMID:27333187 · one of two readings recorded this
hepatic DPA and DHA content
increases
Mice fed AHF + DHA showed increased hepatic EPA, and mice fed AHF + EPA showed increased hepatic docosapentaenoic acid (DPA) and DHA content compared with the AHF group to the similar extent
PMID:27333187 · one of two readings recorded this
hepatic EPA content
increases
Mice fed AHF + DHA showed increased hepatic EPA, and mice fed AHF + EPA showed increased hepatic docosapentaenoic acid (DPA) and DHA content compared with the AHF group to the similar extent
PMID:27333187 · one of two readings recorded this
hepatic EPA content
increases
The amount of hepatic EPA of AHF + EPA group was increased 3.9- and 29-fold in comparison with the chow and AHF groups, respectively
PMID:27333187 · one of two readings recorded this
hepatic EPA content
increases
The amount of hepatic EPA of AHF + EPA group was increased 3.9- and 29-fold in comparison with the chow and AHF groups, respectively
PMID:27333187 · one of two readings recorded this
hepatic F4/80-positive Kupffer cell accumulation
decreases
these cells were decreased in livers of the AHF + EPA and AHF + DHA groups compared to those of the AHF groups
PMID:27333187 · one of two readings recorded this
hepatic FAS, Elovl6 and GPAT-1 mRNA
decreases
Compared to the AHF + DHA group, the AHF + EPA group showed significantly decreased FAS, Elovl6, and GPAT-1 expression
PMID:27333187 · one of two readings recorded this
hepatic HEL (hexanoyl-lysine) staining intensity
decreases
The AHF + EPA and AHF + DHA groups showed decreased the intensity of the staining, with the effect on DHA group stronger
PMID:27333187 · one of two readings recorded this
hepatic JNK phosphorylation
decreases
The AHF + EPA and AHF + DHA groups showed significantly decreased the AHF diet-induced JNK activation
PMID:27333187 · one of two readings recorded this
hepatic lobular inflammatory clusters
decreases
significantly fewer hepatic lobular inflammatory clusters than in the AHF diet group
PMID:27333187 · one of two readings recorded this
hepatic Mmp2 mRNA
decreases
The AHF + DHA group showed significantly decreased Mmp2 expression with a tendency to decreased expression of both Col1a1 and TGFβ1 compared with the AHF group
PMID:27333187 · one of two readings recorded this
hepatic n-6/n-3 fatty acid ratio
decreases
The hepatic n-6/n-3 FA ratio was strongly decreased in the AHF + EPA and AHF + DHA groups in comparison with the AHF group
PMID:27333187 · one of two readings recorded this
hepatic n-6/n-3 fatty acid ratio
decreases
This ratio for the AHF + EPA group was slightly but significantly lower than that of AHF + DHA group
PMID:27333187 · one of two readings recorded this
hepatic p47phox and p22phox mRNA
decreases
The induction of p47phox and p22phox was attenuated in the AHF + DHA group but not in the AHF + EPA group
PMID:27333187 · one of two readings recorded this
hepatic p47phox and p22phox mRNA
no effect
The induction of p47phox and p22phox was attenuated in the AHF + DHA group but not in the AHF + EPA group
PMID:27333187 · one of two readings recorded this
hepatic PPARγ2 and Cidec mRNA
no effect
Compared to the AHF group, the AHF + EPA group showed significantly decreased PPARγ2 and Cidec expression, whereas the AHF + DHA group did not suppress the expression of these genes
PMID:27333187 · one of two readings recorded this
hepatic PPARγ2 and Cidec mRNA
decreases
Compared to the AHF group, the AHF + EPA group showed significantly decreased PPARγ2 and Cidec expression, whereas the AHF + DHA group did not suppress the expression of these genes
PMID:27333187 · one of two readings recorded this
hepatic PPARα and CPT-1a mRNA
no effect
the addition of EPA or DHA to the AHF diet did not change the expression of PPARα and CPT-1a
PMID:27333187 · one of two readings recorded this
hepatic α-SMA protein
decreases
The AHF + EPA and AHF + DHA groups showed significantly decreased α-SMA protein levels compared with the AHF group to a similar extent after loading correction
PMID:27333187 · one of two readings recorded this
hepatic SOD1 mRNA
no effect
addition of EPA or DHA to the AHF diet did not change the expression of SOD1
PMID:27333187 · one of two readings recorded this
hepatic SREBP-1c mRNA and mature SREBP-1 protein
decreases
Addition of EPA or DHA to the AHF diet markedly reduced the levels of SREBP-1c mRNA expression, mature SREBP-1 protein, and FA synthesis gene expression in comparison with both chow and AHF diet groups
PMID:27333187 · one of two readings recorded this
hepatic SREBP-1c mRNA and mature SREBP-1 protein
decreases
Addition of EPA or DHA to the AHF diet markedly reduced the levels of SREBP-1c mRNA expression, mature SREBP-1 protein, and FA synthesis gene expression in comparison with both chow and AHF diet groups
PMID:27333187 · one of two readings recorded this
hepatic SREBP-2, LDLR and HMG-CoA reductase mRNA
decreases
the mRNA abundances of SREBP-2 and its target, low-density lipoprotein receptor (LDLR) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA Red) were significantly decreased in both AHF + EPA and AHF + DHA groups compared with the chow and AHF diet groups
PMID:27333187 · one of two readings recorded this
hepatic TGFβ1 mRNA
no effect
Compared with the AHF group, AHF + EPA group showed significantly decreased Col1a1 and Mmp2 expression but unchanged TGFβ1 expression
PMID:27333187 · one of two readings recorded this
hepatic TNFα and MCP-1 mRNA
decreases
The AHF + DHA but not the AHF + EPA diet significantly attenuated the induction of TNFα and MCP-1 expression relative to the AHF group
PMID:27333187 · one of two readings recorded this
hepatic TNFα and MCP-1 mRNA
no effect
The AHF + DHA but not the AHF + EPA diet significantly attenuated the induction of TNFα and MCP-1 expression relative to the AHF group
PMID:27333187 · one of two readings recorded this
hepatic total cholesterol
decreases
hepatic cholesterol accumulation was equally decreased in both AHF + EPA and AHF + DHA groups
PMID:27333187 · one of two readings recorded this
hepatic total cholesterol
decreases
hepatic cholesterol accumulation was equally decreased in both AHF + EPA and AHF + DHA groups
PMID:27333187 · one of two readings recorded this
hepatic triacylglycerol content, AHF diet with 5% EPA versus AHF diet
decreases
Not recorded as a finding: no outcome node for liver tissue triglyceride (the triglycerides node is serum or plasma after a stated fast)
EPA prevented AHF diet-induced increase in liver TG, but DHA did not significantly prevent the AHF diet-induced increase.
PMID:27333187 · one of two readings recorded this
hepatic triacylglycerol content in AHF diet-fed mice, EPA versus AHF diet alone
decreases, EPA prevented the AHF diet-induced increase in liver TG
Not recorded as a finding: no outcome node for hepatic (tissue) triglyceride content; serum-triglycerides node is a fasting serum assay
EPA prevented AHF diet-induced increase in liver TG, but DHA did not significantly prevent the AHF diet-induced increase.
PMID:27333187 · one of two readings recorded this
hepatic triacylglycerol
no effect
EPA prevented AHF diet-induced increase in liver TG, but DHA did not significantly prevent the AHF diet-induced increase
PMID:27333187 · one of two readings recorded this
hepatic triacylglycerol
decreases
EPA prevented AHF diet-induced increase in liver TG, but DHA did not significantly prevent the AHF diet-induced increase
PMID:27333187 · one of two readings recorded this
liver weight
increases
Liver weight (%body weight) | 4.77 ± 0.11 | 5.14 ± 0.12 | 5.39 ± 0.21 * | 4.97 ± 0.07
PMID:27333187 · one of two readings recorded this
plasma ALT and AST, AHF diet with 5% EPA versus AHF diet
decreases
Not recorded as a finding: the sentence says 'biochemical liver injury markers' and does not name ALT or AST, and it pools the EPA and DHA arms in one clause
These biochemical liver injury markers induced by AHF diet were similarly reduced by dietary EPA and DHA.
PMID:27333187 · one of two readings recorded this
plasma ALT and AST (serum transaminase activities) in AHF diet-fed mice given EPA or DHA
decreases
Not recorded as a finding: the only sentence naming EPA gives 'serum transaminase activities' without saying which enzyme; ALT and AST are separate nodes
In addition, EPA or DHA administration was found to improve liver injury as assessed by serum transaminase activities.
PMID:27333187 · one of two readings recorded this
plasma ALT
decreases
These biochemical liver injury markers induced by AHF diet were similarly reduced by dietary EPA and DHA
PMID:27333187 · one of two readings recorded this
plasma ALT
decreases
These biochemical liver injury markers induced by AHF diet were similarly reduced by dietary EPA and DHA
PMID:27333187 · one of two readings recorded this
plasma ALT
increases
Feeding mice with the AHF diet resulted in approximately 4- and 3-fold increases in levels of plasma ALT and AST, respectively
PMID:27333187 · one of two readings recorded this
plasma AST
decreases
These biochemical liver injury markers induced by AHF diet were similarly reduced by dietary EPA and DHA
PMID:27333187 · one of two readings recorded this
plasma AST
decreases
These biochemical liver injury markers induced by AHF diet were similarly reduced by dietary EPA and DHA
PMID:27333187 · one of two readings recorded this
plasma AST
increases
Feeding mice with the AHF diet resulted in approximately 4- and 3-fold increases in levels of plasma ALT and AST, respectively
PMID:27333187 · one of two readings recorded this
plasma free fatty acids
decreases
Plasma FFA (mM) | 0.55 ± 0.06 | 0.48 ± 0.03 | 0.38 ± 0.03 * | 0.45 ± 0.02
PMID:27333187 · one of two readings recorded this
plasma glucose
no effect
Glucose (mg/dl) | 164 ± 9.4 | 169 ±9.0 | 152 ± 6.7 | 149 ± 5.8
PMID:27333187 · one of two readings recorded this
plasma insulin
no effect
Insulin (ng/ml) | 0.72 ± 0.21 | 0.31 ± 0.07 | 0.52 ± 0.18 | 0.61 ± 0.23
PMID:27333187 · one of two readings recorded this
plasma total cholesterol, AHF + EPA versus AHF
decreases
Not recorded as a finding: sentence says hypercholesterolemia attenuated, not the plasma total cholesterol assay, and uses the arm label AHF + EPA
Hypercholesterolemia was attenuated in both AHF + EPA and AHF + DHA groups.
PMID:27333187 · one of two readings recorded this
plasma total cholesterol
decreases
Plasma T-Cho (mg/dl) | 79.3 ± 2.9 | 143.5 ± 7.0 ** | 114.1 ± 5.5 **, ## | 124.7 ± 5.4 **, ##
PMID:27333187 · one of two readings recorded this
plasma triglycerides
no effect
Plasma TG (mg/dl) | 85.7 ± 5.8 | 54.6 ± 5.3 ** | 56.0 ± 4.5 ** | 64.0 ± 5.1 **
PMID:27333187 · one of two readings recorded this
EPA effect on Trail-induced Tak-1 and JNK phosphorylation and Mmp-9 expression with Gpr-120/Ffar-4 knockdown
no effect
Knockdown of Gpr-120/Ffar-4 abrogated the inhibitory effects of EPA on Trail-induced phosphorylation of Tak-1 and JNK and Mmp-9 expression
PMID:27764222 · one of two readings recorded this
external aortic diameter after AAA induction
decreases
this enlargement was significantly reduced in mice fed the EPA (+) diet
PMID:27764222 · one of two readings recorded this
external aortic diameter after AAA induction
no effect
No significant difference was found in external aortic diameters with or without EPA
PMID:27764222 · one of two readings recorded this
external aortic diameter after CaCl2 aneurysm induction, Opg-KO mice fed EPA (+) versus EPA (-) diet, six weeks
decreases
Not recorded as a finding: no outcome node for aortic diameter
At six weeks, however, obvious enlargement of the external aortic diameter was observed in mice fed the EPA (-) diet, while this enlargement was significantly reduced in mice fed the EPA (+) diet.
PMID:27764222 · one of two readings recorded this
maximum external aortic diameter and medial width in a CaCl2-induced abdominal aortic aneurysm model in Opg-KO mice, 5% EPA diet versus EPA-free diet, measured on aortic photographs and histology (Photoshop, Image-J); cell-culture mechanism work used EPA sodium salt
decreases
Not recorded as a finding: this platform holds no node for the endpoint
At six weeks, however, obvious enlargement of the external aortic diameter was observed in mice fed the EPA (-) diet, while this enlargement was significantly reduced in mice fed the EPA (+) diet.
PMID:27764222 · one of two readings recorded this
medial elastic fiber disruption
decreases
in Opg-KO mice fed the EPA (+) diet, elastic fibers were retained with flattened structures
PMID:27764222 · one of two readings recorded this
mouse body weight, EPA diet versus control diet in CaCl2 aneurysm model
no effect
Not recorded as a finding: agentless one-line statement referring to a supplementary figure, mixed wild-type and Opg-KO mice, no estimate; body-mass node needs scale conditions
No significant change in mouse body weight by EPA was observed (S1A Fig).
PMID:27764222 · one of two readings recorded this
mouse body weight
no effect
No significant change in mouse body weight by EPA was observed
PMID:27764222 · one of two readings recorded this
pJNK and Mmp-9 double-positive area in aortic media
decreases
Mmp-9 and pJNK double-positive areas were significantly increased in Opg-KO mice fed the EPA (-) diet compared to mice fed the EPA (+) diet
PMID:27764222 · one of two readings recorded this
rh-TRAIL-induced Trail mRNA in SMCs with JNK inhibitors
decreases
Trail expression was reduced in a dose-dependent manner, suggesting that Trail induces its own expression via JNK activation in SMCs
PMID:27764222 · one of two readings recorded this
Trail and Mmp-9 up-regulation in aortic media
decreases
EPA suppressed the up-regulation of Trail and Mmp-9 in the media of Opg-KO mice
PMID:27764222 · one of two readings recorded this
Trail-induced JNK phosphorylation and Mmp-9 expression in SMCs
decreases
In addition to Tak-1 inactivation, JNK phosphorylation and Mmp-9 expression were inhibited by GW9508 in a dose-dependent manner
PMID:27764222 · one of two readings recorded this
Trail-induced JNK phosphorylation in SMCs
decreases
EPA reduced Trail-induced JNK phosphorylation and Mmp-9 expression
PMID:27764222 · one of two readings recorded this
Trail-induced Mmp-9 expression in SMCs
decreases
EPA reduced Trail-induced JNK phosphorylation and Mmp-9 expression
PMID:27764222 · one of two readings recorded this
Trail-induced Tak-1 phosphorylation in SMCs
decreases
Tak-1 phosphorylation was completely inhibited with EPA or GW9508 treatment
PMID:27764222 · one of two readings recorded this
width of the medial layer after AAA induction
decreases
This enlargement was significantly reduced with the EPA (+) diet
PMID:27764222 · one of two readings recorded this
ANP mRNA in left ventricle
decreases
but were significantly lower in the MI+EPA group than in the MI+PBS group 28 days after MI
PMID:28223437 · one of two readings recorded this
BNP mRNA in left ventricle
decreases
but were significantly lower in the MI+EPA group than in the MI+PBS group 28 days after MI
PMID:28223437 · one of two readings recorded this
cardiac myocyte cross-sectional area (hypertrophy) in noninfarcted area
decreases
cardiac myocyte hypertrophy was significantly inhibited by EPA treatment 28 days after MI
PMID:28223437 · one of two readings recorded this
cardiac rupture after MI
no effect, p = 0.4248
the occurrence of cardiac rupture was similar between the MI+PBS and MI+EPA groups (38.2% vs 33.9%, P=0.4248
PMID:28223437 · one of two readings recorded this
cardiac rupture mortality after MI in mice
no effect, 38.2% vs 33.9%, p = 0.4248
Not recorded as a finding: no outcome node for cause-specific death by cardiac rupture
However, the occurrence of cardiac rupture was similar between the MI+PBS and MI+EPA groups (38.2% vs 33.9%, P=0.4248; Figure 1C).
PMID:28223437 · one of two readings recorded this
CCL2 mRNA
decreases
gene expression levels of CCL2, mucin‐like hormone receptor‐like 1, and IL‐6, which are proinflammatory genes and are also known as M1 macrophage genes, were lower in the MI+EPA group than in the MI+PBS group
PMID:28223437 · one of two readings recorded this
collagen I mRNA
decreases
The expression levels of the TGF‐β1 gene and downstream genes, such as collagen I and collagen III, during the remodeling phase were significantly lower in the MI+EPA group than in the MI+PBS group
PMID:28223437 · one of two readings recorded this
collagen III mRNA
decreases
The expression levels of the TGF‐β1 gene and downstream genes, such as collagen I and collagen III, during the remodeling phase were significantly lower in the MI+EPA group than in the MI+PBS group
PMID:28223437 · one of two readings recorded this
collagen volume fraction in noninfarcted area
decreases
the collagen volume fraction detected by picro‐sirius red staining in the noninfarcted area was significantly higher in the MI+PBS group than in the MI+EPA group
PMID:28223437 · one of two readings recorded this
death due to heart failure after MI in mice
decreases, 20.6% vs 6.8%, p = 0.0102
Not recorded as a finding: no outcome node for cause-specific death from heart failure
We also found that the incidence of death due to heart failure after MI was significantly higher in the MI+PBS group than in the MI+EPA group (20.6% vs 6.8%, P=0.0102; Figure 1B).
PMID:28223437 · one of two readings recorded this
death due to heart failure after MI, mice
decreases, 20.6% vs 6.8% (MI+PBS vs MI+EPA), p = 0.0102
Not recorded as a finding: cause-specific death classified by autopsy; cardiovascular-mortality node requires an adjudicated or registry underlying cause in a stated follow-up, not mouse autopsy classification
We also found that the incidence of death due to heart failure after MI was significantly higher in the MI+PBS group than in the MI+EPA group (20.6% vs 6.8%, P=0.0102; Figure 1B).
PMID:28223437 · one of two readings recorded this
death due to heart failure after MI
decreases, p = 0.0102
the incidence of death due to heart failure after MI was significantly higher in the MI+PBS group than in the MI+EPA group (20.6% vs 6.8%, P=0.0102
PMID:28223437 · one of two readings recorded this
EMR1 (mucin-like hormone receptor-like 1) mRNA
decreases
gene expression levels of CCL2, mucin‐like hormone receptor‐like 1, and IL‐6, which are proinflammatory genes and are also known as M1 macrophage genes, were lower in the MI+EPA group than in the MI+PBS group
PMID:28223437 · one of two readings recorded this
F4/80-positive macrophages in noninfarcted area
decreases
significantly more macrophages in the noninfarcted areas of the hearts of the MI+PBS group than in those of the MI+EPA group 28 days after MI
PMID:28223437 · one of two readings recorded this
fibrosis area in noninfarcted area
decreases
fibrosis detected by AZAN staining in the noninfarcted area 28 days after MI was significantly attenuated by EPA treatment
PMID:28223437 · one of two readings recorded this
heart and lung weight to tibial length ratios in sham mice
no effect
were similar between the sham+PBS and sham+EPA groups 28 days after the sham operation
PMID:28223437 · one of two readings recorded this
heart weight to tibial length ratio
decreases
EPA administration significantly decreased both ratios
PMID:28223437 · one of two readings recorded this
IL-6 mRNA
decreases
gene expression levels of CCL2, mucin‐like hormone receptor‐like 1, and IL‐6, which are proinflammatory genes and are also known as M1 macrophage genes, were lower in the MI+EPA group than in the MI+PBS group
PMID:28223437 · one of two readings recorded this
IRF5 mRNA and protein upregulation after MI
decreases
EPA treatment significantly attenuated this upregulation in the infarcted heart 28 days after MI
PMID:28223437 · one of two readings recorded this
lung weight to tibial length ratio
decreases
EPA administration significantly decreased both ratios
PMID:28223437 · one of two readings recorded this
LV systolic function (LVEF and %FS)
increases
A greater deterioration in LV systolic function was observed in the MI+PBS group than in the MI+EPA group 28 days after MI
PMID:28223437 · one of two readings recorded this
LVEDD and LVESD
decreases
LVEDD and LVESD were significantly larger in the MI+PBS group than in the MI+EPA group 28 days after MI
PMID:28223437 · one of two readings recorded this
LVEF, %FS, LVEDD and LVESD
no effect
However, LVEF, %FS, LVEDD, and LVESD were comparable between the MI+PBS and MI+EPA groups within 7 days after MI
PMID:28223437 · one of two readings recorded this
MRC1 mRNA
increases
gene expression levels of MRC1 and VEGF, which are anti‐inflammatory (M2 macrophage) genes, were higher in the MI+EPA group than in the MI+PBS group
PMID:28223437 · one of two readings recorded this
percentage of CD11b+F4/80+ macrophages
no effect, p = 0.9999
the percentage of CD11b+F4/80+ macrophages in the MI+PBS group was similar to that in the MI+EPA group (72.73±1.2% vs 72.0±2.4%, respectively; P>0.9999)
PMID:28223437 · one of two readings recorded this
percentage of M1 macrophages
decreases, p = 0.0317
the percentage of M1 macrophages was significantly higher in the MI+PBS group than in the MI+EPA group (7.6±0.4% vs 5.4±0.6%, P=0.0317)
PMID:28223437 · one of two readings recorded this
percentage of M2 macrophages
no effect, p = 0.9999
The same observation was made regarding the percentage of M2 macrophages (56.1±2.0% vs 57.7±0.5%, respectively; P>0.9999)
PMID:28223437 · one of two readings recorded this
post-infarct mortality
decreases, p = 0.0361
The incidence of postinfarct mortality was significantly lower in the MI+EPA group than in the MI+PBS group (59.3% vs 41.2%, P=0.0361)
PMID:28223437 · one of two readings recorded this
ratio of M1 to M2 macrophages
decreases, p = 0.0317
the ratio of M1 to M2 macrophages was significantly higher in the MI+PBS group than in the MI+EPA group (0.1355±0.004% vs 0.0944±0.010%, P=0.0317)
PMID:28223437 · one of two readings recorded this
Smad2 and Smad3 phosphorylation
decreases
EPA treatment significantly attenuated the phosphorylation of Smad2 and Smad3 28 days after MI
PMID:28223437 · one of two readings recorded this
TGF-β1 mRNA
decreases
The expression levels of the TGF‐β1 gene and downstream genes, such as collagen I and collagen III, during the remodeling phase were significantly lower in the MI+EPA group than in the MI+PBS group
PMID:28223437 · one of two readings recorded this
total CD45+ cells and macrophages infiltrating left ventricle
no effect
there were no significant differences in the total number of CD45+ cells and macrophages infiltrated into the left ventricle between the MI+PBS and MI+EPA groups 28 days after MI
PMID:28223437 · one of two readings recorded this

The whole record — 906 rows